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ABSTRACT 
For decades, there has been a lot of focus on the development of new carriers for drug 
delivery applications.  From all of the carriers, stimuli-responsive liposomes have been studied 
extensively, but only a handful have been enzyme-responsive liposomes.  Therefore, the field of 
endogenous proteins as activators of liposomes is a fertile field worthy of exploration.  
The research described in this dissertation involves how structural changes on the 
quinone moiety altered their electronic properties, as well as their behavior toward the human 
enzyme NAD(P)H:quinone oxidoreductase type-1 (hNQO1, over expressed in certain tumor 
tissues), thus yielding a series of triggerable quinones to be used in the formation of enzyme-
activated liposomes.  The step-wise process to achieve the ultimate research objective includes: 
(1) measurement by cyclic voltammetry of–the electronic properties of naked, propionic acid 
quinones and those attached to an ethanolamine handle, (2) detailed kinetics (Michaelis constant 
(Km), maximum velocity (Vmax), catalytic constant (kcat), enzyme efficiency (kcat/Km)) and 
computational docking studies for a series of quinone derivatives against hNQO1, and (3) 
preparation of quinone-based liposomes and evaluation in the presence of the different 
components included in an hNQO1 assay.  
Structural alterations on the quinone ring had an effect on their reduction behavior.  
Electrochemical studies exposed a trend in reduction potential; quinones with electron-
withdrawing groups were easy to be reduced and the opposite happens to quinones with electron- 
donating groups.  Enzyme and docking studies showed the different quinone responses obtained 
from the interaction of hNQO1 with structural-altered quinones.  Liposome experiments 
provided all the obstacles that need to be overcome when designing an enzyme-responsive 
liposome system.  The inclusion of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or 
cholesterol decreased the leakage of contents from the liposome systems.  Gathering all this 
xxi 
 
information provided me a strong background on the fundamentals of structure-reactivity 
relationships between quinones and hNQO1 and their importance toward the design of a 
triggerable drug delivery system. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Research Goals and Aims 
The goal of the research presented in this dissertation is the characterization of quinone 
trigger groups that are to be used to further develop enzyme-responsive liposomes.  In particular, 
liposomes activated by human NAD(P)H:quinone oxidoreductase type-1 (hNQO1), an          
over-expressed enzyme in certain solid tumors (e.g. non-small cell lung, colon and pancreas 
tumors),1-5 are targeted because they are expected to selectively deliver to the desired site more 
drug units per carrier than will a prodrug system.  
The challenge of producing a prodrug or drug delivery system that actively releases its 
contents at the desired site but maintains its integrity in the bloodstream for long periods of time 
has been a continuing issue for researchers around the world over the past 30 years.  Liposomes 
have been able to address one of those issues as a result of the addition of lipids possessing 
poly(ethylene glycol) chains (PEG) that have led to increased liposome circulation times in the 
body.6  PEGylated liposomes are able to circulate in the bloodstream for sufficient periods of 
times that they are able to accumulate at tumor sites via the enhanced permeability and retention 
(EPR) effect.7,8  Nevertheless, while drug-loaded PEGylated liposomes are in the circulatory 
system, non-specific interactions still occur, resulting in drug leakage from liposomes, an event 
that impacts healthy cells.  Also, due to the slow nature of drug delivery at the target site, high 
concentration of liposomes is required, causing side effects, such as mucositis and hand-foot 
syndrome.9  In today’s market, there are 11 approved liposomal formulations and 6 more 
currently in clinical development;10 however, none of those 17 liposomal formulations deliver 
their contents as a result of enzyme triggering.  Therefore, the use of endogenous enzymes as an 
active stimulus for liposome contents release is a fertile field worthy of exploration.    
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Currently, extensive literature for enzyme-activated prodrugs is available;11 this 
information has been an important contribution in the design of enzyme-responsive liposomes. 
However, the design and formulation of enzyme-responsive liposomes is still in the early stages.  
Only a few research groups have explored endogenous enzymes (e.g. elastase, alkaline 
phosphatase, phospholipase C, phospholipase A2 (PLA2) and matrix metalloproteinases 
(MMPs)) as trigger stimuli for liposome contents release.9,12,13   
The design of a liposome with triggerable groups that can be activated by an enzyme will 
allow for selective and site-specific controlled delivery of the liposomal contents.  This scenario 
results in a lower frequency of drug administration and minimizes systemic side effects.  The 
McCarley research group developed a redox-responsive liposome that contains a quinone head 
group and a fusogenic lipid, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).14  It was 
demonstrated that the liposomes are able to be opened and then release their contents as a result 
of a two-electron/two-proton chemical reduction, but their contents release has yet to be explored 
by a reductive enzyme.15  Among the different reductive enzymes used as stimuli for prodrug 
activation,16,17  NQO1 is an enzyme that specifically reduces quinones to hydroquinones by a 
two-electron/two-proton process.18 NQO1 has also been studied for bioreductive activation of 
anticancer drugs19 and prodrugs16,17 but to date has been investigated as a trigger for liposome 
contents release. 
 
Figure 1.1. Illustration of quinone derivatives investigated in this dissertation. 
The first aim of this research was the electrochemical characterization of a series of 
quinone derivatives: naked quinones (no propionic acid side chain), quinones containing a 
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propionic acid side chain, and quinones containing a trimethyl-lock motif (R3 = Y = methyl), 
Figure 1.1.  All quinones used underwent a two-electron/two-proton reduction process in 
aqueous media, and their electronic properties were measured by cyclic voltammetry (CV).  
Cyclic voltammetry is an electrochemical technique that provides information regarding the 
reduction potential and cyclization kinetics of the quinone derivatives.  The main advantage of 
tuning the reduction potential of quinones is that these compounds can undergo reduction in a 
particular environment such as where a high concentration of NQO1 is available but remain 
inactive in healthy cells.  It is crucial for the stability of quinone-based liposomes that their 
quinone derivatives have a reduction potential that can only be reduced by human NQO1, thus 
avoiding any non-specific reduction by other reducing species present inside the human body.  
Furthermore, the reduction/cyclization process resulting from quinone derivatives possessing the 
trimethyl-lock system is also believed to be dependent on the electronic properties of the 
quinones.   
The second aim of this research was the characterization of quinone derivatives by 
enzyme assays and docking studies using the human enzyme NQO1.  Enzyme kinetic assays 
gathered information on how structural changes of the quinone moiety affected the interaction 
between recombinant human NQO1 (rhNQO1) and the quinone derivatives.  This information 
was based on the kinetic parameters Km (Michaelis constant), Vmax (maximum velocity), kcat 
(catalytic constant), and kcat/Km (enzyme efficiency) extracted from the rhNQO1 assays.  In 
addition, molecular docking studies were used to determine the possible interaction and optimum 
orientations between quinone derivatives and human NQO1. 
The ultimate goal was the preparation of quinone-based liposome systems and 
observations of their behavior under rhNQO1 assay conditions.  A variety of quinone-based 
liposome systems were prepared following a modified version of the well-known “lipid thin-film 
and extrusion” method.20,21  The stability of the quinone-liposome systems in the presence of 
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bovine serum albumin (BSA), reduced nicotinamide adenine dinucleotide (NADH) and rhNQO1 
were investigated by fluorescence spectroscopy.  As a probe, the self-quenching dye calcein was 
loaded into the liposome systems at concentrations where the dye is non-fluorescent.  Liposome 
leakage caused by the introduction of BSA, NADH, or rhNQO1 to the liposome solution will 
result in the dilution of calcein and consequently a fluorescent signal is observed.  In addition, 
chemical release curves for the new liposome formulations were investigated using the reducing 
agent sodium dithionite (Na2S2O4).  Calcein-loaded liposome formulations were characterized 
with UV-vis spectroscopy, dynamic light scattering (DLS) and zeta potential. 
From the results in this work, there is a clear understanding of the structure-activity 
relationship of quinone derivatives with recombinant human NQO1 and the interaction between 
rhNQO1 assay contents and quinone-based liposome systems.  These nanosizes structures are a 
promising tool as triggered release carriers because they hold potential for selectively unload 
their contents in a controlled manner at the desired site.       
1.2 Prodrugs Activated by Endogenous Oxidoreductase Enzymes Other Than NQO1 
 Conventional chemotherapeutic drugs have been limited in their use due to low 
therapeutic index, and poor selectivity for tumor cells.11  One of the most promising technologies 
to overcome this issue is the use of prodrugs where nontoxic drugs are carried and activated at 
the specific tumor site by over-expressed enzymes.  Numerous tumor-associated enzymes have 
been exploited for prodrug activation in the field of gene- and virus-directed enzyme prodrug 
therapy (GDEPT, VDEPT), but effectiveness has been limited by insufficient transduction of 
tumor cells in vivo.11,22  Endogenous enzymes such as transferases, phosphorylases, kinases, 
hydrolases and oxidoreductases have also been investigated as a strategy to achieve local 
activation of prodrugs.11  In the section that follows, the characteristics, localization and prodrug 
developments towards human oxidoreductases (except NQO1 that will be detailed reviewed in 
the last section) will be discussed. 
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1.2.1 Aldehyde Oxidase 
 Aldehyde oxidase (AO) is a homodimeric enzyme with a molecular mass of 300 kDa 
containing 1338 amino acids.23-25  Its structure contains flavin adenine dinucleotide (FAD), 
molybdenum, and heme-iron groups.11,23,25  This cytosolic protein is present in high levels in 
human liver, lung, adrenal, testis and prostate tissue; however, little is known about the 
difference in the concentration levels of AO between normal and tumor tissues.26  AO oxidizes 
aldehydes to the corresponding acids using molecular oxygen, and it catalyzes the oxidation of 
pyrroles, pyridines, purines, pterins, and pyrimidines.11   
AO has been used in an attempt to increase organ selectivity of 5-ethynyluracil, a 
compound that prevents the rapid breakdown of 5-fluorouracil (5-FU), a well-known anticancer 
agent.  Porter and co-workers assayed the 5-ethynyl-2(1H)-pyrimidinone as a potential liver-
specific prodrug; however, their results showed lack of liver selectivity.27  Later, Guo et al. 
synthesized a 5-fluoro-2-pyrimidinone prodrug to increase organ selectivity towards the liver.  
Even though the authors succeeded in their task, this prodrug had similar cytostatic activity as 
the conventional drug 5-FU.28  AO has also been explored as an enzyme to increase the 
bioavailability of drugs.  In this matter, a prodrug of the radiosensitizer 5-iodo-2'-deoxyuridine 
(IUdR) was developed; it exhibited promising results and is currently under phase I clinical 
trials.29-31  Few attempts have been made to target AO as an enzyme that activates prodrugs, due 
to the wide distribution of this enzyme in humans.27  Moreover, AO differs greatly in substrate 
specificity between species, and what may be promising in animal models is not always 
successful in humans.11 
1.2.2 Amino Acid Oxidases 
Amino acid oxidases (AAO) are dimeric flavoproteins that contain FAD as a prosthetic 
group, and they stereoselectively catalyze the oxidative deamination (loss of an amine group) of 
amino acids to the corresponding α-keto acids, ammonia and hydrogen peroxide, as noted in 
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Figure 1.2.11,32-34  These enzymes also catalyze the β-elimination reactions of β-chloroalanine, β-
cyanoalanine, and selenocysteine Se-conjugates (SeCys conjugates) that result in the production 
of chloride, cyanide, and selenols, along with the formation of pyruvate and ammonia.11    
 
Figure 1.2.  Mechanism of action of D-amino acid oxidase.   Adapted from Pollegioni (2007).32 
LAAO (catalyzes the oxidative deamination of L-amino acids) has a molecular mass between 85 
and 150 kDa, while the molecular mas range of DAAO (catalyzes the oxidative deamination of 
D-amino acids) is between 38 and 125 kDa.11  High levels of AAO have been found in human 
tissues such as those of the kidney and liver, while low levels of AAO were found in brain 
tissue.33  
 SeCys conjugates have been the most studied approach in the targeting of AAO.11  
Several Se-conjugates have been shown to possess chemopreventive and antitumor 
properties.34,35  So far, investigations on the β-elimination mechanism of Se-conjugates have 
been done with rat renal cytosol, rat and human kidney cytosol but targeting β-lyse enzymes.36,37  
Later, Rooseboom et. al. demonstrated the activation of Se-conjugates by purified LAAO from 
Crotalus adamanteous and by DAAO from porcine kidney.38 The activation of Se-conjugates is 
stereoselective, thus, it needs to be taken into account when designing a prodrug to activate 
DAAO or LAAO. 
1.2.3 NADPH-Cytochrome P450 Reductase 
 Cytochrome P450 reductase (CPR) is a NADPH-ferrihemoprotein that catalyzes the 
reduction of cytochrome P450s, as well as the reduction of aldehydes (to form alcohols) and 
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quinones (to form semiquinone free radicals).11  Human CPR is localized in the endoplasmic 
reticulum and has a molecular mass of approximately 82 kDa that includes 676 amino acids.39,40  
CPR is a multidomain protein divided into a hydrophobic N-terminal domain, a flavin 
mononucleotide-binding (FMN) domain, and a FAD/NADPH binding domain (flavin adenine 
dinucleotide/nicotinamide adenine dinucleotide phosphate).41,42  The mechanism of this enzyme 
consists of accepting a pair of electrons from NADPH as a hydride ion, with FAD and FMN 
being the points of entry and exit, respectively.  Then, these electrons are transferred to 
cytochrome P450s, or to aldehydes or quinones.43  High levels of CPR were found in liver, lung, 
and small intestine based on immunohistochemical staining of human tissues.44  CPR was also 
found in a variety of tumor cells, such as lung, breast, and liver.45  However, only liver tumor 
cells were shown to have a significant increase in activity (2-fold) of CPR versus normal 
tissue.46,47  Moreover, in general, CPR activity is lower in tumor tissue than in the corresponding 
normal tissue.48   
 CPR has been explored as a target for prodrug activation under hypoxic conditions (low 
oxygen levels) where the one-electron reduction of substrates by CPR generates toxic free 
radicals that cause cell damage.  Studies on Chinese hamster ovary cells demonstrate CPR is the 
major enzyme that activates mitomycin C (MMC) and its analog porfiromycin under hypoxic 
conditions.49,50  In those studies, the hamster ovary cells where transfected with human CPR and 
compared with the parental cells.  The authors found that porfiromycin exhibited greater 
cytotoxicity under hypoxic conditions than under aerobic conditions, while MMC had the same 
toxicity regardless of the oxygenation state.49,50  RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-
methyl-1,4-benzoquinone) prodrug was also demonstrated to be reduced by CPR of pig liver 
origin.51  However, studies in human cancer cell lines (T47D human breast cancer cells and 
T47D-P450 transfected with P450 Red gene) did not demonstrate any significant increase in 
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cytotoxicity after treatment with RH1.52  Therefore, human CPR does not appear to have a 
substantial contribution in the activation of RH1.  
 To date, the major focus on CPR-targeted prodrugs has been the bioreductive agent 
tirapazamine (TPZ).  In the late 1980s, it was demonstrated that TPZ could be activated by CPR 
leading to DNA cleavage, as noted in Figure 1.3.11,17,53  Several in vitro investigations led to 
promising clinical trials; however, those results did not translate into in vivo success.  It is 
believed poor drug penetration through the extravascular tumor was the key factor in affecting in 
vivo activity.11,17,53   
 
Figure 1.3.  Reductive activation of TPZ.   Adapted from Chen (2009).17 
1.2.4 Cytochrome P450s 
 Cytochrome P450s (CYPs) consist of a family of several isoenzymes containing a heme 
prosthetic group that catalyzes the monooxygenation of a variety of substrates (from small 
molecules to large antibiotics) by incorporating one atom of molecular oxygen into a substrate 
and reducing the other oxygen atom to water.11  CYPs accept electrons from either the enzyme 
CPR or from NADPH and use them in its catalytic cycle.11  Human CYPs encoded by 57 genes 
are divided into families based on their homology in amino acid sequence identity.54  The most 
important human isoenzymes are CYP1A1/2, 2C9/19, 2D6, 2E1 and 3A4.11  Based on the three-
dimensional structure availability, Johnson and Stout compared the structure of CYP2A6, 2C8, 
2C9, and 3A4.55  The investigation revealed that 3A4 and 2A6 share less than 40% amino acid 
CPR 
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identity, whereas the active site of 2A6 is one-sixth the volume of that for 3A4.  The authors also 
reported that 3A4 and 2C8 active sites are similar in size but different in shape, while the active 
site of 2C9 is larger than 2A6, but smaller than 2C8.  The difference in active site architecture 
and chemical properties of the amino acids involved are probably the reasons why for all the 
CYPs, CYP3A4 contributes to over 60% of the metabolism of drugs reported to date.54   
Human CYPs are located in the endoplasmic reticulum, mainly in liver and adrenal gland 
tissues; however, low concentrations of CYPs were also found in kidney and testis tissues.56  
CYPs in general have lower levels in tumor tissues than in normal tissue,11 yet higher levels of 
the enzyme isoforms CYP1A and CYP3A were found in tumors versus their corresponding 
normal tissues.56 
Most CYPs chemotherapeutic agents were not initially designed as prodrugs to target 
CYPs; however, later investigations demonstrated that they could be activated by CYPs.11  That 
was the case for the example of 4-ipomeanol (1-(3-furyl)-4-hydroxy-1-pentanone) which is 
metabolized by CYP1A2, 3A3, and 3A4.  Although bioactivation was demonstrated, 4-
ipomeanol failed in clinical trials towards lung cancer.11  Another example is Tegafur, a prodrug 
of 5-FU (anticancer drug) that was initially thought to be activated by thymidine phosphorylase 
and CYPs, but later it was demonstrated that Tegafur was mainly activated by CYPs.11  
Investigations revealed that the isoenzymes responsible for its activation are CYP1A2, 2A6, and 
2C8/9.57,58  Dacarbazine (DTIC) is another CYP-activated prodrug used in the treatment of 
malignant melanoma and Hodgkin’s lymphoma.59  It has been demonstrated that isoforms 
CYP1A1, 1A2, and 2E1 account for the activation of DTIC.11  However, in spite of the 
successful antitumor effect in rodents, an insufficient amount of antitumor activity was exhibited 
in humans.11  
To date, the major prodrug compounds activated by CYPs are oxazaphosphorines and 
1,4-bis [2-(dimethylamino-N-oxide) ethyl] amino-5,8-dihydroxyanthracene-9,10-dione 
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(AQ4N).11  Oxazaphosphorines, in particular cyclophosphamide, is the most used alkylating 
agent with widespread application in cancer therapy.  This prodrug and its isomer are activated 
by the isoforms CYP2B6 and 3A4.  Cyclophosphamide, along with its isomer ifosfamide, 
presented issues because of the high concentration of CYPs in liver and low levels in tumor 
cells.11  Those obstacles were overcome by gene-directed enzyme prodrug therapy (GDEPT).60 
AQ4N is converted into a potent topoisomerase II inhibitor after bioreduction by CYPs 
(in particular the isoform 3A4) to AQ4, Figure 1.4.11  AQ4 is also a high-affinity DNA-binding 
agent where its tertiary amine side chains ensure good uptake of the compound into the cells.17  
AQ4 is currently in phase-2 clinical trials for brain tumor, chronic lymphocytic leukemia, and 
non-Hodgkin’s lymphoma.17   
 
Figure 1.4.  Reductive activation of AQ4N.   Adapted from Chen (2009).17    
The major drawbacks on targeting CYPs are their high concentration levels in liver and 
adrenal glands, their low turnover rates resulting in generally slow drug formation, and their low 
activity in tumors cells compared with normal cells.  However, several prodrugs activated by 
CYPs are successfully used in the clinic.11     
1.2.5 Tyrosinase 
 Tyrosinase is a copper enzyme (two copper ions per enzyme molecule) that catalyzes the 
oxidation of L-tyrosine to the corresponding o-quinone dopaquinone as well as the oxidation of 
phenols and catechols to o-diphenols and o-quinones, respectively.11,61  This enzyme was found 
to have an approximate molecular mass of 67 kDa by SDS electrophoresis.61  The X-ray 
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structure of human tyrosinase has not yet been determined; however, the three-dimensional 
structure from Streptomyces castaneoglobisporus (gram-positive bacteria) has been solved, and 
it has been useful to describe in detail the tyrosinase catalytic mechanism, Figure 1.5.62  The 
authors proposed that first a peroxide ion is bridged to copper ions following a proton extraction 
from the phenolic hydroxyl to later have the deprotonated oxygen atom bound to copper.  At this 
point, copper is hexa-coordinated and an ortho-carbon of the substrate is approached by the 
peroxide ion which adds one of the peroxide oxygens to the ortho-carbon of monophenol. 
 
Figure 1.5.  Catalytic mechanism of tyrosinase.  Adapted from Matoba (2006).62 
 Tyrosinase is responsible for skin pigmentation abnormalities and has the very peculiar 
property that it is only located in melanoma cells, making this enzyme a very attractive target for 
treatment of the cancer, melanoma.63  The first prodrug dependent on tyrosinase activity was 2,4-
dihydroxyphenylalanine.64  This prodrug showed good selectivity towards tyrosinase-containing 
cells versus tyrosinase-lacking cells.  In spite of these findings, the potential of 2,4-
dihydroxyphenylalanine as a prodrug was not further evaluated.11  4-S-Cysteaminylphenol (4-S-
CAP) and N-acetyl-4-S-cysteaminylphenol (N-Ac-4-S-CAP) are other two prodrugs that showed 
tyrosine-mediated cytotoxicity.11  Later, analogs of N-Ac-4-S-CAP were synthesized and 
presented activities comparable to that of cisplatin, a well-known chemotherapy drug.65  Phenyl- 
12 
 
and urea- mustard prodrugs were also synthesized and assayed for tyrosinase activity.66,67  The 
authors found a positive correlation between prodrug toxicity and tyrosinase activity.  More 
recently, the stability of these prodrugs in the presence of phosphate buffer and bovine serum 
were evaluated;68 the authors identified the urea prodrugs as the lead compounds for further 
studies.  
1.3 Enzyme-Activated Liposomes 
 Currently marketed drug delivery systems based on liposomes and polymeric materials 
rely on passive diffusion or slow non-specific degradation of the liposomal carrier.9  To improve 
therapeutic efficiency, scientists have been putting their effort in designing carriers for active 
targeting (e.g. ligands on carrier surface) and active triggering (e.g. hyperthermia) to safely 
deliver carrier cargo to and at the desired site.9  These systems are composed of nanosize 
particles, ranging from liposomes to macromolecular dendrimers.6,13,69-71  It is not the intent of 
this dissertation to focus on each of these systems, but rather the few ones so far published that 
correspond to enzyme-responsive liposomes.  The activation of liposomes by the endogenous 
enzymes elastase, alkaline phosphatase, phospholipase C, phospholipase A2 and 
metalloproteinase, and their characteristics will be discussed below.  
1.3.1 Elastase 
 Elastase is an enzyme released from the azurophil granules (cytoplasmic small particles 
in white blood cells) of activated neutrophils (50–70% of all white blood cells).  Human 
neutrophil elastase has an approximate molecular mass of 30 kDa that includes 218 amino acids 
with two asparagine-linked carbohydrate side chains and four disulfide bonds.72  This enzyme 
became of particular interest in the activation of liposomes because it is ubiquitously present in 
inflammatory (e.g. rheumatoid arthritis,73,74 acute respiratory distress syndrome,75 emphysema,76 
cystic fibrosis77,78) and tumor (e.g. breast,79 skin80) tissues.  Elastase has been used to activate 
enzyme-triggered liposomes where DOPE is capped with a short peptide sequence (e.g. N-Ac-
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ala-ala) that is a substrate for the enzyme, Figure 1.6; stable non-fusogenic liposomes can be 
formed from N-Ac-ala-ala-DOPE.81  The stable peptide-DOPE liposome system became unstable 
upon cleavage of the peptide by elastase, resulting in liposome fusion with cells.  
 
Figure 1.6. Cleavage of peptide-DOPE structure by elastase.  Adapted from Pak (1998).81 
This liposome system was further improved by attachment of a different peptide named 
N-methoxy-succinyl-ala-ala-pro-val (MeO-suc-AAPV) to the DOPE lipid that exhibited greater 
sensitivity and selectivity towards elastase than the previous peptide N-Ac-ala-ala.  MeO-suc-
AAPV-DOPE liposomes (250 μM) were proved to be activated by 0.42 μM elastase, an amount 
that is between 3 and 20 fold less than the amount found in cystic fibrosis tissue, with subsequent 
transfer of their aqueous content probes into adherent cells.82  The authors also observed that 
heat-inactivated elastase (95 °C for 1h) did not activate the MeO-suc-AAPV-DOPE liposomes.  
Other potential elastase substrates have been designed and are currently under development.12 
1.3.2 Alkaline Phosphatase 
 Alkaline phosphatase is a non-specific phosphomonoesterase enzyme that is present in 
serum and on the cell membrane, as well as over-expressed in certain tumor tissues (e.g. 
testicular and ovarian).83,84  Its structure is the one of a dimeric metalloprotein with two Zn2+ ions 
and a Mg2+ ion in each active site.85  The earlier demonstration on the ability of alkaline 
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phosphatase to activate prodrugs86 and remove the phosphate group from a polysaccharide,87 
suggested the application of the enzyme to activate liposomes composed of phospholipid 
derivatives.  Szoka and co-workers have been the only ones that took advantage of those results 
to design an alkaline phosphatase-sensitive liposome system composed of DOPE lipid and 
cholesterol phosphate derivatives.88  They found that the liposome with the most sensitive 
behavior towards the enzyme exhibited a leakage of encapsulated fluorophore of 40% in 24 
hours, while no leakage was observed in the presence of heat-inactivated enzyme.88  The nature 
of the enzyme after being inactivated by heat could not be established because of the lack in 
information about the time and temperature at what the procedure was performed.  The wide 
distribution of this enzyme in the body limited its use, unless the enzyme is directed to activate 
conjugated prodrugs (e.g. antibody).11    
1.3.3 Phospholipase C 
 Phospholipase C (PC-PLC) is an enzyme found in human gallbladder bile.89,90  High 
levels of PC-PLC have been found in rheumatoid arthritis tissues as well as in epithelial ovarian 
cancer cells and breast tumor cells.91-93  The molecular mass of PC-PLC found in human 
monocytic U937 cell lines was 40kDa as determined by SDS gel electrophoresis.91  Later, a 
study on natural killer cells (NK cells) demonstrated the presence and subcellular localization of 
two PC-PLC isoforms with molecular masses of 40 and 66 kDa, respectively.94  PC-PLC 
requires the presence of calcium ion as cofactor for its catalytic function for the hydrolysis of the 
phosphoester bond of lecithin to yield the amphiphile diacylglycerol (DAG) and the headgroup 
phosphocholine.95-97   
This enzyme was the first catalytic agent to induce fusion of liposomes, an investigation 
done by Nieva and co-workers in the late 1980s.95  The same investigation demonstrated that 
bilayer composition is critical.  Phosphatidylethanolamine (PE) and cholesterol are essential, in 
addition to phosphatidylcholine (PC), for significant liposome fusion to occur at low levels of 
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phospholipase C.95  In addition, it was later found that PC-PLC becomes inhibited by DAG, the 
end product, when DAG concentration is over 20 mol% in the liposome bilayer.96  Contrary to 
the observation of Nieva, pure lecithin liposomes underwent aggregation and fusion with 
concomitant leakage of vesicle contents in the presence of PC-PLC, as reported by Luk.98  
However, in the fusion process described by Nieva, no leakage was observed.95  In summary, 
PC–PLC-induced liposome fusion may be considered to happen in three steps: generation of 
DAG in the bilayer, aggregation of liposomes, and fusion of apposed membranes.96    
1.3.4 Phospholipase A2 (PLA2) 
Phospholipase A2 (PLA2) and metalloproteinases have been the two enzymes most 
widely studied for liposome activation;13 the latter will be discussed in the next section.  PLA2 is 
an enzyme present in a wide variety of mammalian cells,99,100 and it hydrolyzes 
phosphoglycerides–such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), and 
phosphatidylserine (PS)–at the acyl ester bond at the sn-2 position, yielding the corresponding 
lysophospholipid and fatty acid, as described in Figure 1.7.101 
 
Figure 1.7. Mode of action of PLA2 versus other phospholipases.  AA = arachidonic acid.  
Adapted from Kaiser (1999).101  
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Mammalian PLA2 is composed of three distinct isozymes: group I (PLA2-I), group II 
(PLA2-II), and cytosolic PLA2 (cPLA2).102  Group I is the secretory pancreatic type, with a 
molecular mass of approximately 14 kDa, and it requires millimolar amounts of Ca2+ for 
activation.101  The complete sequence of PLA2-I consists of a single polypeptide chain of 125 
amino acids with seven cross-linked disulfide bridges.103  Group II is the non-pancreatic PLA2 
that can be further subdivided into secretory enzymes and membrane-associated enzymes.102  
PLA2-II has the same molecular mass and requirements of activation as PLA2-I.  The major 
difference is the absence of cysteine residues at position 11 and 77, along with the corresponding 
disulfide bridge in PLA2-II.  In spite of these differences, their respective active sites and 
hydrophobic regions are similar.101  Cytosolic PLA2 enzymes have a molecular mass of 
approximately 80 kDa, with some being Ca2+ dependent (c PLA2) enzymes and others are Ca2+ 
independent (i PLA2) enzymes.101  An 85 kDa cPLA2 was purified from human monocytic cell 
line (U937) and sequenced.104  This cPLA2 consisted of 749 amino acids and had no apparent 
disulfide bonds, in contrast to the PLA2 enzymes found in Group I and II.104  PLA2 has been a 
target for cancer therapy because of its over expression in various types of cancer, such as 
pancreatic, breast, lung, stomach, and prostate; PLA2-II is found in elevated concentrations in all 
types of cancer.9,101,105  In addition, high amounts of PLA2-II in blood have been associated with 
systemic bacterial infections and malaria.101  Furthermore, it has been reported that elevated 
serum levels of PLA2-II has been found in effusions from 47 patients with various cancers.102 
It has been essential to gain knowledge about the physical properties of liposomes (e.g. 
charge) and how that affects the substrate specificity towards PLA2 for the rational design of a 
degradable drug delivery system.  It was reported in the early 1990s that pig PLA2 had a slight 
preference for anionic phospholipids (2–3 fold).106  This preference was confirmed later by 
various investigations on the interaction of PLA2-II and anionic membranes.107-111  Those 
investigations reported that the specificity of the enzyme for anionic membranes is a result of the 
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electrostatic nature of the active site of PLA2-II that is high in cationic residues that provides 
non-specific electrostatic interactions that in turn promote surface binding.  This specificity 
prevents PLA2-II from interacting with unperturbed mammalian cells that are composed mostly 
of neutral lipids such as sphingomyelin, phosphatidylcholines, and cholesterol.110   
PLA2 has a fascinating feature of preference for aggregated lipid substrates, such as 
liposomes over lipid monomers.9  Thus, the design of liposomes with appropriate lipid 
composition will maximize PLA2-II activity.112  In addition, it has been proved that the addition 
of PEG modified lipids into the liposomal formulation did not preclude PLA2 from binding to 
the liposome surface.  On the contrary, PEG-lipid addition enhanced PLA2 activity due to the 
anionic headgroup of the PEG-lipid.112-114 
So far, the literature has presented two liposome designs: one is composed of different 
lipids and the other is formed by prodrug-lipid conjugates.  Thompson and co-workers designed 
a cascade liposomal system that utilizes liposome photooxidation and contents release to activate 
PLA2.115  This method employs a mixture of two liposomes, one composed of a photosensitive 
synthetic lipid, namely 1,2-dihexadec-1’-enyl-sn-glycero-3-phosphocholine (DPPIsCho) in 
conjunction with Ca2+, and the other composed of 1,2-dihexadecanoyl-sn-glycero-3-
phosphocholine (DPPC) with the DPPC liposome containing the encapsulated fluorophore 
calcein.  Upon light irradiation at 800 nm, the photosensitive liposome released Ca2+ ions thereby 
promoting PLA2 activation which lead to a 50% calcein release in 40 min.  A few years later, 
Davidsen et al. developed an experimental model using liposomes composed of 1,2-
dihexadecanoyl-sn-glycero-3-phosphocholine/1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(poly(ethylene glycol))-2000], (DPPC/DPPE-PEG2000); these 
were activated by PLA2 that caused destabilization of a second type of liposome inert to PLA2 
activity (mimicking stability of a target cell).116  Specifically, the generation of lysolipids and 
fatty acids by PLA2 from a DPPC/DPPE-PEG2000 liposome caused cargo leakage from the inert 
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liposomes 1,2-O-octadecyl-sn-glycero-3-phosphocholine (1,2-di-O-SPC) that were in close 
proximity to the DPPC/DPPE-PEG2000 liposomes. 
Anticancer ether lipids (AELs) are a class of drugs that inhibit tumor cell growth without 
causing mutagenic or myelosuppressive effects.9  However, the use of AELs was limited by 
severe hemolysis.9  In order to circumvent this issue, Andresen and co-workers synthesized AEL 
prodrugs (proAELs) to be included into a liposomal formulation sensitive to PLA2.117,118  
ProAEL liposomes successfully delivered the AELs into tumor cells showing no hemolytic 
toxicity.117-119  Very recently, Andresen et al. reported the synthesis of retinoid phospholipid 
prodrugs and proved that those pro-lipids can form liposomes sensitive to PLA2.  The ProAEL 
structures and their mechanism of release are represented in Figure 1.8.  In addition to the work 
made by the Andresen group, Linderoth and co-workers reported the synthesis of a thio-ester 
anticancer ether lipid (S-ProAEL) and subsequent liposome formulations that were also sensitive 
to the enzyme PLA2.120    
 
Figure 1.8. ProAELs structures and mechanism of AELs release in the presence of PLA2.  
Adapted from Andresen (2005).9   
 
1.3.5 Matrix Metalloproteinase (MMP) 
 Matrix metalloproteinases (MPPs) are zinc-dependent endopeptidases (they break peptide 
bonds of nonterminal amino acids) that together can degrade all components of the extracellular 
matrix (ECM).121  There are 21 members of the MMP family located in the membrane, as well as 
in the extracellular environment.121  Most of the MMPs secreted by cells are inactive zymogens 
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(or proenzyme, inactive enzyme precursors) that require proteolytical activation by tissue or 
plasma proteinases, bacterial proteinases or others MMPs.121  From the 21 MMPs known, MMP–
2 (Gelatinase A) and MMP–9 (Gelatinase B) have been exploited for prodrug and liposome 
activation, because high levels of these enzymes are present in a variety of tumor cells, such as 
bladder, colorectal, gastric, lung, and ovarian with all of these causing poor prognosis and 
survival rate.121  MMP–2 has a molecular mass of 72 kDa in the inactive form and 62 kDa in the 
active form, while MMP–9 has a molecular mass of 92 kDa in the inactive form and 82 kDa in 
the active form.122  X-ray structures for both proenzymes have been reported.123,124  The 
structures of MMP–2 and MMP–9 are very similar; they both have two zinc ions in the catalytic 
site and three calcium ions in different parts of the enzyme.123,124  They also share the same 
number of domains consisting of the N-terminal propeptide domain (where the enzyme is 
activated), the catalytic domain (S1' pocket), the C-terminal domain and an additional three- 
tandem fibronectin type II (FnII) domain (4 versus 3 in the other MMPs).124  The major 
differences between MMP–2 and MMP–9 rely on the side chain of Arg424 in MMP–9 that is 
angled slightly away from the S1' pocket when compared with the corresponding residue in 
MMP–2 (Thr424) and on the position of the second FnII domain.124 
  The mode of action of the MMPs is cleavage of the peptide sequence, acetyl-L-prolyl-L-
leucyl-glycyl-L-leucine (Ac-Pro-Leu-Gly-Leu), at the Gly-Leu bond.125  Thus, prodrugs 
derivatized with that peptide should be substrates for MMP–2 and MMP–9, as envisioned by 
Kline and co-workers, who synthesized four peptides and four peptidomimetic compounds.  
From the 8 molecules synthesized, only two peptides were substrates for the enzymes, with one 
having higher cleavage rates for MMP–9.125  Likewise, Chau et al. synthesized dextran-peptide-
methotrexate conjugates for drug delivery in tumors that expressed MMP–2 and MMP–9.  Pro-
Val-Gly-Leu-Ile-Gly was the optimal peptide linker between the fully neutralized dextran and 
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the methotrexate drug.126  This new peptide prodrug exhibited a bimolecular rate constant 
(kcat/Km) of 1.21 × 105 M–1 s–1 for MMP–2 and 3.60 × 103 M–1 s–1 for MMP–9. 
 Prodrug activation by MMPs gave the precedent for the design of triggerable liposomes 
capable of releasing their contents via MMP activation.  Triple helical collagen-mimetic peptides 
conjugated to stearic acid (lipopeptides), along with 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC), were used to form the first liposomal formulation to be activated by MMP-9 which 
causes bilayer destabilization and release of liposomal contents.127  In a later paper, the authors 
showed the mechanistic studies of liposomal formulations composed of three different 
lipopeptides integrated with 1-palmitoyl-2-oleoy-sn-glycero-3-phosphocholine (POPC), 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC) or DSPC lipids.128  Those studies concluded that 
the rate and extent of leakage was dependent on MMP–9 concentration, and that upon MMP–9 
activation, release of contents occurs due to lipid mismatch between the lipopeptide and the other 
lipids present in the liposome.  Moreover, they proved that the lipopeptide liposomes did not 
release their contents in the presence of trypsin, even though the individual peptide is a substrate 
of the enzyme.129  Recently, the same research group reported the release profile of liposome-
encapsulated carboxyfluorescein in the presence of cancer cells.130  They observed a 40% release 
in the presence of MCF7 cells (high levels of MMP–9) in 30 min versus a 10% release when 
liposomes where incubated with HT-29 cells (low levels of MMP–9) in the same amount of time. 
 In addition to the release mechanisms mentioned above, a different research group 
investigated the interactions between PEG-peptide-DOPE-liposomes and MMP–2.131  They 
found that MMP–2 hydrolyzed the peptide between PEG and DOPE.  This indicates that the 
inclusion of PEG in the liposomal system to increase circulation time in vivo did not prevent 
MMP–2 from accessing the peptide substrate. 
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1.4 NAD(P)H:Quinone Oxidoreductase Type-1 (NQO1) 
 Prodrug activation by oxidoreductase enzymes other than NQO1, as well as enzyme-
responsive liposomes, were discussed previously.  This section will review NQO1 
characteristics, as well as the different approaches to target NQO1 for cancer treatment.       
1.4.1 Origin, Types, Structure, Mechanism, Location and Over Expression 
 NAD(P)H:quinone oxidoreductase Type-1 (NQO1, DT-diaphorase, EC 1.6.99.2) was 
accidentally discovered in 1955 and 1956 by Drs. Lars Ernster and Franco Navazio.132,133  The 
first published report (1958) of NQO1 described the enzyme as a soluble diaphorase found in 
animal tissue.134  The term DT-diaphorase came later in order to differentiate NQO1 from other 
diaphorases specific to NADH135 or NADPH.18  DT-diaphorase (NQO1) has the ability to accept 
electrons from the cofactors NADH (initially called DPNH) and NADPH (initially called 
TPNH).136  Today, DT-diaphorase officially corresponds to NQO Type 1 (NQO1).137  NQO has 
five genetic loci: NQO1 and NQO2 correspond to the human genes, as well as other mammals; 
NQO3 belongs to eubacteria; NQO4 belongs to fungi; and NQO5 belongs to archaebacteria.137  
 NQO1 is a homodimeric flavoprotein of 62 kDa containing 273 amino acids; each of the 
monomers has a non-covalently but tightly-attached FAD prosthetic group that remains bound 
during the catalytic cycle.138,139  The amino acid sequences and crystal structures of rat,138 
mouse139 and human139 NQO1s have been determined and are an important tool in identifying 
the similarities and differences among them.     
In 1995, Li and co-workers reported the crystal structure of rat NQO1 (rNQO1) 
complexes with duroquinone and cibacron blue (2.1 Å resolution), where each subunit was 
shown to contain two separate domains: a major, catalytic domain (residues 1-220) folded in a 
predominantly α/β structure, and a small, C-terminal domain (residues 221-273).138  The 
isoalloxazine moiety of the FAD interacts with different enzyme residues; the major interactions 
are those with aromatic residues Tyr104, Trp105, Phe106 and Leu103.138  The oxygen atoms on 
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the isoalloxazine ring form hydrogen bonds with the –NH of Phe106 and Gly150, whereas the 
nitrogen atoms of the isoalloxazine ring form hydrogen bonds with the –NH of Gly149 and 
Trp105 as described in Figure 1.9.138  The nicotinamide of NADP+ is stacked on top of the ring 
that contains the methyl groups of the isoalloxazine at a distance of approximately 3.4 Å.  The 
nitrogen atom on the amine attached to the carbonyl group on the NADP+ makes hydrogen bonds 
with the –OHs (hydroxyl groups) of Tyr126 and Tyr128.138 
  Fifteen years later, the crystal structure of human NQO1 (hNQO1) containing only the 
FAD prosthetic group (1.7 Å resolution), as well as the crystal structure of mouse NQO1 
(mNQO1, 2.8 Å resolution) revealed that most of the FAD-enzyme interactions in human and 
mouse NQO1 are highly homologous to those described in the structure of rat NQO1, Figure 
1.9.139  The residues' interaction with the cofactor of NQO1 were identified in the 
rNQO1/NADP+ structure; however, in human and mouse NQO1s, residues in loop 9 shift their 
positions by several Å, thereby closing the cleft.  Moreover, Tyr128 retrocedes from the cleft, 
resulting in widening of the cleft by 0.5 Å in hNQO1 relative to rNQO1. 139 
  
Figure 1.9. Schematic representation of FAD interactions with rat NQO1 (A) and human NQO1 
(B).  A) Shows hydrogen bonds of FAD with residues.  W means water.  B) Shows hydrogen 
bonds and van der Waals interactions of FAD with hNQO1.  Open radiated circles indicate 
hydrophobic interactions.  Hydrogen bonds are represented by dashed green lines; water 
molecules are shown as blue filled circles.  Adapted from Li (1995)138 and Faig (2000).139 
 
Overall, the sequence and structural similarities between hNQO1 and mNQO1 and 
hNQO1 and rNQO1 are both 86%, while it is 94% between mNQO1 and rNQO1.139  The 86% 
similarity between rat and human NQO1 accounts for a difference of 37 amino acids.140  The 
A B 
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major differences involve the replacement of Tyr104 present in the rNQO1 with Gln104 in the 
hNQO1 and mNQO1 structures, along with the absence of several water molecules in the 
rNQO1.139  Comparison of the X-ray structures of hNQO1 and mNQO1 versus rNQO1 shows 
replacement of the bulky aromatic residue (Tyr104) with a smaller aliphatic residue (Gln104) 
increases the space in the binding pocket of hNQO1 and mNQO1, thus allowing the 
dimethylbenzene ring of the FAD (ring C in Figure 1.9 (B)) to be located 0.5–0.7 Å deeper in the 
enzyme cavity.139,140  Those differences are reflected by the ability of NQO1 to activate different 
antitumor compounds, such as Mitomycin C and Streptonigrin (both with 5-fold lower rates for 
hNQO1 versus rNQO1).141  In addition, Walton et al. have found that rNQO1 and hNQO1 
catalyzed the reduction of menadione with a similar Km (1.4–3.1 µM) but the Vmax was 7 to 8-
fold lower for hNQO1.142  The same authors found that rNQO1 readily reduced the antitumor 
agent, EO9; however, no activity could be detected with hNQO1.142  Mutation studies replacing 
residues in rNQO1 with the human sequence and residues in hNQO1 with the rat sequence have 
shown that amino acid 104 (Tyr in rat and Gln in human) accounts for the catalytic differences 
between hNQO1 and rNQO1.143  Therefore, it is important to assay quinoid substrates with 
human NQO1 and not to rely on the data described for rat NQO1. 
The catalytic site has three distinct regions in all types of NQO1: one that binds to FAD, 
one that binds to the adenine ribose portion of NAD(P), and one that binds to either the hydride 
acceptor (substrate) or the hydride donor (NADH or NADPH).139  The binding pocket where the 
substrate and the cofactor bind has an internal wall (Phe106, Gly174, Phe178, Trp105), a floor 
(isoalloxazine ring), a roof (Tyr126, Tyr128) and an entrance (Gly149, Gly150, His194, 
Pro68).139  The non-occupied substrate binding pocket is 10 Å wide, 9 Å deep and 4 Å high.139  
Comparison of the X-ray structure of apo-hNQO1 (no quinone substrate present) with that of the 
hNQO1/duroquinone complex shows that duroquinone binds to the enzyme mainly by 
hydrophobic interactions, and that the plane of the quinone ring stacks 3.5 Å from the 
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isoalloxazine ring of hNQO1.139  It also revealed that Tyr128 adopts different conformations, 
resulting in opening and closing of the binding site.139   
NQO1 follows a ping-pong mechanism where the cofactor (NADH or NADPH) binds to 
NQO1 and donates a hydride to reduce FAD to FADH2.  Then, the cofactor leaves the binding 
pocket and a quinone binds to NQO1 and gets reduced to hydroquinone.18  This direct two-
electron reduction of quinones is unique among the reductive enzymes.18,144  In the X-ray 
structure of the hNQO1/duroquinone complex, it is shown that the closest distances from the 
flavin N5 (hydride donor) to the possible atom acceptors (of the hydride ion) in the quinone are 
4.5 Å to oxygen, 4.1 Å to carbon, and 3.55 Å to the other carbon.139  The details of the reduction 
of quinone to hydroquinone by the NQO1 mechanism are not fully understood, but it is believed 
residues Tyr155 and His161 play an important role in the charge stabilization of NQO1 during 
the hydride transfer process.138,145   
For the most part, NQO1 is located in the cytosol of cells, but it has also been found in 
the nucleus,146 membrane,147 endoplasmic reticulum,148 mitochondria,18,149 and in the 
extracellular environment.150  In human tissue, NQO1 has been primarily detected in epithelial 
and endothelial cells,3,4,151 and it is over expressed in various solid tumors, such as those of the 
liver (20 to 50-fold),1 lung (12 to 18-fold),3,11 pancreas,152 colon (3 to 4-fold)11 and breast (3-
fold).11  For that reason, hNQO1 is a promising target for bioreductive activation of therapeutic 
agents. 
1.4.2 Inhibitors of Human NQO1 
 NQO1 is considered a detoxifying enzyme because it prevents superoxide formation by 
reducing quinone radicals (before they react with molecular oxygen to form superoxides) to the 
less damaging hydroquinone compounds.153,154  Therefore, deactivation of NQO1 will lead to 
superoxide accumulation and cell death.  Dicoumarol is the best known competitive inhibitor for 
NQO1 with respect to the cofactors NADH and NADPH.18  The major problem with the use of 
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dicoumarol is its non-specific nature and ability to inhibit other enzymes besides hNQO1.155,156  
In addition, the effective concentration of dicoumarol that is required to inhibit NQO1 depends 
on the efficiency of the second substrate based on the NQO1 ping-pong mechanism.155  Few 
research groups have been investigating different quinone derivatives as inhibitors of NQO1 to 
use them as a possible route for cancer treatment. 
 The tumor blood-flow inhibitors flavone-8-acetic acid (FAA) and 5,6-
dimethylxanthenone-4-acetic acid (DMXAA) were reported by Phillips as competitive inhibitors 
of hNQO1 with respect to NADH.157  DMXAA and FAA presented relatively high Ki values (20 
µM and 75 µM); however, therapeutically-achievable levels of DMXAA and FAA would be 
sufficient to inhibit hNQO1 activity in vivo (IC50 of 49.6 µM and 110.9 µM).157  It was also 
reported that 3.55 mM of FAA exhibited only 6.51% inhibition on cytochrome b5 activity while 
DMXAA was found to partially inhibit cytochrome b5 (25% inhibition).  The authors also found 
that 1.77 mM of FAA partially inhibited cytochrome P450 while 2 mM of DMXAA had only an 
8.9% inhibition on the same enzyme.157 
Ross and collaborators reported in 2001 a more specific inhibitor (ES936) for hNQO1.158  
ES936 is a mechanism-based inhibitor that depends on NADH to deactivate hNQO1.158  
Incubation of ES936 (2 µM) with NADH (100 µM) and hNQO1 (2 µg·mL–1) resulted in more 
than 99% inhibition of enzyme activity in less than 5 min.158  X-ray, ESI-LC/MS/MS and 
MALDI-TOFMS analysis confirmed alkylation on one of the tyrosine residues (Tyr126 or 
Tyr128) in the active site of hNQO1.158  Later, ES936 analogs were investigated by Ross and 
coworkers as possible inhibitors of hNQO1.159  Growth inhibition activity in MIA PaCa-2 cells 
and computational-based molecular docking simulations revealed that ES936 and analog 2 were 
the best inhibitors of hNQO1 (~95% inhibition) and they stopped cell growth (IC50 of 
approximately 0.63 µM and 0.64 µM).159  Analogs 5, 6, and 7 were found to be good inhibitors 
(~90% inhibition) of hNQO1, but they were not effective in stopping cell growth.159 
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In 2006, Bryce et al. identified novel inhibitors of hNQO1 from the National Cancer 
Institute (NCI) compound database.160  They applied a virtual screening on thousands of 
compounds and narrowed them down to 28 for biological activity testing towards recombinant 
human NQO1.  From those 28 compounds, only the most potent inhibitor (NSC645827) had an 
observed IC50 of 0.7 µM that was comparable with that of dicoumarol (IC50 = 0.45 µM in the 
presence of BSA).160  In 2007, the same research group investigated 26 coumarin analogs as 
inhibitors of hNQO1 from the NCI database.161  Analogs were assayed in the presence and 
absence of BSA, providing information on the effect of nonspecific protein binding.  In the case 
of dicoumarol, it was found that the IC50 = 0.45 µM in the presence of BSA and IC50 = 0.005 
µM in the absence of BSA towards recombinant human NQO1, confirming its non-specific 
nature.161  The best inhibitors in the presence of BSA towards recombinant human NQO1 
comparable to dicoumarol were compound 2, 22, and 23 having IC50 values of 0.35 µM, 0.65 
µM and 0.60 µM, respectively.161  Cell growth inhibition studies on MIA PaCa-2 cell lines in the 
presence of dicoumarol, compound 2, 22 and 23 gave IC50 values of 75, 190, 150 and 140 µM, 
respectively.161  A few years later in a continued study on coumarin analogs, Bryce and 
collaborators investigated 29 dicoumarol analogs (with greater water solubility) as potential 
hNQO1 inhibitors.162  From those 29 analogs, several of them had IC50 values comparable or 
even better than the IC50 value of dicoumarol towards recombinant human NQO1; however, 
none of the analogs were as toxic as dicoumarol when incubated with MIA PaCa-2 or HCT116 
cell lines.162  More recently, Bryce and colleagues reported a range of triazoloacridin-6-ones 
(structurally related to NSC645827) as novel inhibitors of hNQO1.163  In this work, all of the 
fifteen compounds were assayed in the absence of BSA and had an IC50 far from dicoumarol’s 
IC50 value of 0.005 µM towards recombinant hNQO1.163 
In summary, ES936 and analog 2 have been the only reported mechanism inhibitors of 
hNQO1, with IC50 values comparable to that of dicoumarol.  In spite of the effort made by 
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research groups to find better inhibitors on structurally similar dicoumarol compounds, 
dicoumarol is still the most potent inhibitor of hNQO1.  Today, there are a handful of X-ray 
structures of hNQO1/inhibitor complexes that has been solved to gain an understanding of the 
mechanism of action of the different inhibitors and for the development and identification of 
additional potent inhibitors of hNQO1.158,162,164 
1.4.3 Bioreductive Drugs Activated by Human NQO1 
 NQO1 is known to reductively activate anticancer agents, such as mitomycins (MMC), 
aziridinyl benzoquinones (AZQ, MeDZQ, RH1), indolequinone EO9, streptonigrin, β-lapachone 
and benzoquinone ansamycins.19,43,154,165,166  The mechanism of action of those antitumor agents 
depends on the reactivity of the corresponding hydroquinone, Figure 1.10.43 
 
Figure 1.10. Mechanism of action of antitumor agents after bioreductive activation by human 
NQO1.  Adapted from Siegel (2008).43 
 
Mitomycin C (MMC) is one of a series of mitomycin antibiotics isolated in the late 
1950s.167 It was found to be effective towards different human tumors,168 but there has been 
controversy with respect to hNQO1 activation of MMC.  In the presence of air, hNQO1 activates 
MMC in a pH-dependent manner;169,170 however, under hypoxic conditions, hNQO1 detoxifies 
the drug.165  Despite this controversy, there is agreement that hNQO1 is the enzyme that 
activates MMC which in turn results in DNA crosslinking.  Experiments with HT-29 (high 
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hNQO1 expression) and BE (deficient hNQO1 expression) cells have shown that cells with high 
expression of hNQO1 are about 6-fold more sensitive to MMC.170  However, it has become 
evident that superior substrates for hNQO1 exist, and that the response to MMC in vivo cannot 
be predicted on the basis of hNQO1 activity.19,171,172 
EO9 is an indolequinone antitumor drug developed to undergo bioreductive activation 
similar to MMC.43,173  Beall et al. found that EO9 was a good substrate for hNQO1, having a Km 
value of 13.6 µM and a kcat value of 778 min–1.  They also observed that the reduction rate of 
EO9 by hNQO1 was 50% faster than that of MMC at a 50 µM quinone concentration.172  
However, EO9 failed to demostrate a significant antitumor response in clinical trials because its 
poor pharmacokinetics properties, such as short half-life and poor tissue penetration.17,174,175 
Aziridinylbenzoquinones are another class of DNA alkylating quinones.  In this series, 
MeDZQ was found to have a better response than AZQ toward killing HT-29 human cell (high 
hNQO1 expression) with IC50 values of 0.075 and 7.6 µM, respectively.176  The same 
compounds were tested later against recombinant hNQO1.  It was observed that MeDZQ was an 
excellent substrate with a reduction rate of 860 µmol·min–1·µmol–1, while the AZQ reduction 
rate was 160 µmol·min–1·µmol–1, both at a 100 µM quinone concentration.141 However, 
MeDZQ’s use was limited by its poor solubility.19  A few years later, Ross and coworkers 
identified a new azidinybenzoquinone, RH1, as an NQO1-directed antitumor agent.177  RH1 had 
an increased solubility versus MeDZQ and was found to be more effective than MeDZQ towards 
recombinant human NQO1 at a 50 µM quinone concentration (NADH oxidation rates RH1 = 
45.2 µmol·min–1·mg–1 and MeDZQ = 21.6 µmol·min–1·mg–1).177  RH1 toxicity was confirmed 
toward high expression NQO1 human cell lines (H460 and HT29), with IC50 values of 0.002 and 
0.011 µM, respectively.177  It was also reported that bioreductive activation of RH1 by other 
reductive enzymes would be unlikely because high concentrations of RH1 (0.5 µM) will be 
required for that to happen, while 0.05 µM of RH1 is already enough to produce 100% DNA 
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cross-linking on human blood mononuclear cells.178  RH1 has also proven to be efficient against 
paediatric tumor cell lines.179  Furthermore, RH1 has recently completed Phase I trials in adults 
in the United Kingdom and further clinical evaluation is ongoing.179 
Streptonigrin (SN) and β-lapachone (β-lap) are examples of redox-cycling quinones.43  
Streptonigrin was found to be the best substrate when compared to MeDZQ and EO9 towards 
recombinant hNQO1 with a Km value of 35.6 µM and a kcat value of 7,320 min–1 (MeDZQ 
values were 33.2 µM and 3940 min–1 and EO9 values were 13.6 µM and 778 min–1).172  The 
same study reported SN as the antitumor agent with better selectivity ratios (86-fold more toxic) 
when compared with the IC50 of human cell lines H596 (deficient in NQO1) with H460 (high 
NQO1 expression).172  In addition, it was reported that SN was much more cytotoxic towards 
human colon carcinoma cell line HT-29 with high NQO1 expression than human colon 
carcinoma BE (deficient NQO1 activity).180  In the 1960s, clinical use of SN was limited by 
myelotoxicity.181,182  β-lap was found to have enhanced cytotoxicity towards breast cancer cells 
expressing NQO1 versus deficient NQO1 cell line.  It was determined that 4 µM of β-lap was 
sufficient to kill over 99% of the cells with high NQO1 content.183  β-lap was also found to be an 
efficient  cytotoxic compound towards human pancreatic cancer cells (MIA PaCa-2) that over-
express NQO1.184,185 
 Benzoquinone ansamycin compounds such as geldanamycin, 17-AAG, 17-DMAG, and 
17AG have been identified as substrates for hNQO1; these compounds generate a hydroquinone 
that inhibits the heat shock protein 90 (HSP90), causing degradation of several important 
oncogenic client proteins.43,186  In two independent in vitro studies between the lead 
geldanamycin derivative 17-AAG and human cancer cell lines, a positive relationship was 
observed between hNQO1 expression level and growth inhibition by 17-AAG.187  Moreover, 
Guo and coworkers have reported a detailed study of the reduction of 17-AAG to 17-AAGH2 by 
hNQO1 and its 12-fold increase in growth inhibition towards MDA468/NQ16 cells (high 
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hNQO1 content) versus MDA468 cells (deficient hNQO1 content) based on its IC50 values.188  A 
year later, Guo and coworkers extended their detailed study to the reduction 17-AAG analogs by 
hNQO1 and found that these analogs also presented higher sensitivity towards MDA468/NQ16 
cells versus MDA468 cells.189  17-AAG and 17-DMAG (a more water soluble derivative of 17-
AAG) were found to be the most sensitive compounds in the series and are currently in clinical 
trials.189         
Out of all the bioreductive drugs mentioned above, just a few like RH1 are still in clinical 
trials.  The structures of the different bioreductive drugs that did not make it out of the clinical 
trials have been taken as models to design analogs that could have better response in cancer 
treatments.190  In the last 15 years, several research groups have emphasized their work on the 
structure–activity relationships between antitumor agents such as indolequinones,191-195 
benzoquinone mustards,196,197 benzimidazoles,198 quinolinequinones,199 lavendamycins200 and 
human NQO1 with the aim of finding new therapeutic agents.  Among the antitumor compounds, 
indolequinone analogs received the most attention as a possible prodrug system.16,190  Following 
this strategy, Borch et al. examined the delivery of phosphoramide mustards attached to 
indolequinones by hNQO1 activation.  The authors found that compounds substituted at the 2-
position were excellent substrates for hNQO1 (kcat/Km = (2–5) × 106 M–1·s–1) and potent 
inhibitors of cell growth with GI50 (growth inhibition) values in the low micromolar to 
nanomolar range.201 To date, none of the analogs developed have been approved for clinical 
use.17  In addition, the X-ray structure of three antitumor quinones (ARH019, RH1, EO9) 
complexed with human NQO1 were reported to improve the knowledge regarding the interaction 
of model compounds and hNQO1.202   
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1.4.4 Prodrugs Presenting the Trimethyl-Lock System Activated by Human NQO1 
  This section will focus on the quinone moieties, which after being reduced by hNQO1; 
release their cytotoxic agents by intramolecular cyclization facilitated by the presence of the 
trimethyl-lock system. 
 Chikhale et al. investigated benzoquinone-prodrugs (TDDS) that can selectively deliver 
the anticancer drug methylester of melphalan (MME) based on their electronic nature.203,204  The 
authors found that TDDS presenting less negative reduction potential had a higher amount of 
TDDS reduced under reductive chemical conditions and the extent of drug-delivery was 
proportional to the amount of TDDS reduced.203  In their follow up paper, they reported TDDS 
reduction by purified hNQO1 and found that the H-TDDS analog had the fastest rate of 
reduction followed by the Br-TDDS analog based on their t1/2 values of 3 min and 15 min, 
respectively.204  
 In 2007, Volpato et al. reported the human NQO1 activation of a benzoquinone prodrug 
conjugated to a 4-aminophenyl nitrogen mustard with a Km value of ~ 3 µM and a Vmax value of 
~ 12 µmol·min–1·mg–1.205  The authors identified the formation of lactone and 4-aminophenyl 
nitrogen mustard using LC/MS after the prodrug was reduced by hNQO1 in a cell free assay.  In 
addition, chemosensitivities studies show the prodrug is selectively toxic to cells that have 
elevated levels of NQO1 (H460) versus cells that are NQO1-deficient (BE) with IC50 values of 
36 µM and greater than a 100 µM, respectively.205 
 More recently, Moody and colleagues reported a benzoquinone prodrug conjugated to an 
antiangiogenic agent (SU5416) derivative as a potent inhibitor of the vascular endothelial growth 
factor (VEGF).206  The authors proved 100% inhibition of VEGF-stimulated angiogenesis in 
HUEVs (human umbilical vein endothelial cells with NQO1 expression) by addition of 10 µM of 
two different benzoquinone prodrugs conjugated with SU5416. 
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CHAPTER 2 
ELECTROCHEMICAL BEHAVIOR OF QUINONE DERIVATIVES POTENTIALLY 
USABLE FOR DRUG DELIVERY APPLICATIONS 
 
2.1 Introduction 
Quinones are known to be electrochemically active and undergo a two-electron, two-
proton reduction in aqueous media where the pH is below the pKa of the corresponding 
hydroquinone1 as presented in Scheme 2.1.  Electrochemical techniques, such as cyclic 
voltammetry (CV), can provide important thermodynamic as well as kinetic information on 
quinone-related compounds.2  The electrochemical properties of quinones can be tuned by subtle 
structural changes of the quinone moiety by adding a functional group or a handle, such as a 
propionic acid chain; in that way, the electronic properties of these compounds can be affected 
and a change in their reduction potential is possible.   
The goal of this work is to construct a series of quinone derivatives with various 
electronic properties that will be later tested with the human enzyme NAD(P)H:quinone 
oxidoreductase type 1 (hNQO1), which is known to reduce quinones to hydroquinones;3-5 thus 
these quinones may be used as triggers for endogenous target activation.  More explicitly, the 
research in the McCarley group focusses on the use of quinone triggers in the formation of 
enzyme-responsive liposomes for drug delivery applications.  It is known that the half-wave 
reduction potential of the flavin adenine dinucleotide (FAD) center of  rat NQO1 is –0.159 V vs. 
the standard hydrogen electrode (SHE).6  This enzyme follows a ping-pong mechanism using 
reduced nicotinamide adenine dinucleotide (NADH) or reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) as the electron source.  It is also known that the reduction 
potentials of NADH/NAD+ and NADPH/NADP+ are –0.310 V and –0.320 V versus SHE, 
respectively.7,8   
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To successfully assess the quinones as substrates of  hNQO1, it is necessary that their 
reduction potential be more positive than –0.159 V, but not so positive that the quinone substrate 
is possibly reduced directly by NADH or NADPH, as previously demonstrated in the literature 
for simple quinones.8  In addition, it is important to tune the reduction potential of quinone 
triggers to prevent non-specific interactions with potential reducing species that are endogenous 
in biological environments, such as glutathione (E1/2 = –0.22 V vs. SHE)9 and ascorbate (E1/2 = 
0.051 vs. SHE),10 so as to avoid the opening of  liposomes at undesired locations.  The 
thermodynamic parameters of cathodic reduction peak (Ep,c), anodic oxidation peak (Ep,a) and 
half-wave potential  (E1/2) of quinone derivatives were measured.   The half-wave potentials 
were calculated using Equation 2.1. 
𝐸1
2
= �∆𝐸p
2
�+ 𝐸p, c                                                 Equation 2.1 
Moreover, it has been well established in earlier works that quinones possessing a 
trimethyl-lock system (R3 = R4 = R5 = CH3) experience an intramolecular cyclization passing 
through a tetrahedral intermediate after being reduced to the corresponding hydroquinone and 
forming the lactone compound as is depicted in Scheme 2.2.11  Such a reduction/cyclization 
process for propionic acid quinones is also thought to be dependent on the reduction potential 
(electronic properties) of the corresponding quinone; thus, the rate constant for the disappearance 
of hydroquinone was calculated using the peak current ratios (ip,a/ip,c) and their evaluation by the 
Nicholson and Shain method.12,13  Therefore, it may be possible to estimate the time for release 
of a target, such as a drug to be delivered after reduction occurs on the quinone moiety.   
O
O
OH
OH
+ +2 H+ 2 e-
 
Scheme 2.1. Reduction of 1,4-benzoquinone to 1,4-hydroquinone. 
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Scheme 2.2. Cyclization process of trimethyl-lock propionic acid 1,4-benzoquinones. 
 
2.2 Experimental Section 
2.2.1 Materials and Methods 
Quinone synthesis was previously described by a colleague in our group.14  Cyclic 
voltammetry (CV) experiments were performed with a computer-controlled EG&G PAR model 
273 A potentiostat (Princeton, NJ).  The electrochemical cell was composed of three electrodes: 
a (pretreated) glassy-carbon working electrode (A=0.07 cm2, CH Instruments, Austin, TX), a 
homemade 99.9 % platinum counter electrode (d=0.05 cm), and an Ag/AgCl (3.0 M KCl, CH 
Instruments) reference electrode.  The procedure starts with the polishing of the carbon electrode 
on a Buehler microcloth with 1 micron alpha alumina slurry micropolish, followed by 
pretreatment of this electrode by applying +1.5 V for 10 minutes while the electrode is immersed 
in the buffer solution used for the evaluation of the quinones. Polishing the working electrode 
eliminates any species that the electrode may absorb, and pretreatment activates the surface of 
the electrode, permitting a reproducible electron transfer at the working electrode surface.15  
Scans were conducted at a rate of 0.1 V s–1 at room temperature (22±2 °C) in a degassed 0.1 M 
phosphate buffer (PB)/0.1 M KCl (pH=7.1).  Each solution was degassed with nitrogen for 10 
min before obtaining the voltammogram.  Before the quinone was tested, the buffer was scanned 
to confirm a clear background with no unexpected peaks present.   Each individual quinone was 
tested on a different day, with 4 replicates per day.  Between replicates, no polishing or cleaning 
of the electrodes was performed.  Quinone solutions contained 1% ethanol or where sufficiently 
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soluble, solutions were sonicated for 30 min to ensure complete dissolution in the buffer 
solution; quinone concentrations ranged from 0.3 to 1 × 10-3 M. 
2.3 Results and Discussion 
2.3.1 Thermodynamic Parameters of Naked Quinones 
In Table 2.1 are summarized the thermodynamic results for six naked (not containing 
propionic acid) quinones whose voltammograms are presented in Figure 2.1.  It can be noted that 
all of the naked quinones, except the QBr, deviated from the ideal peak separation (ΔEp) of 30 
mV that corresponds to a total two proton/two electron reversible system.16  Instead, these 
compounds follow the behavior of a quasireversible system, which may be due to the slow 
electron transfer kinetics at the electrode surface.17-19  Therefore, the half-wave potential (E1/2) of 
each of the naked quinones was used as an approximation of the formal potential (E°') in these 
systems. 
Theoretically, quinones with electron withdrawing groups (EWG) attached to the ring 
will possess a more positive reduction potential (easier to reduce); while for quinones with 
electron donating groups (EDG), the opposite should happen.  In Table 2.1, it can be seen that 
1,4-benzoquinone is the easiest quinone to be reduced with a peak cathodic potential (Ep,c) of 
0.286 V and an E1/2 of 0.326 V.  When functional groups are added to the benzoquinone, its 
potential changes following a trend close to our expectations with E1/2 values of 0.220 V for QBr, 
0.212 V for QH, 0.196 V for QdiMeO, 0.155 V for QMe, and 0.078 V for DQ.  QBr, where bromine 
has the property of withdrawing electron density from the quinone moiety by the inductive 
effect, has a more positive Ep,c and E1/2 than the hydrogen, methoxy and methyl analogs, as I 
anticipated.  Even though the trend was clear, when comparing the QBr to the QH, the difference 
in the half-way potential was only 0.008 V more positive for the bromine analog.  This similarity 
of potential between QH and QBr may be explained by the inductive effect of the bromine being 
counteracted by a resonance effect and a lone pair contribution to the electron density of the 
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quinone moiety by the halogen as reported in earlier work.20  Another interesting observation 
was the dimethoxy substituted quinone case; QdiMeO was expected to be more negative than the 
methyl analog due to its strong resonance effect; however, the opposite was observed.  A 
colleague in our group determined the crystal structure of QdiMeO and observed that one of the 
methoxy groups is twisted from the quinone plane when two methoxy groups are adjacent on the 
quinone ring.14  Such a conformation for the QdiMeO results in a decrease of the resonance effect.  
This finding was supported by previous research groups that came to the same conclusion for 
quinones where two adjacent methoxy groups are present.21,22    
Table 2.1. Thermodynamic results for naked quinones.  Potential scans were conducted at a rate 
of 0.1 V s–1 at 22±2 °C in a pH 7.1 0.1 M PB/0.1 M KCl buffer solution.  A three-electrode cell 
was used containing a glassy carbon electrode, a platinum counter electrode, and an Ag/AgCl 
(3M KCl) reference electrode.  Potentials were converted to values versus the standard hydrogen 
electrode (SHE) by adding 0.210 V.23  Results are reported as the mean of 4 replicates ± one 
standard deviation. 
Quinone Ep,c (V) vs. SHE Ep,a (V) vs. SHE ΔEp (V)  
E1/2 (V) vs. 
SHE 
O
O  
BQ 
0.286±0.001 0.365±0.001 0.079±0.001 0.326±0.001 
O
O
Br
 
QBr 
0.202±0.000 0.239±0.001 0.037±0.001 0.220±0.001 
O
O  
QH 
0.176±0.000 0.249±0.000 0.073±0.000 0.212±0.001 
O
O
O
O
 
QdiMeO 
0.143±0.000 0.249±0.003 0.106±0.003 0.196±0.002 
O
O  
QMe 
0.107±0.001 0.204±0.000 0.097±0.001 0.155±0.001 
O
O  
DQ 
0.033±0.001 0.123±0.001 0.090±0.000 0.078±0.001 
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Figure 2.1. Cyclic voltammograms of naked quinones.  Potential scans were conducted at a rate 
of 0.1 V s–1 at room temperature (22±2 °C) in a pH 7.1 0.1 M PB/0.1 M KCl buffer solution.  A 
three-electrode cell was used containing a glassy carbon electrode (A=0.07 cm2), a platinum 
counter electrode, and an Ag/AgCl (3M KCl) reference electrode (0.210 V vs. SHE).23  Potential 
sweeps started at 0.6 V to –0.6 and back to 0.6 V.  Positive current peak corresponds to the 
reduction peak (Ep,c) and negative current corresponds to oxidation peak (Ep,a). Colored lines 
represent 4 trials performed on each quinone and dashed line represents the buffer solution. 
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2.3.2 Thermodynamic Parameters of Propionic Acid Quinones and QMe-ETA 
In Table 2.2 are shown the thermodynamic values for eleven propionic acid quinones and 
one quinone propionic acid derivatized with an ethanolamine group.  In Figure 2.2 are contained 
the voltammograms for each of the quinone compounds mentioned above.  All the quinones in 
Table 2.2, with the only exception being NQ-COOH, had a ΔEp ranging between 0.242 V and 
0.446 V meaning, that these systems are electron-transfer irreversible.  This is not surprising, as 
the quinone propionic units have disturbed benzoquinone rings,14 while the conversely 
hydroquinone rings are expected to be planar.24  Thus, there is a significant change in ring 
geometry during the electron-transfer process that should lead to kinetics sluggishness.   
To compare the electronic properties of the various quinones, the reduction peak (Ep,c) 
was selected, as it is a better approximation for the reduction potential than  E1/2 for this type of 
system.  In Table 2.2, the first 10 quinones are subdivided into two groups: quinones without a 
trimethyl lock system (quinones 1–3) and quinones possessing it (quinone 4–10).  In the first 
group (NQ-COOH, Q’-COOH, QnogemMe-COOH), the Ep,c decreases from 0.249 V to 0.004 V 
when methyl groups are added to the quinone ring, as expected because methyl functions as an 
electron donating group and will provide electron density to the ring, resulting in a lower 
reduction potential for the quinone (harder to be reduced).  In the second group are quinones 
where the only difference is the functional group at the 2-position on the ring.  How much an 
electron donating or withdrawing group affects the reduction of quinones is represented clearly 
in this series.  When a halogen (Br or I) is attached to the quinone propionic acid, the Ep,c is –
0.026 V and  –0.047 V, respectively, and thus are the easier quinones to reduce in the series.  
When an electron donating group, such as methoxy or methyl, is present, the Ep,c value shifts 
negatively to  –0.107 V and –0.125 V, respectively.  It is interesting to observe that the more 
negative value of Ep,c between QMeO-COOH and QMe-COOH, corresponds to the methyl analog 
and not to the methoxy analog, as it was expected.  This result, opposite to what it was 
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anticipated, may be due to the not planar conformation that a methoxy group (hindered by a 
methyl at the 3-position) can acquired with respect to the quinone ring which will decrease the 
electron density contribution that the methoxy group can bring to the quinone.22  Moreover, 
when the functional group at the 2-position on the quinone ring is an n-propyl amine or a methyl 
amine, the reduction peak shifts even further negative achieving a value of –0.188 V and –0.219 
V respectively.  Such a strong electron density on the quinone moiety makes them the hardest in 
this series to be reduced.  The last quinones in Table 2.2 are QdiMeO-COOH and QMe-ETA.  The 
Ep,c of QdiMeO-COOH  differs by only 0.012 V from QMeO-COOH, meaning that addition of an 
adjacent methoxy group does not alter the electronic properties, probably because the quinone 
can receive electron density from just one methoxy group, as stated before for the naked 
quinones.  In the case of QMe-ETA, the electronics are virtually the same as QMe-COOH, 
meaning that the nature of the propionic acid side change (neutral or anionic at pH 7.1) does not 
impact electronic properties of the quinone moiety, as judged by voltammetry. 
Finally, when comparing the naked quinone, such is duroquinone, to the QnogemMe-COOH 
with a propionic acid handle, the reduction peak moves to the negative side by 0.029 V.  
Likewise, when compared QMe to Q’-COOH, having a propionic acid handle that include the 
presence of germinal methyls, the reduction peak moves to the negative side by 0.085 V.  
Moreover, the reduction peak of QMe-COOH, presenting the trimethyl-lock, compared with the 
reduction peak of duroquinone, is 0.158 V more negative.  This confirms the fact that the 
addition of a handle makes the quinones more difficult to be reduced and that this difficulty 
increases as the handle includes germinal methyls or the whole trimethyl-lock system is present.  
The reason for the furthest shift of Ep,c to the negative side, is that the trimethyl-lock induces 
conformational strain onto the quinone ring, resulting in a deviation from a typical planar 
conformation by roughly 20°.  These observations were made from X-ray crystallography on 
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each of these compounds14 and supported by a previous study by Wang et al. that also described 
the strain caused by the trimethyl-lock system.25 
Table 2.2. Thermodynamic results for propionic acid quinones.  Potential scans were conducted 
at a rate of 0.1 V s–1 at 22±2 °C in a pH 7.1 0.1 M PB/0.1 M KCl buffer solution.  A three-
electrode cell was used containing a glassy carbon electrode, a platinum counter electrode, and 
an Ag/AgCl (3M KCl) reference electrode.  Potentials were converted to standard hydrogen 
electrode (SHE) by adding 210 mV.23  Results are reported as the mean of 4 replicates ± one 
standard deviation. aThe anodic peak potential of lactone oxidation, Ep,l, is reported for those 
propionic acid quinones that exhibit this voltammetric feature. 
Quinone Ep,c (V) vs. SHE 
Ep,a (V) vs. 
SHE ΔEp (V)  
E1/2 (V) vs. 
SHE 
Ep,l (V) vs. 
SHEa 
O
O
OH
O
 
NQ-COOH 
0.249±0.002 0.321±0.001 0.072±0.003 0.285±0.001 N/A 
O
O
OH
O
 
Q’-COOH 
0.022±0.001 0.267±0.001 0.245±0.001 0.144±0.001 N/A 
O
O
OH
O
 
QnogemMe-COOH 
0.004±0.002 0.281±0.002 0.277±0.003 0.143±0.002 N/A 
O
O
OH
O
 
QH-COOH 
–0.019±0.002 0.253±0.002 0.272±0.001 0.117±0.002 0.659±0.002 
O
O
OH
O
Br
 
QBr-COOH 
–0.026±0.001 0.216±0.003 0.242±0.004 0.095±0.001 0.706±0.002 
O
O
OH
O
I
 
QI-COOH 
–0.047±0.003 0.289±0.005 0.336±0.008 0.121±0.001 0.711±0.003 
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Table 2.2 continued. 
Quinone Ep,c (V) vs. SHE 
Ep,a (V) vs. 
SHE ΔEp (V) 
E1/2 (V) vs. 
SHE 
Ep,l (V) vs. 
SHE 
O
O
OH
O
O
 
QMeO-COOH 
–0.107±0.002 0.303±0.002 0.410±0.003 0.098±0.001 0.612±0.003 
O
O
OH
O
 
QMe-COOH 
–0.125±0.001 0.218±0.005 0.343±0.007 0.047±0.002 0.615±0.003 
O
O
OH
O
H
N
 
Qn-pr-NH-COOH 
–0.188±0.001 0.144±0.002 0.332±0.003 –0.022±0.001 0.640±0.004 
O
O
OH
O
H
N
 
QMe-N-COOH 
–0.219±0.002 0.165±0.002 0.384±0.005 –0.027±0.001 0.618±0.003 
O
O
OH
O
O
O
 
QdiMeO-COOH 
–0.095±0.000 0.351±0.002 0.446±0.002 0.128±0.001 0.694±0.004 
O
O
N
H
O
OH
 
QMe-ETA 
–0.118±0.002 0.199±0.000 0.317±0.002 0.041±0.001 0.640±0.003 
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Figure 2.2. Cyclic voltammograms of quinones with a propionic acid side chain.  Potential scans 
were conducted at a rate of 0.1 V s–1 at 22±2 °C in a pH 7.1 0.1 M PB/0.1 M KCl buffer solution.  
A three-electrode cell was used containing a glassy carbon electrode (A=0.07 cm2), a platinum 
counter electrode, and an Ag/AgCl (3M KCl) reference electrode (0.210 V vs. SHE).23  Potential 
sweeps started at 0.6 V to –0.6 and back to 0.6 V.  Positive current peak corresponds to the 
reduction peak (Ep,c) and negative current corresponds to oxidation peak (Ep,a). Colored lines 
represent 4 trials performed on each quinone and dashed lines represent the buffer solution. 
-4.0E-5
-3.0E-5
-2.0E-5
-1.0E-5
0.0E+0
1.0E-5
2.0E-5
3.0E-5
4.0E-5
-0.6-0.4-0.200.20.40.6
I (
A
) 
Potential (V) 
NQ-COOH 
Buffer
T1
T2
T3
T4
-2.5E-5
-1.5E-5
-5.0E-6
5.0E-6
1.5E-5
2.5E-5
3.5E-5
4.5E-5
-0.6-0.4-0.200.20.40.6
I (
A
) 
Potential (V) 
Q'-COOH 
Buffer
T1
T2
T3
T4
-2.0E-5
-1.0E-5
0.0E+0
1.0E-5
2.0E-5
3.0E-5
-0.6-0.4-0.200.20.40.6
I (
A
) 
Potential (V) 
QnogemMe-COOH 
Buffer
T1
T2
T3
T4
-2.0E-5
-1.0E-5
0.0E+0
1.0E-5
2.0E-5
3.0E-5
4.0E-5
-0.6-0.4-0.200.20.40.6
I (
A
) 
Potential (V) 
QH-COOH  
Buffer
T1
T2
T3
T4
-2.0E-5
-1.0E-5
0.0E+0
1.0E-5
2.0E-5
3.0E-5
4.0E-5
5.0E-5
-0.6-0.4-0.200.20.40.6
I (
A
) 
Potential (V) 
QBr-COOH 
Buffer
T1
T2
T3
T4
-4.0E-5
-2.0E-5
0.0E+0
2.0E-5
4.0E-5
6.0E-5
8.0E-5
1.0E-4
-0.6-0.4-0.200.20.40.6
I (
A
) 
Potential (V) 
QI-COOH  
Buffer
T1
T2
T3
T4
  
  
  
64 
 
Figure 2.2 continued. 
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2.3.3 Propionic Acid Quinones and Their Cyclization Behavior 
Earlier voltammograms of propionic acid quinones containing the trimethyl-lock system 
dissolved in 50% acetonitrile/buffer solutions, showed a lactone peak appearing when QH-
COOH is reduced to its corresponding hydroquinone.26  The cyclic voltammetry data obtained 
here in aqueous buffer electrolyte on our trimethyl-lock quinones, led to observation of a lactone 
peak (Ep,l) when these quinones were reduced to their hydroquinones under the experimental 
conditions used here.  However, quinone propionic acid where the trimethyl-lock is absent (NQ-
COOH, Q’-COOH, QnogemMe-COOH) does not present a lactone peak.  Such a difference 
between the quinone propionic acid is due to the fact that when the trimethyl-lock system is 
absent, the cyclization rate is significantly slower, as was reported previously in our group and in 
earlier works.24,27-30  In Scheme 2.2 is presented the reaction sequence for the lactone formation.  
It is important to our final goal not only to determine the ease of reduction of our quinones but 
also to find the rate at what hydroquinone disappear to become a lactone.  In this matter, the peak 
current ratio for quinone reduction and hydroquinone oxidation was measured for all the 
propionic acid quinone and subsequently predicted according to Nicholson and Shain for a 
chemical step following electron transfer.13  As a result, the rate constant for the disappearance 
of hydroquinone, called kf was obtained.  In Table 2.3 are presented the rate for the 
disappearance of hydroquinone after reduction of the quinone.  The results from Table 2.3 
revealed that quinones with no trimethyl-lock have the slowest rate among the propionic acid 
series (NQ-COOH = 0.02 s–1, QnogemMe-COOH = 0.08 s–1, Q’-COOH = 0.13 s–1).  Those values 
confirm the rate enhancement produced by the trimethyl-lock presence when lactone is form by 
the cyclization of propionic acid quinones. 
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Table 2.3. Rate constant for the disappearance of propionic acid hydroquinones.  aRatio 
measured between peaks current where the potential scan was conducted at a rate of 0.1 V s–1 at 
22±2 °C in a pH 7.1 0.1 M PB/0.1 M KCl buffer solution.  bRatio measured between peaks 
current where the potential scan was conducted at a rate of 1 V s–1 22±2 °C in a 0.1 M PBS / 0.1 
M KCl pH 7.1 buffer solution.  A three-electrode cell was used containing a glassy carbon 
electrode, a platinum counter electrode, and an Ag/AgCl (3M KCl) reference electrode.  
Quinone kf (s-1) 
NQ-COOH 0.02a 
QnogemMe-COOH 0.08a 
Q’-COOH 0.13a 
QH-COOH 0.19a 
QMeO-COOH 0.27a 
QdiMeO-COOH 0.29a 
QMe-N-COOH 0.37a 
Qn-pr-NH-COOH 0.39a 
QMe-COOH 1.0b 
QI-COOH 1.8b 
QBr-COOH 2.4b 
 
 
Figure 2.3.  Cyclic voltammograms of QMe-COOH.  Potential scans were conducted at a rate of 
0.1 V s–1 at 22±2 °C in the specified buffer solution.  A three-electrode cell was used containing 
a glassy carbon electrode (A=0.07 cm2), a platinum counter electrode, and an Ag/AgCl (3M KCl) 
reference electrode (0.210 V vs. SHE).23  Potential sweeps started at 0.6 V to –0.6 and back to 
0.6 V.  Positive current peak corresponds to the reduction peak (Ep,c) and negative current 
corresponds to oxidation peak (Ep,a), and to the anodic peak of the lactone (Ep,l).  
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To conclude the study on the cyclization rate of propionic acid quinones, the influence of 
buffer catalysis and salt concentration was investigated for QMe-COOH.  In Figure 2.3 is clearly 
shown that the increase in buffer concentration increases the rate of cyclization as seen by the 
bigger size on the lactone peak and the change on the current peak ratio.  On the other hand, 
adding more salt does not have an effect on the current ratio peak, thus, no impact is seen in the 
cyclization rate.  
2.4 Conclusions 
The electronic properties of six naked quinones, eleven propionic acid quinones, and a 
quinone propionic acid with an ethanolamine handle were characterized by cyclic voltammetry.  
In all cases, it was demonstrated that structural changes on the quinone moiety altered their 
reduction behavior.  In the case of naked and trimethyl-lock propionic acid quinones, their 
reduction potentials were changed by addition of different functional groups to the benzoquinone 
moiety.  Both type of quinones followed the same trend where quinones with a halogen had the 
more positive (or less negative) reduction potential, and quinones with a group that donates 
electron density to the ring, such as methyl, methoxy or amine, had more negative reduction 
potentials.  However, it seems that halogens donate some electron density to the quinone ring 
because their reduction potentials with respect to their hydrogen variant were very close (–0.026 
V vs. –0.019 V).  A similar conclusion was reached for iodo, chloride and bromine substituted 
quinones in Novak work.20  I also observed that propionic acid quinones without the presence of 
the trimethyl-lock system had a more positive reduction potential and more easily reduced than 
those where the trimethyl-lock system is present.  The contorted strain produced onto the 
quinone ring by the trimethyl-lock makes the transfer of electrons more difficult.  Although, 
quinone derivatives are harder to reduce when the trimethyl lock is present, its inclusion is 
fundamental to create quinones that can have a fast cyclization, as seen previously by in our 
group and by other research groups.24,27-30  In Figure 2.3, it is stated that an increase in buffer 
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concentration increases the cyclization rate but that no impact is seen when more salt is present 
into the solution.  As shown in Table 2.3, quinone propionic acids without the presence of 
trimethyl lock had the slowest rate for the disappearance of the hydroquinone after reduction of 
the quinone moiety occurred.  It is important to mention that the nature of the handle does not 
alter the reduction potential of the quinone as seen when comparing QMe-COOH versus QMe-
ETA.  From our summarized results, I can conclude that halogen, hydrogen, methyl, and 
methoxy trimethyl-lock propionic acid quinones can be assayed against the human enzyme 
NQO1 without further concerns of non-enzymatic reduction with the aim of finding possible 
trigger-quinones for enzyme activation.   
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CHAPTER 3 
TRIGGERABLE QUINONES ACTIVATED BY NAD(P)H:QUINONE 
OXIDOREDUCTASE TYPE I (HNQO1) FOR POTENTIAL DRUG DELIVERY 
APPLICATIONS 
 
3.1 Introduction 
In the last two decades, there has been remarkable interest in the activation of drug 
delivery systems and cellular process by enzymes associated with inflammatory diseases and 
cancer.1  The latter has been addressed in two ways: 1) using such endogenous, unregulated 
proteins to selectively activate antitumor compounds,2 prodrugs,3-6 and very recently liposomes7-
13 and 2) deactivating the enzyme which causes cell death through accumulation of damaged 
species, such as superoxide.14  Among the enzymes used as stimuli for these therapeutic routes, a 
significant research effort has been directed at a subgroup of  reductase enzymes, of which 
NAD(P)H: quinone oxidoreductase-1 (NQO1, DT-diaphorase, EC 1.6.99.2)15,16 has become of 
great interest.17  This homodimeric flavoprotein is unique among reductases, as it catalyzes the 
direct two-electron reduction of a wide variety quinones using NADH or NADPH as cofactor 15.  
NQO1 is located mainly in the cytosol of cells, but can also be found in the nucleus, endoplasmic 
reticulum, membrane and mitochondria, as well as extracellularly.15,18-24  The over-expression of 
human NQO1 in certain tumor tissues (e.g. non-small cell lung, pancreas and colon)25-29 makes it 
a valuable target for activating stimuli-responsive drug delivery systems based on quinone 
derivatives.  As a result, many groups have been actively studying its molecular structure using 
crystallography methods so as to improve our understanding about its nature (e.g. human code 
1D4A),30 as well as its behavior with substrates or inhibitors (e.g. duroquinone-enzyme code 
1DXO).30-35  Importantly, the ability of NQO1 to reductively activate sophisticated quinone and 
quinoidal compounds such as antitumor compounds36 and prodrugs37 has been studied a great 
deal  in the past.  However, the interaction of rhNQO1 with simple quinones or quinones useful 
for trigger groups in prodrugs and delivery vehicles, has to date not been studied.   
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Trigger groups that upon activation by a reductive stimulus are subsequently cleaved 
from a targeted group,6 hold much promise in the development of endogenously-triggered 
prodrugs and drug delivery vehicles, such as liposomes.  Our group has shown that reductively-
activated liposomes can have their contents delivered upon self-cleavage of the reduced quinone 
headgroup of the fusogenic lipids composing the liposomes.38  The key step of this delivery 
process is the initial reduction of the cleavable quinone head group, which should be controlled 
by the structure of the trimethyl-locked quinone propionic acid trigger (QPA), Scheme 3.1. 
 
Scheme 3.1. Reduction and cyclization process on quinone propionic acid triggers (QPA).   
Variants of the QPA trigger groups have also been investigated for prodrugs, such those 
based on mustard39 and oxindoles.40  Tunability in the reductive triggering of QPA groups for 
either prodrug or liposome delivery applications will be achieved by substituent variation at R1, 
R2, and R3 (Scheme 3.1).  Although others groups have previously demonstrated that simple 
quinones can be tuned for better interaction with rat NQO1,41-43 and there exist a good number of 
reports on structure-relationship activity44-51 and docking studies of NQO1 inhibitors and 
substrates for anticancer therapy,14,32,52-56 there is little data in the literature for the interaction of 
simple quinones with recombinant human NQO1.  Volpato et al. found that rhNQO1 activated 
an aromatic nitrogen mustard prodrug containing the QPA group with R1=R2=R3=R4=CH3.39  In 
this paper, we examine a good number of QPA derivatives as potential substrates for human 
NQO1.  We report detailed solution-phase kinetic parameters, as well as molecular docking 
studies, to help understand how these quinones interact with hNQO1.  Using the known crystal 
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structure of the hNQO1-duroquinone complex (1DXO),30 six different receptors (changing 
interface radius, oxidation state of cofactor, and method to define active site) were defined.  
Quinone derivatives were docked in each receptor to see if there was any difference on the 
outcomes and to have a better prediction for the orientation of our quinones into the active site of 
hNQO1.  Furthermore, we intended to correlate the experimental free energies extracted from the 
kinetic assays with the theoretical free energies from the docking studies.    
3.2 Experimental Section 
3.2.1 Materials   
Recombinant human enzyme NAD(P)H:quinone oxidoreductase-1 (EC 1.6.99.2) 
(rhNQO1), nicotinamide adenine dinucleotide reduced (β-NADH) and bovine serum albumin 
(BSA) were purchased from Sigma (D1315, N8129, A3294).  Potassium dihydrogen phosphate 
(KH2PO4, Fluka 60219), dipotassium hydrogen phosphate (K2HPO4, Fisher P288), potassium 
chloride (KCl, Sigma P9541) and potassium hydroxide pellets (KOH, Mallinckrodt) were used to 
make the buffer.  Ethyl alcohol (200 Proof-Absolute-Anhydrous) was purchased from Pharmaco-
AAPER.  Nanopure water was obtained from a Nanopure Diamond Barnstead System (18.2 MΩ-
cm).  Quinone substrates were synthesized as previously described or as outlined in the 
Appendix.57  The quartz 96-well microplate used in the enzyme assays was purchased from 
Hellma (730.009-QG).  FLUOstar Optima plate reader from BMG Labtech was used to follow 
NADH consumption during the enzyme assay.  
3.2.2 Enzyme Kinetic Assay 
Enzyme activities were determined using UV-vis spectroscopy by adapting a previous 
assay58 to a 96-well plate reader. The oxidation of NADH at 340 nm was measured using an 
experimental determined extinction coefficient of 4390 M–1cm–1 (Table A.1 and Figure A.1).  
Kinetic experiments were performed on three different days with at least three replicates of each 
condition performed.  The assay solution consisted of 0.1 M PB/0.1 M KCl buffer solution at pH 
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7.10 containing 0.007% of bovine serum albumin, 100 µL of appropriate concentration of 
quinone substrate, 50 µL of a 400 µM NADH solution, and 50 µL of enzyme solution (0.11–3.00 
µg).  The total assay volume was 200 µL.  All stock quinone solutions were prepared by 
dissolving each quinone in ethanol (100 µL) with subsequent dilution to 10.00±0.02 mL with 
0.007% BSA solution.  Quinone solutions of the desired concentrations were made by taking the 
appropriate volume from the quinone stock solution and diluting it to 10.00±0.02 mL in a 
volumetric flask.  The solutions were kept at room temperature (22±2 °C), in the dark, for 
approximately 2 hours before the experiments were started.  Once the 96-well plate was filled 
with the assay solutions, except the NADH solution, it was placed into the instrument and left to 
sit for 5 min before starting the measurements.  The enzyme reaction was started by automated 
dispensing of the NADH solution, and the absorbance change at 340 nm was measured for 1.6 
min at room temperature (22 to 26 °C).  The linear portion of the absorbance vs. time graphs (the 
first 20 seconds to 1 min) were fitted and slopes were calculated.  The average slopes from the 
replicates was used to calculate the kinetic parameters, with the Q–test being applied so as to 
reject values outside of the 90% confidence level.59  Plots of velocity versus quinone 
concentration were used to obtain Km and Vmax values from non-linear least squares analysis.60  
T-test was applied to the close values in the kinetic parameters so as to see if they were 
statistically different at the 95% confidence level.61  Due to instrument sensitivity, quinones with 
Km values lower than 15 µM could only be estimated.  
3.2.3 Molecular Docking 
Docking studies were performed using FlexX from LeadIT (1.3.0 version).62-69  Quinone 
structures were prepared in Chemdraw3D and subsequently minimized using Sybyl-X (Version 
1.1.1) using the Tripos force field for suitable bond distances and angles and the Gasteiger-
Hückel method for charge calculation.  Enzyme coordinates used in the FlexX software were 
obtained from The Protein Data Bank (code: 1DXO).  A molecular visualization system called 
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PyMOL was used to prepare the docking frames.  Construction of six different receptors was 
done with the FlexX software by selecting the active site containing amino acids from monomer 
A and C of the enzyme crystal structure.  Two water molecules were present in each of the 
receptors.  Receptor 1 includes FAD (as it is in the X-ray coordinates) as a cofactor with 
duroquinone as the reference ligand (X-ray coordinates edited by FlexX for correct atom 
hybridization and bond type) and the binding site is defined within an interface of 6 Å 
encompassing the reference ligand.  Receptor 2 includes FADH2 (FAD X-ray coordinates 
modified) as a cofactor with duroquinone as the reference ligand (X-ray coordinates edited by 
FlexX for correct atom hybridization and bond type) and the binding site is defined within an 
interface of 6 Å encompassing the reference ligand.  Receptor 3 is the same as Receptor 1 but 
has an interface radius of 8 Å.  Receptor 4 is the same as Receptor 2 but has an interface radius 
of 8 Å.  Receptor 5 includes FAD as a cofactor with the active site defined by a sphere of 8.5 Å 
with N5 from FAD as its center.  Receptor 6 includes FADH2 as a cofactor with the active site 
defined by a sphere of 8.5 Å with N5 from FADH2 as its center.   
In FlexX flexible docking calculations, the initial position of the substrate is outside the 
active site.  Then, an algorithm for fragmenting the quinone substrate is executed, and a base 
fragment is automatically selected and placed in the active site on which an incremental 
construction algorithm is performed.  From these calculations, each substrate examined using 
different receptors, has a set of solutions where the closest poses (based on score, position and 
interactions with the protein) were selected for detailed investigation.  On these selected poses, 
the influence of the cofactor state (oxidized FAD or reduced FADH2 form), receptor radius, and 
the inclusion or not of a reference ligand was studied.  In addition, the total score was used as an 
estimate of the free energy of binding and was subsequently used to plot theoretical free energies 
of binding versus experimental free energies of binding (ΔG = –RTLnKm).63 
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The docking method is based on the experimental observed range of nonbonded contact 
geometries revealed by statistical analysis of the Cambridge Structural Database (CSD), the 
analysis of the CSD is used to define the range of allowed angles and dihedrals describing the 
nonbonded contact geometry.70 The program discards any solution with electrostatic repulsion 
(based on a threshold limit distance).  The scoring function accounts for hydrogen bonds, ionic 
interactions, hydrophobic contact surface, and the number of rotatable bonds in the substrate.  
The limitations of the scoring function is that it does not account for differences in binding 
strengths between various neutral hydrogen bonds or ionic interactions, and it does not include 
the conformational energy of the substrate.63,70 The FlexX algorithm breaks down the substrate 
into fragments where one is automatically elected as the base fragment,66 and then the fragments 
are connected flexibly during docking in an incremental way.65  In the triangle algorithm, 
triangles of interaction centers are formed using the base fragment, and those are mapped onto 
triangle points lying on the receptor’s surface.  As an alternative to the triangle algorithm, a line 
algorithm is used when only two interactions exist simultaneously between the substrate and the 
enzyme.   The receptor is rigid and the ligand is flexible for both algorithms.  The scoring 
function is a modification of Böhm’s function.66-68  
3.3 Results and Discussion 
3.3.1 Kinetic Studies on Triggerable Quinones   
All the rhNQO1 kinetic parameters for the different quinone derivatives studied here are 
presented in Table 3.1.  To compare our data, we divided our complete list of quinone 
derivatives into 3 groups: a) changing the substituents at the 2-position (R1) on the quinone ring 
for the trimethyl lock series (R3=R4=CH3), b) presence versus absence of the trimethyl lock 
system, and c) charged versus neutral quinone propionic acid. 
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Table 3.1. Kinetic parameters for the reduction of quinone derivatives by hNQO1.  Values are 
the mean ± one standard deviation for three independent determinations. 
Quinone Km (µM) 
Vmax (µmol·min–1·mg–1 
of hNQO1) kcat (min
–1) kcat/Km  (min–1·µM–1) 
O
O
OH
O
Br
 
QBr-COOH 
41±8 88±7 5500±400 
 
133±28 
 
O
O
OH
O
  
QH-COOH 
50±11 83±8 5100±500 103±25 
O
O
OH
O
  
QMe-COOH 
158±41 38±5 2400±300 15±4 
O
O
OH
O
O
  
QMeO-COOH 
447±102 42±5 2600±300 6±1 
O
O
OH
O
  
Q’-COOH 
20±3 78±3 4800±200 242±37 
O
O
OH
O
  
QnogemMe-COOH 
5±1 66±4 4100±200 853±178 
O
O
OH
O
O
O
  
QdiMeO-COOH 
376±87 14±1 800±100 2±0.5 
O
O
N
H
O
OH
  
QMe-ETA 
132±32 60±7 3700±400 28±7 
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• Changing the Substituent at the 2-position on the Quinone Ring–Trimethyl Lock Series.   
We obtained the kinetic parameters for four quinones that differ in their functional group 
at the 2-position on the quinone ring (bromine, hydrogen, methyl, methoxy).  Of this group, QBr-
COOH (R1=Br) and QH-COOH (R1=H) appear to be the best substrates based on its Km, Vmax 
and kcat/Km values.  The Michaelis constant values of Km = 41 µM (QBr-COOH) and Km = 50 
µM (QH-COOH), as well as, the maximum velocity values of Vmax = 88 µmol·min–1·mg–1 (QBr-
COOH) and Vmax = 83 µmol·min–1·mg–1 (QH-COOH) were found to be statistically equal at the 
95% confidence level.  Both QBr-COOH and QH-COOH are efficient substrates for rhNQO1, 
based on their kcat/Km values of 133 min–1·µM–1 and 103 min–1·µM–1, respectively.  In the case 
of QMe-COOH, there are two clear effects on the kinetic parameters as a consequence of the 
presence of a methyl group at the 2-position of the quinone ring.  First, the presence of the 
methyl group increases the electron density of the quinone core (due to its electron donating 
character) possibly making the analog less wishful to accept the electrons that come from the 
enzyme cofactor FADH2.  Second and more prominent, the methyl substituent causes steric 
interactions between the quinone ring and the hNQO1 active site, resulting in an unfavorable 
alignment and position of the quinone, causing lower binding, thus lowering the reduction rate.  
Steric hindrance at R1 position on the quinone ring has been previously observed to be an 
important factor in changing the rate of reduction between human NQO1 and structures such as 
indolequinones and benzoquinone mustard compounds.48,51,56  Lastly, QMeO-COOH has a very 
similar turnover rate compared to its methyl analog, and even though the methoxy group has a 
higher electron-donating ability, the alignment of this group with respect to the quinone ring 
reduces its power and make it behaves as a methyl.  The alignment distortion is caused by the 
methyl group at the 3-position of the quinone ring, because when a hydrogen is placed instead, 
the methoxy group adopt a coplanar conformation with the quinone ring that permits fully 
contribution of the electron density.71,72  However, the Km value of the QMeO-COOH differs from 
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that of its methyl analog because the methoxy group is a bulkier substituent than methyl.  
Consequently, steric interactions between the quinone and the hNQO1 active site, lead to 
decreased QMeO-COOH binding affinity, resulting in it being the worst substrate for hNQO1 in 
this series.  To complete the enzyme kinetic analysis of different functional groups at R1 position 
on the quinone rings, attempts were made to investigate QMe-N-COOH and Qn-pr-NH-COOH 
responses toward rhNQO1 but the results obtained are not reliable because both substrates 
absorb at the wavelength (340 nm) that NADH consumption is measured.   
• Special Note to QdiMeO-COOH.   
Although this analog possesses the trimethyl-lock structural motif, QdiMeO-COOH does 
not fall into the category discussed above, because it does not have a methyl group at the 3-
position on the quinone ring.  However, it was synthetically readily achievable and so it was 
investigated.  The pressure of one more methoxy group versus QMeO-COOH does not alter the 
Km value, which are statistically equal.  However, the Vmax value of QdiMeO-COOH is 1/3 times 
that of the quinone with only one methoxy group, QMeO-COOH (Vmax=42 µmol·min–1·mg–1).  
The cause associated with the rate difference, may be the presence of adjacent methoxy groups in 
the QdiMeO-COOH analog.  It has been reported before that when methoxy groups are in adjacent 
locations on the quinone ring, one of them is coplanar to the quinone ring, and the other one is 
not.71,72  Therefore, the quinone ring will receives full electron density contribution from the 
coplanar methoxy group making the quinone not as happy to receive electrons.  Moreover, the 
steric hindrance caused by the second methoxy group, which is a bulkier group than a methyl at 
R2 position on the quinone ring, could also affect the reduction rate of the quinone by hNQO1.        
• The Presence versus the Absence of the Trimethyl-Lock Motif in the Quinone.   
QBr-COOH, QH-COOH, QMe-COOH and QMeO-COOH all contain the trimethyl-lock 
motif, whereas Q’-COOH and QnogemMe-COOH do not.  All quinone structures are shown in 
Table 3.1.  In Q’-COOH, a hydrogen is present (instead of a methyl) at the 5-position on the 
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quinone ring and its observed Michaelis constant of 20 µM, it is substantially lower than that of 
QMe-COOH that possesses the trimethyl-lock motif (158 µM).  In addition, QH-COOH and Q’-
COOH, both have a hydrogen group on the quinone ring but the difference in position of that 
hydrogen at R1 and R3, respectively, make QH-COOH a trimethyl-lock derivative and Q’-
COOH  not.  This difference is reflected on the Km value of 50 µM for QH-COOH and 20 µM 
for Q’-COOH, resulting the last one a better substrate toward the hNQO1 enzyme.  This change 
in affinity can be explained by the ease of the trimethyl-lock strain when hydrogen is placed on 
the quinone ring on the same side as the propionic acid chain.  To further probe the effect of the 
trimethyl-lock motif, a quinone with no germinal methyl groups on the propionic side chain was 
examined, QnogemMe-COOH.  It was found that QnogemMe-COOH was even more specific 
toward the enzyme, as stated by its Km value of roughly 5 µM (Km values lower than 15 µM 
could only be estimated).   
• The Role of Charged Quinone versus Neutral Quinone.   
To investigate the effect of a neutral quinone in the active site, versus a negatively-
charged quinone, we studied a quinone with an ethanolamine (QMe-ETA) attached to the 
propionic acid group via an amide bond (with a pKa around 10)73 and compared its hNQO1 
values obtained for the QMe-COOH that is anionic at physiological pH.74  QMe-ETA presents a 
higher maximum velocity; however, the Michaelis constant values (Km) are statistically equal, 
therefore, no significant difference is presented in binding affinity.  The increase of 22 
µmol·min–1·mg–1 in maximum velocity for the QMe-ETA could be due to the absence of charge 
on the molecule or to the longer extended chain that QMe-ETA presents, that permits a different 
arrangement of the quinone-ethanolamine derivative into the active site of the enzyme.  This 
hypothesis will be later discussed by analysis of the docking outcomes. 
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3.3.2 Docking Studies on Triggerable Quinones 
In order to validate the docking methods used for the various quinone propionic acids, we 
examined docking results for duroquinone.  It was found that excellent results were achieved 
with all of the receptors, with an observed root mean square deviation (RMSD) < 0.5 Å for the 
best prediction and a RMSD < 1.34 Å for the lowest score.  In all of these outcomes, it was 
found that the orientation of the duroquinone was very similar, with differences of less than 1.2 
kJ·mol–1 from the lowest energy to the 20th lowest energy in each receptor.  In Figure 3.1, the 
best pose for duroquinone is shown and compared with the original crystal structure.   
 
Figure 3.1. Best prediction for the docked duroquinone in receptor 1 compared with the position 
of the duroquinone in the original crystal structure.  Docked duroquinone (pink) differ from the 
original duroquinone (yellow) by 0.4530 Å. Representation of amino acids (stick display; color 
by atom type, carbon atoms colored in purple) and FAD (sticks display; color by atom type, 
carbon atoms colored in cyan) in receptor 1.      
• Which Receptor Gives the Best Prediction?  
In docking, the way in which a receptor is defined affects in different ways the 
predictions of substrate interactions.  It is important to know what amino acids are to be included 
(defined by the radius of interaction), and the cofactor oxidation state must also be selected.  For 
the catalyzed NQO1 reduction of quinones with NADH, there is still much debate as to where 
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the negative charge stays after the first hydride transfer happens.  The most prominent proposal 
is that in which the negative charge stays on O2 and then this oxygen gets protonated to become 
an OH and the hydride is transferred to form FADH2.37,75,76  Scheme 3.2 represents the charge 
relay process and the possible atom sites on the quinone moiety where the hydride can be 
transferred to.   
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Scheme 3.2. Hydride transfer mechanism on all possible atom sites on QPAs. 
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There are also concerns about the geometry of FAD versus FADH2 and how the 
protonation can affect its conformation.  In the literature, it is reported that the conformation of 
FADH2 changes to a butterfly-like shape in solution (versus planar for FAD), but in most 
modeling structures FADH2 retains its planar conformation.30,75  To elucidate the possible 
influence of all these factors on the computed interactions between the QPAs and hNQO1, a 
variety of receptors were defined and evaluated.  All the QPAs tested in the kinetic assays were 
docked in the active site of hNQO1.  In addition, the QPA amine derivatives, QN-Me-COOH and 
Qn-pr-NH-COOH, were also docked in the active site of hNQO1with the aim of predicting their 
position and binding energy because of the lack of kinetic data for them.  
• FAD (Oxidized) versus FADH2 (Reduced).  
The outcome solutions from docking the quinone analogs in different receptors, having 
the active site FAD or FADH2 as cofactor, were examined.  For this, we compared the results 
from receptor 1 versus receptor 2, receptor 3 versus receptor 4, and receptor 5 versus receptor 6.  
In all cases, the positions of the quinones were the same.  The only slight difference was the 
energy score.  For the lowest energy score a slight increase of 0.6 kJ·mol–1 was observed for the 
outcome solution of the receptor containing FAD versus the receptor containing FADH2 and for 
the best prediction energy the increase was of 0.8 kJ·mol–1.  
• Interface Radius of 6 Å versus Interface Radius of 8 Å.   
The binding conformations of the quinone analogs were examined where the only 
difference was the interface radius of the active site.  We compared receptor 1 versus receptor 3 
and receptor 2 versus receptor 4.  In this case, the orientation of the quinone analogs in all the 
receptors mentioned above were the same, and the outcome solution with the lowest score 
energy for the duroquinone in each receptor differ by only 1 kJ·mol–1.  
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• Defining Active Site (Reference Ligand versus Sphere).   
The binding conformations of the quinone analogs were examined by defining the active 
site differently.  In the case of receptor 3 and 4, the ligand bound to the enzyme was used as 
reference ligand (duroquinone) and had an interface radius of 8 Å defined from its position.  In 
the case of receptor 5 and 6, the nitrogen N5 from the cofactor FAD or FADH2 was used as the 
sphere center and had an interface radius of 8.5 Å defined from it.  We compared receptor 3 
versus receptor 5 and receptor 4 versus receptor 6.  In these scenarios, the outcome with the 
lowest score and the best prediction differ in their orientations only for duroquinone but not for 
the other quinone analogs.  However, the outcome for the lowest energy value and the one 
associated with the best orientation is different for all of the quinones.  The lower energy score is 
smaller by 1 kJ·mol–1 in the receptors where the active site is defined by the 8.5 Å radius sphere.  
The best prediction corresponds to the quinone located deeper in the receptors 5 and 6.  In this 
case the energy is 0.6 kJ·mol–1 lower than in receptors 3 and 4.  We conclude that in this case for 
quinone analogs, even though there is a difference in score energy, this difference is minimal and 
does not affect the outcome.  Therefore, there is no apparent effect of active site definition on 
quinone positions or score energies.  
After comparing all the receptors, we observed that there is no effect of the oxidation 
state of the cofactor or of the interface radius in the docking outcomes.  There is little influence 
on the docking solutions when the active site was defined in different ways.  While the observed 
difference in the docking outcomes was major for duroquinone, the rest of the quinone analogs 
were unaffected.  In Figures A.5 and A.6 are represented the lower score frame of QBr-COOH 
(representative example of outcomes for all of the quinone analogs) in each of the receptors, and 
its corresponding poseview so as to help to visually support the conclusions made above.  These 
conclusions are also based on data in Table A.2 that contains the lowest score energies for QBr-
COOH in all the receptors.   
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The docking solutions of receptor 1 were used to compare the quinone analogs among 
themselves, and those outcomes are an accurate representation of what happened in all the 
receptors, Figure 3.2.   
  
  
  
  
Figure 3.2. Structural frames of FlexX-docked quinones in the active site of hNQO1.  Stick 
display in all the frames,  FAD (color by atom type; carbon atoms colored in cyan), amino acids 
(color by atom type, carbon atoms colored in purple) and docked-quinones (color by atom type, 
carbon atoms in pink): (A) QBr-COOH, (B) QH-COOH, (C) QMe-COOH, (D) QMeO-COOH, (E) 
QdiMeO-COOH, (F) Q'-COOH, (G) QnogemMe-COOH, (H) QMe-ETA, (I) Q(Me-N)-COOH, and (J) 
Q(n-pr-NH)-COOH.                                                                       
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Figure 3.2 continued. 
  
It was observed that QBr-COOH, QH-COOH and QMe-COOH all lay parallel to the 
isoalloxazine ring of the FAD cofactor, but the carbon site of the quinone for the possible 
hydride transfer is different due to the slight variance in the binding orientation with respect to 
FAD.  In the case of the methoxy and amine quinone derivatives, they do not bind as tightly as 
the other quinone analogs.  The obvious possible explanation for this is that the bulky 
substituents on the ring need more space, thereby preventing these analogs from venturing as 
deeply into the active site.  Other research groups reported in the past that a bulky amine at 2-
position of the quinone ring for indolequinones and quinolinequinones, decreased tremendously 
the reduction rate of these compounds with hNQO1 making them not a good substrate for this 
enzyme.46,47,49 
Furthermore, the theoretical binding energies from these docking outcomes were used in 
an attempted correlation with the experimental binding affinities. The experimental binding 
energies were calculated using the free energy equation ΔG = RTlnK,63 so as to plot |ΔG 
(experimental)| versus |ΔG (theoretical)|.  To our disappointment, there was no clear correlation 
between these values (Figure A.7).  However, this is not surprising based on the controversy that 
exist in the literature about whether or not docking binding energies can be correlated with 
experimental reactivity.35,53-55,77  In addition, other attempts were made to correlate reactivity 
with the information extracted from the docking outcomes.  The only correlation observed was 
the one between the log (atom distance) and the log (kcat/Km) as seen in Figure 3.3.  The atom 
distance corresponds to the distance between the closer atom on the quinone ring and the N5 
I J 
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atom of FAD.  This correlation indicates that the closer the atoms on the quinone are to receive a 
hydride from the N5 of FAD, the more reactive the quinone derivative will be with hNQO1.  
Based on this observation, the reactivity of the amine derivatives with hNQO1 should be similar 
to the one observed for the methoxy analogs. 
 Energy results for the more accurate score of each quinone and the distance from N5 of 
the FAD center in hNQO1 to the possible hydride transfer atoms of the quinone substrates78 are 
presented in Table 3.2.  It can be deduced that the hydride transfer for most of the quinones will 
be accepted by the carbon atom, except in the case of the quinones containing methoxy groups 
where the orientation favors a hydride transfer to the carbonyl oxygen.  In the case of the amine-
quinone derivatives, no conclusion can be made because the preferred site for Q(N-Me)-COOH is 
the oxygen and the preferred site for Q(n-pr-NH)-COOH is the carbon. 
Table 3.2.  Energy score and distance from N5 of FAD to the possible hydride transfer atoms.  
Atoms closer in distance to N5 are highlighted in red. 
Quinone Score (kJ·mol–1)  d [N5-C](Å) d [N5-C=O](Å) d [N5-O](Å) 
QBr-COOH - 25.2018 3.25 3.47 3.58 
QH-COOH - 24.0028 3.40 4.11 4.50 
QMe-COOH -26. 4276 3.58 3.54 3.71 
QMeO-COOH -20.3317 3.83 3.90 3.50 
QdiMeO-COOH -28.3849 4.05 4.05 3.68 
Q’-COOH -26.9646 3.18 3.81 3.92 
QnogemMe-COOH -25.8435 3.22 3.49 3.68 
QMe-ETA -28.4801 3.43 3.73 3.81 
Q(N-Me)-COOH -24.8434 3.95 3.90 3.45 
Q(n-pr-NH)-COOH -20.9808 3.68 4.36 4.32 
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Figure 3.3. Correlation between the log (distance of the closer atom on the quinone ring with 
respect to N5 of FAD) and the log (kcat/Km).   
Superimposed images of the quinones containing trimethyl-lock motif (Figure A.2), 
quinones with the trimethyl-lock motif present and absent (Figure A.3) and quinones differing on 
the molecule charge (Figure A.4), were prepared to see if there was any correlation between the 
kinetic results and the docking studies.  In Figure A.2, it was found that QBr-COOH holds the 
deepest location into the active site, whereas QMeO-COOH penetrates the least deep.  These 
observations are in accordance with the kinetic data for these quinone series.  In Figure A.3, 
QnogemMe-COOH is the closest to the FAD and QMe-COOH the one located further from the 
isoalloxazine ring.  These observations agree with the order of reactivity of these compounds 
with hNQO1.  In Figure A.4, the longer chain present in the QMe-ETA permits the quinone to 
accede to a deeper location in the active site of the enzyme.  This could be the cause for the 
increase of 22 µmol·min–1·mg–1 in maximum velocity for the QMe-ETA. 
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3.4 Conclusions 
In conclusion, we studied the reduction of eight quinone derivatives by human 
recombinant NQO1 using a 96-well microplate enzyme assay and obtained kinetic parameters 
Km and Vmax having excellent reproducibility.  Minor alterations in structure resulted in 
significant changes in the kinetic parameters; for example QBr-COOH is much more active at a 
low concentration than is QMe-COOH, and so is the case for QMe-COOH versus QMeO-COOH, 
and QMeO-COOH versus QdiMeO-COOH.  QBr-COOH appears to be the preferred substrate 
among the quinones containing the trimethyl-lock system based on its higher kcat/Km value of 
133 min–1·µM–1.  It is also notable that sterics seems to predominate over electronic effects 
among the trimethyl-lock series, an outcome similar in nature for the benzoquinone mustards.48,51  
As far as the best substrate in Table 3.1, the quinone without the geminal methyls is the most 
efficient of all with the highest product formation at small concentration of reactant (kcat/Km = 
853 min–1·µM–1).  This conclusion guides us to believe that the presence of the trimethyl-lock 
affects the geometry of the quinone ring, which has somewhat of an effect on the interaction of 
the quinone with the active site of the enzyme. 
The docking studies completed on ten quinone derivatives suggested that small 
modifications of the quinone core alter the ability of the quinone to be reduced by the enzyme, 
results that are in agreement with those of indolequinones.56  Based on the kinetic and modeling 
studies with the QPAs, hNQO1 can accommodate a range of quinones having characteristics 
binding affinities.  The unsuccessful correlation between experimental binding energy versus 
theoretical binding energy makes us think that, in order to quantitatively analyze the influence of 
a functional group in the quinone core, experimental assays are required.  However, we were 
able to qualitatively visualize the different positions of the quinone trimethyl-lock series in the 
active site, and our results are in qualitative agreement with the experimental binding values 
(strongest toward weakest  QBr > QH > QMe > QMeO).  In the same manner, we obtained the same 
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qualitative correlation for quinones either containing or lacking the trimethyl-lock (QnogemMe > Q’ 
> QMe).  Lastly, docking and kinetics studies revealed that the presence of a longer side chain 
attached to the quinone (i.e. QMe-ETA versus QMe-COOH) can cause the quinone core to 
penetrate deeper into the active site.  This suggest that addition of spacers to the quinone 
derivatives79 may increase quinone-enzyme binding and perhaps the enzyme rate of conversion. 
The combination of the experimental kinetic and theoretical docking data support our 
predictions: changing functional groups on the quinone ring affects how deep the quinone is 
located in the active site of the enzyme, and this difference in position has consequences on the 
binding affinity and on the hydride transfer rate. Overall, this analysis will enrich the knowledge 
for simple quinones and hNQO1 interactions, providing valuable information for the design of 
enzyme triggerable systems.     
3.5 References 
(1) Andresen, T. L.; Jensen, S. S.; Jorgensen, K., Advanced Strategies in Liposomal Cancer 
Therapy: Problems and Prospects of Active and Tumor Specific Drug Release. Prog. 
Lipid Res. 2005, 44 (1), 68-97. 
(2) Asche, C., Antitumour Quinones. Mini-Rev. Med. Chem. 2005, 5 (5), 449-467. 
(3) de Groot, F. M. H.; Damen, E. W. P.; Scheeren, H. W., Anticancer Prodrugs for 
Application in Monotherapy: Targeting Hypoxia, Tumor-Associated Enzymes, and 
Receptors. Curr. Med. Chem. 2001, 8 (9), 1093-1122. 
(4) Jaffar, M.; Abou-Zeid, N.; Bai, L.; Mrema, I.; Robinson, I.; Tanner, R.; Stratford, I. J., 
Quinone Bioreductive Prodrugs as Delivery Agents. Curr. Drug Delivery 2004, 1, 345-
350. 
(5) Rooseboom, M.; Commandeur, J. N. M.; Vermeulen, N. P. E., Enzyme-Catalyzed 
Activation of Anticancer Prodrugs. Pharmacol. Rev. 2004, 56 (1), 53-102. 
(6) Chen, Y.; Hu, L. Q., Design of Anticancer Prodrugs for Reductive Activation. Med. Res. 
Rev. 2009, 29 (1), 29-64. 
92 
 
(7) Davis, S. C.; Szoka, F. C., Cholesterol Phosphate Derivatives: Synthesis and 
Incorporation into a Phosphatase and Calcium-Sensitive Triggered Release Liposome. 
Bioconjugate Chem. 1998, 9 (6), 783-792. 
(8) Davidsen, J.; Vermehren, C.; Frokjaer, S.; Mouritsen, O. G.; Jorgensen, K., Drug 
Delivery by Phospholipase a(2) Degradable Liposomes. Int. J. Pharm. 2001, 214 (1-2), 
67-69. 
(9) Jorgensen, K.; Davidsen, J.; Mouritsen, O. G., Biophysical Mechanisms of Phospholipase 
A2 Activation and Their Use in Liposome-Based Drug Delivery. FEBS Lett. 2002, 531 
(1), 23-27. 
(10) Davidsen, J.; Jorgensen, K.; Andresen, T. L.; Mouritsen, O. G., Secreted Phospholipase 
a(2) as a New Enzymatic Trigger Mechanism for Localised Liposomal Drug Release and 
Absorption in Diseased Tissue. Biochim. Biophys. Acta 2003, 1609 (1), 95-101. 
(11) Meers, P., Enzyme-Activated Targeting of Liposomes. Advanced Drug Delivery Reviews 
2001, 53 (3), 265-272. 
(12) Sarkar, N.; Banerjee, J.; Hanson, A. J.; Elegbede, A. I.; Rosendahl, T.; Krueger, A. B.; 
Banerjee, A. L.; Tobwala, S.; Wang, R. Y.; Lu, X. N.; Mallik, S.; Srivastava, D. K., 
Matrix Metalloproteinase-Assisted Triggered Release of Liposomal Contents. 
Bioconjugate Chem. 2008, 19 (1), 57-64. 
(13) Banerjee, J.; Hanson, A. J.; Gadam, B.; Elegbede, A. I.; Tobwala, S.; Ganguly, B.; Wagh, 
A. V.; Muhonen, W. W.; Law, B.; Shabb, J. B.; Srivastava, D. K.; Mallik, S., Release of 
Liposomal Contents by Cell-Secreted Matrix Metalloproteinase-9. Bioconjugate Chem. 
2009, 20 (7), 1332-1339. 
(14) Reigan, P.; Colucci, M. A.; Siegel, D.; Chilloux, A.; Moody, C. J.; Ross, D., 
Development of Indolequinone Mechanism-Based Inhibitors of Nad(P)H : Quinone 
Oxidoreductase 1 (Nqo1): Nqo1 Inhibition and Growth Inhibitory Activity in Human 
Pancreatic Mia Paca-2 Cancer Cells. Biochemistry 2007, 46 (20), 5941-5950. 
(15) Ernster, L., Dt-Diaphorase - a Historical Review. Chem. Scripta 1987, 27A, 1-13. 
(16) Ernster, L.; Navazio, F., Soluble Diaphorase in Animal Tissues. Acta Chem. Scand. 1958, 
12 (3), 595-595. 
(17) Siegel, D.; Reigan, P.; Ross, D., One- and Two-Electron-Mediated Reduction of 
Quinones: Enzymology and Toxicological Implications. Biotechnology: Pharmaceutical 
Aspects 2008, 9, 169-197. 
93 
 
(18) Winski, S. L.; Koutalos, Y.; Bentley, D. L.; Ross, D., Subcellular Localization of 
Nad(P)H : Quinone Oxidoreductase 1 in Human Cancer Cells. Cancer Res. 2002, 62 (5), 
1420-1424. 
(19) Villalba, J. M.; Navarro, F.; Arroyo, A.; Martin, S. F.; Bello, R. I.; de Cabo, R.; Burgess, 
J. R.; Navas, P., Protective Role of Ubiquinone in Vitamin E and Selenium-Deficient 
Plasma Membranes. Biofactors 1999, 9 (2-4), 163-170. 
(20) Ernster, L., Dt Diaphorase. Methods Enzymol. 1967, 10, 309-317. 
(21) Nakamura, M.; Hayashi, T., One-Electron and 2-Electron Reduction of Quinones by Rat-
Liver Subcellular-Fractions. J. Biochem.-Tokyo 1994, 115 (6), 1141-1147. 
(22) Siegel, D.; McGuinness, S. M.; Winski, S. L.; Ross, D., Genotype-Phenotype 
Relationships in Studies of a Polymorphism in Nad(P)H : Quinone Oxidoreductase 1. 
Pharmacogenetics 1999, 9, 113-121. 
(23) Sreerama, L.; Hedge, M. W.; Sladek, N. E., Identification of a Class 3 Aldehyde 
Dehydrogenase in Human Saliva and Increased Levels of This Enzyme, Glutathione S-
Transferases, and Dt-Diaphorase in the Saliva of Subjects Who Continually Ingest Large 
Quantities of Coffee or Broccoli. Clin. Cancer Res. 1995, 1 (10), 1153-1163. 
(24) Reicks, M. M.; Appelt, L. C., Soy Induces Phase Ii Enzymes but Does Not Inhibit 
Dimethylbenz[a]Anthracene-Induced Carcinogenesis in Female Rats. J. Nutr. 1999, 129 
(10), 1820-1826. 
(25) Cresteil, T.; Jaiswal, A. K., High-Levels of Expression of the Nad(P)H-Quinone 
Oxidoreductase (Nqo1) Gene in Tumor-Cells Compared to Normal-Cells of the Same 
Origin. Biochem. Pharmacol. 1991, 42 (5), 1021-1027. 
(26) Fitzsimmons, S. A.; Workman, P.; Grever, M.; Paull, K.; Camalier, R.; Lewis, A. D., 
Reductase Enzyme Expression across the National Cancer Institute Tumor Cell Line 
Panel: Correlation with Sensitivity to Mitomycin C and E09. J. Natl. Cancer Inst. 1996, 
88 (5), 259-269. 
(27) Siegel, D.; Franklin, W. A.; Ross, D., Immunohistochemical Detection of Nad(P)H : 
Quinone Oxidoreductase in Human Lung and Lung Tumors. Clin. Cancer Res. 1998, 4 
(9), 2065-2070. 
(28) Siegel, D.; Ross, D., Immunodetection of Nad(P)H : Quinone Oxidoreductase 1 (Nqo1) 
in Human Tissues. Free Radical Biol. Med. 2000, 29 (3-4), 246-253. 
94 
 
(29) Jamieson, D.; Wilson, K.; Pridgeon, S.; Margetts, J. P.; Edmondson, R. J.; Leung, H. Y.; 
Knox, R.; Boddy, A. V., Nad(P)H : Quinone Oxidoreductase1 and Nrh : Quinone 
Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower Nrh 
: Quinone Oxidoreductase 2 Activity Associated with an Nqo2 Exon 3 Single-Nucleotide 
Polymorphism. Clin. Cancer Res. 2007, 13 (5), 1584-1590. 
(30) Faig, M.; Bianchet, M. A.; Talalay, P.; Chen, S.; Winski, S.; Ross, D.; Amzel, L. M., 
Structures of Recombinant Human and Mouse Nad(P)H : Quinone Oxidoreductases: 
Species Comparison and Structural Changes with Substrate Binding and Release. Proc. 
Natl. Acad. Sci. U. S. A. 2000, 97 (7), 3177-3182. 
(31) Li, R.; Bianchet, M. A.; Talalay, P.; Amzel, L. M., The Three-Dimensional Structure of 
Nad(P)H:Quinone Reductase, a Flavoprotein Involved in Cancer Chemoprotection and 
Chemotherapy: Mechanism of the Two-Electron Reduction. Proceedings of the National 
Academy of Science 1995, 92, 8846-8850. 
(32) Faig, M.; Bianchet, M. A.; Winski, S.; Hargreaves, R.; Moody, C. J.; Hudnott, A. R.; 
Ross, D.; Amzel, L. M., Structure-Based Development of Anticancer Drugs: Complexes 
of Nad(P)H : Quinone Oxidoreductase 1 with Chemotherapeutic Quinones. Structure 
2001, 9 (8), 659-667. 
(33) Winski, S. L.; Faig, M.; Bianchet, M. A.; Siegel, D.; Swann, E.; Fung, K.; Duncan, M. 
W.; Moody, C. J.; Amzel, L. M.; Ross, D., Characterization of a Mechanism-Based 
Inhibitor of Nad(P)H: Quinone Oxidoreductase 1 by Biochemical, X-Ray 
Crystallographic, and Mass Spectrometric Approaches. Biochemistry 2001, 40 (50), 
15135-15142. 
(34) Asher, G.; Dym, O.; Tsvetkov, P.; Adler, J.; Shaul, Y., The Crystal Structure of Nad(P)H 
Quinone Oxidoreductase 1 in Complex with Its Potent Inhibitor Dicoumarol. 
Biochemistry 2006, 45 (20), 6372-6378. 
(35) Nolan, K. A.; Doncaster, J. R.; Dunstan, M. S.; Scott, K. A.; Frenkel, A. D.; Siegel, D.; 
Ross, D.; Barnes, J.; Levy, C.; Leys, D.; Whitehead, R. C.; Stratford, I. J.; Bryce, R. A., 
Synthesis and Biological Evaluation of Coumarin-Based Inhibitors of Nad(P)H: Quinone 
Oxidoreductase-1 (Nqo1). J. Med. Chem. 2009, 52 (22), 7142-7156. 
(36) Danson, S.; Ward, T. H.; Butler, J.; Ranson, M., Dt-Diaphorase: A Target for New 
Anticancer Drugs. Cancer Treatment Reviews 2004, 30 (5), 437-449. 
(37) Colucci, M. A.; Moody, C. J.; Couch, G. D., Natural and Synthetic Quinones and Their 
Reduction by the Quinone Reductase Enzyme Nqo1: From Synthetic Organic Chemistry 
to Compounds with Anticancer Potential. Org. Biomol. Chem. 2008, 6 (4), 637-656. 
95 
 
(38) Ong, W.; Yang, Y. M.; Cruciano, A. C.; McCarley, R. L., Redox-Triggered Contents 
Release from Liposomes. J. Am. Chem. Soc. 2008, 130 (44), 14739-14744. 
(39) Volpato, M.; Abou-Zeid, N.; Tanner, R. W.; Glassbrook, L. T.; Taylor, J.; Stratford, I.; 
Loadman, P.; Jaffar, M.; Phillips, R. M., Chemical Synthesis and Biological Evaluation 
of a Nad(P)H:Quinone Oxidoreductase-1-Targeted Tripartite Quinone Drug Delivery 
System. Mol. Cancer Ther. 2007, 6 (12), 3122-3130. 
(40) Moody, C. J.; Maskell, L.; Blanche, E. A.; Colucci, M. A.; Whatmore, J. L., Synthesis 
and Evaluation of Prodrugs for Anti-Angiogenic Pyrrolylmethylidenyl Oxindoles. 
Bioorg. Med. Chem. Lett. 2007, 17 (6), 1575-1578. 
(41) Anusevicius, Z.; Sarlauskas, J.; Cenas, N., Two-Electron Reduction of Quinones by Rat 
Liver Nad(P)H : Quinone Oxidoreductase: Quantitative Structure-Activity Relationships. 
Arch. Biochem. Biophys. 2002, 404 (2), 254-262. 
(42) Cenas, N.; Anusevicius, Z.; Nivinskas, H.; Miseviciene, L.; Sarlauskas, J., Structure-
Activity Relationship in Two-Electron Reduction of Quinones. Methods Enzymol. 2004, 
382, 258-277. 
(43) Zhou, Z. G.; Fisher, D.; Spidel, J.; Greenfield, J.; Patson, B.; Fazal, A.; Wigal, C.; Moe, 
O. A.; Madura, J. D., Kinetic and Docking Studies of the Interaction of Quinones with 
the Quinone Reductase Active Site. Biochemistry 2003, 42 (7), 1985-1994. 
(44) Beall, H. D.; Murphy, A. M.; Siegel, D.; Hargreaves, R. H. J.; Butler, J.; Ross, D., 
Nicotinamide Adenine-Dinucleotide (Phosphate)Quinone Oxidoreductase (Dt-
Diaphorase) as a Target for Bioreductive Antitumor Quinones - Quinone Cytotoxicity 
and Selectivity in Human Lung and Breast-Cancer Cell-Lines. Mol. Pharmacol. 1995, 48 
(3), 499-504. 
(45) Phillips, R. M., Bioreductive Activation of a Series of Analogues of 5-Aziridinyl-3-
Hydroxymethyl-1-Methyl-2-[1h-Indole-4,7-Dione] Prop-Beta-En-Alpha-Ol (Eo9) by 
Human Dt-Diaphorase. Biochem. Pharmacol. 1996, 52 (11), 1711-1718. 
(46) Beall, H. D.; Winski, S.; Swann, E.; Hudnott, A. R.; Cotterill, A. S.; O'Sullivan, N.; 
Green, S. J.; Bien, R.; Siegel, D.; Ross, D.; Moody, C. J., Indolequinone Antitumor 
Agents: Correlation between Quinone Structure, Rate of Metabolism by Recombinant 
Human Nad(P)H : Quinone Oxidoreductase, and in Vitro Cytotoxicity. J. Med. Chem. 
1998, 41 (24), 4755-4766. 
(47) Swann, E.; Barraja, P.; Oberlander, A. M.; Gardipee, W. T.; Hudnott, A. R.; Beall, H. D.; 
Moody, C. J., Indolequinone Antitumor Agents: Correlation between Quinone Structure 
96 
 
and Rate of Metabolism by Recombinant Human Nad(P)H : Quinone Oxidoreductase. 
Part 2. J. Med. Chem. 2001, 44 (20), 3311-3319. 
(48) Fourie, J.; Oleschuk, C. J.; Guziec, F.; Guziec, L.; Fiterman, D. J.; Monterrosa, C.; 
Begleiter, A., The Effect of Functional Groups on Reduction and Activation of Quinone 
Bioreductive Agents by Dt-Diaphorase. Cancer Chemother. Pharmacol. 2002, 49 (2), 
101-110. 
(49) Fryatt, T.; Pettersson, H. I.; Gardipee, W. T.; Bray, K. C.; Green, S. J.; Slawin, A. M. Z.; 
Beall, H. D.; Moody, C. J., Novel Quinolinequinone Antitumor Agents: Structure-
Metabolism Studies with Nad(P)H : Quinone Oxidoreductase (Nqo1). Bioorg. Med. 
Chem. 2004, 12 (7), 1667-1687. 
(50) Newsome, J. J.; Swann, E.; Hassani, M.; Bray, K. C.; Slawin, A. M. Z.; Beall, H. D.; 
Moody, C. J., Indolequinone Antitumour Agents: Correlation between Quinone Structure 
and Rate of Metabolism by Recombinant Human Nad(P)H : Quinone Oxidoreductase. 
Org. Biomol. Chem. 2007, 5 (10), 1629-1640. 
(51) Begleiter, A.; El-Gabalawy, N.; Lange, L.; Leith, M. K.; Guziec, L. J.; Guziec Jr, F. S., A 
Model for Nad(P)H:Quinoneoxidoreductase 1 (Nqo1) Targeted Individualized Cancer 
Chemotherapy. Drug Target Insights 2009, 4, 1-8. 
(52) Skelly, J. V.; Sanderson, M. R.; Suter, D. A.; Baumann, U.; Read, M. A.; Gregory, D. S. 
J.; Bennett, M.; Hobbs, S. M.; Neidle, S., Crystal Structure of Human Dt-Diaphorase: A 
Model for Interaction with the Cytotoxic Prodrug 5-(Aziridin-1-Yl)-2,4-
Dinitrobenzamide (Cb1954). J. Med. Chem. 1999, 42 (21), 4325-4330. 
(53) Suleman, A.; Skibo, E. B., A Comprehensive Study of the Active Site Residues of Dt-
Diaphorase: Rational Design of Benzimidazolediones as Dt-Diaphorase Substrates. J. 
Med. Chem. 2002, 45 (6), 1211-1220. 
(54) Hassani, M.; Cai, W.; Koelsch, K. H.; Holley, D. C.; Rose, A. S.; Olang, F.; Lineswala, J. 
P.; Holloway, W. G.; Gerdes, J. M.; Behforouz, M.; Beall, H. D., Lavendamycin 
Antitumor Agents: Structure-Based Design, Synthesis, and Nad(P)H : Quinone 
Oxidoreductase 1 (Nqo1) Model Validation with Molecular Docking and Biological 
Studies. J. Med. Chem. 2008, 51 (11), 3104-3115. 
(55) Nolan, K. A.; Humphries, M. P.; Barnes, J.; Doncaster, J. R.; Caraher, M. C.; Tirelli, N.; 
Bryce, R. A.; Whitehead, R. C.; Stratford, I. J., Triazoloacridin-6-Ones as Novel 
Inhibitors of the Quinone Oxidoreductases Nqo1 and Nqo2. Bioorg. Med. Chem. 2010, 
18, 696-706. 
97 
 
(56) Phillips, R. M.; Naylor, M. A.; Jaffar, M.; Doughty, S. W.; Everett, S. A.; Breen, A. G.; 
Choudry, G. A.; Stratford, I. J., Bioreductive Activation of a Series of Indolequinones by 
Human Dt-Diaphorase: Structure-Activity Relationships. J. Med. Chem. 1999, 42 (20), 
4071-4080. 
(57) Carrier, N. H. Redox-Active Liposome Delivery Agents with Highly Controllable 
Stimuli-Responsive Behavior. Ph.D. Dissertation, Louisiana State University, Baton 
Rouge, LA, 2011. 
(58) Osman, A. M.; Boeren, S., Studies on the Dt-Diaphorase-Catalysed Reaction Employing 
Quinones as Substrates: Evidence for a Covalent Modification of Dt-Diaphorase by 
Tetrachloro-P-Benzoquinone. Chem.-Biol. Interact. 2004, 147 (1), 99-108. 
(59) Harris, D. C., Statistics. In Quantitative Chemical Analysis, 7th ed.; Byrd, M. L., Ed. W. 
H. Freeman and Company, New York: 2007; p 65. 
(60) Cleland, W. W., Statistical Analysis of Enzyme Kinetic Data. Methods Enzymol. 1979, 
63, 103-138. 
(61) Harris, D. C., Statistics. In Quantitative Chemical Analysis, 7th ed.; Byrd, M. L., Ed. W. 
H. Freeman and Company, New York: 2007; p 59. 
(62) Bohm, H. J., The Computer-Program Ludi - a New Method for the Denovo Design of 
Enzyme-Inhibitors. J. Comput. Aid. Mol. Des. 1992, 6 (1), 61-78. 
(63) Bohm, H. J., The Development of a Simple Empirical Scoring Function to Estimate the 
Binding Constant for a Protein Ligand Complex of Known 3-Dimensional Structure. J. 
Comput. Aid. Mol. Des. 1994, 8 (3), 243-256. 
(64) Rarey, M.; Wefing, S.; Lengauer, T., Placement of Medium-Sized Molecular Fragments 
into Active Sites of Proteins. J. Comput. Aid. Mol. Des. 1996, 10 (1), 41-54. 
(65) Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G., A Fast Flexible Docking Method Using 
an Incremental Construction Algorithm. J. Mol. Biol. 1996, 261 (3), 470-489. 
(66) Rarey, M.; Kramer, B.; Lengauer, T., Multiple Automatic Base Selection: Protein-Ligand 
Docking Based on Incremental Construction without Manual Intervention. J. Comput. 
Aid. Mol. Des. 1997, 11 (4), 369-384. 
(67) Kramer, B.; Rarey, M.; Lengauer, T., Casp2 Experiences with Docking Flexible Ligands 
Using Flexx. Proteins 1997, 221-225. 
98 
 
(68) Kramer, B.; Rarey, M.; Lengauer, T., Evaluation of the Flexx Incremental Construction 
Algorithm for Protein-Ligand Docking. Proteins 1999, 37 (2), 228-241. 
(69) Rarey, M.; Kramer, B.; Lengauer, T., Docking of Hydrophobic Ligands with Interaction-
Based Matching Algorithms. Bioinformatics 1999, 15 (3), 243-250. 
(70) Bohm, H. J., Ludi - Rule-Based Automatic Design of New Substituents for Enzyme-
Inhibitor Leads. J. Comput. Aid. Mol. Des. 1992, 6 (6), 593-606. 
(71) Burie, J. R.; Boullais, C.; Nonella, M.; Mioskowski, C.; Nabedryk, E.; Breton, J., 
Importance of the Conformation of Methoxy Groups on the Vibrational and 
Electrochemical Properties of Ubiquinones. J. Phys. Chem. B 1997, 101 (33), 6607-6617. 
(72) Silverman, J.; Stam-Thole, I.; Stam, C. H., Crystal and Molecular Structure of 2-Methyl-
4,5-Dimethoxy Para Quinone (Fumigatin Methyl Ether), C9h10o4. Acta Cryst. B-Struc. 
1971, B 27 (Oct15), 1846-1851. 
(73) Robitaille, P. M. L.; Robitaille, P. A.; Brown, G. G.; Brown, G. G., An Analysis of the 
Ph-Dependent Chemical-Shift Behavior of Phosphorus-Containing Metabolites. J. Magn. 
Reson. 1991, 92 (1), 73-84. 
(74) Milstien, S.; Cohen, L. A., Stereopopulation Control .1. Rate Enhancement in 
Lactonizations of Ortho-Hydroxyhydrocinnamic Acids. J. Am. Chem. Soc. 1972, 94 (26), 
9158-9165. 
(75) Cavelier, G.; Amzel, L. M., Mechanism of Nad(P)H : Quinone Reductase: Ab Initio 
Studies of Reduced Flavin. Proteins 2001, 43 (4), 420-432. 
(76) Deller, S.; Macheroux, P.; Sollner, S., Flavin-Dependent Quinone Reductases. Cell Mol. 
Life Sci. 2008, 65 (1), 141-160. 
(77) Nolan, K. A.; Timson, D. J.; Stratford, I. J.; Bryce, R. A., In Silico Identification and 
Biochemical Characterization of Novel Inhibitors of Nqo1. Bioorg. Med. Chem. Lett. 
2006, 16 (24), 6246-6254. 
(78) Carlson, B. W.; Miller, L. L., Mechanism of the Oxidation of Nadh by Quinones - 
Energetics of One-Electron and Hydride Routes. J. Am. Chem. Soc. 1985, 107 (2), 479-
485. 
99 
 
(79) Tranoy-Opalinski, I.; Fernandes, A.; Thomas, M.; Gesson, J. P.; Papot, S., Design of 
Self-Immolative Linkers for Tumour-Activated Prodrug Therapy. Anti-Cancer Agent Me 
2008, 8 (6), 618-637. 
 
 
 
100 
 
CHAPTER 4 
QUINONE TRIGGER-BASED LIPIDS FOR FORMING ENZYME-RESPONSIVE 
LIPOSOMES AND THEIR RESPONSE TOWARD HNQO1 ASSAY CONDITIONS   
 
4.1 Introduction 
In general, quinones have been applied to different systems with the aim of improving 
therapeutic responses in the area of targeting cancer, such is the case for antitumor compounds 
and prodrugs; both being activated by reductive enzymes.1-3  The McCarley research group went 
a step further from prodrugs and designed a quinone-based liposome system to be specifically 
activated by the human reductive enzyme NAD(P)H:quinone oxidoreductase type-1 (hNQO1), 
which is over-expressed in certain solid tumors,4-7 with the objective of adding more deliverable 
drug units per delivery carrier.  Such liposome systems have been proved by the McCarley group 
to open by chemical reduction under bench-top conditions.8  However, these liposomes still need 
to be assayed against the human enzyme NQO1 for the development of enzyme-responsive 
liposomes.  Initial information was extracted from the characterization of trimethyl-lock quinone 
derivatives by cyclic voltammetry (chapter 2), enzyme assays and docking (chapter 3).  With 
such knowledge in hand, it was expected that contents release would occur for quinone-based 
liposomes (Q-liposomes) upon hNQO1 activation (reduction) of the quinone headroup to the 
hydroquinone, and as a result, destabilization of the liposome bilayer would lead to cargo 
release, Scheme 4.1.  In order to clearly demonstrate liposome opening through this enzyme 
mechanism, first proper control experiments needed to be done wherein in the dye-containing 
liposomes are examined in the sole presence of bovine serum albumin (BSA), reduced nicotine 
adenine dinucleotide (NADH), and hNQO1, common components of the NQO1 assay.9  Those 
control experiments will provide knowledge on the interaction between quinone-liposome 
systems and hNQO1 assay components.  
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Scheme 4.1. Proposed enzyme-responsive liposome system. 
4.2 Experimental Section 
4.2.1 Materials  
Potassium dihydrogen phosphate (KH2PO4, Fluka 60219), dipotassium hydrogen 
phosphate (K2HPO4, Fisher P288), potassium chloride (KCl, Sigma P9541) and potassium 
hydroxide pellets (KOH, Mallinckrodt) were used to make the buffer.  Recombinant human 
enzyme NAD(P)H:quinone oxidoreductase type 1 and type 2 (rhNQO1 and rhNQO2 ), 
nicotinamide adenine dinucleotide reduced (β-NADH) and bovine serum albumin (BSA) were 
purchased from Sigma Aldrich (D1315, Q0380, N8129, A3294).  Triton X-100 (> 99% pure, 
Sigma T8787) was also purchased from Sigma Aldrich.  Calcein (85% pure, Acros Organics) 
was purchased from Fisher Scientific.  1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] 
(PEG2000-DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and cholesterol (CHO) 
were purchased from Avanti Polar Lipids and used without further purification.  Sephadex Fine 
G-50 was purchased from GE Healthcare.  NORM-JECT syringes were purchased from Fisher 
Scientific.  Nanopure water was obtained from a Nanopure Diamond Barnstead system (18.2 
MΩ·cm).  Q-DOPE syntheses and characterizations were published previously.10  The 
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instrument used was a Perkin-Elmer LS 55 Fluorescence Spectrometer with a PTP-1 
Fluorescence Peltier System and PCB 1500 Water Peltier System (PerkinElmer, Waltham, MA). 
4.2.2 Calcein-loaded Liposome Preparation  
Liposomes were prepared using a modified version of the well-known lipid thin-film and 
extrusion method.11,12  Around 20 mL of pH 7.1 0.1M phosphate buffer (PB)/0.1 M KCl was 
placed under argon to degas.  1–3 mg of quinone-DOPE (taken out of the freezer 20 min before 
weighing) was dissolved in a minimal amount of chloroform (approximately 1 mL).  Depending 
on the liposome system to be prepared, appropriate amounts of PEG2000-DOPE, DOPC, or 
cholesterol were weighed, and subsequently dissolved in certain volume of chloroform to reach 
the desired concentration for later addition to the Q–DOPE solution.  Then, the solution was 
transferred into a 10-mL (14/20) ground joint test tube.  Chloroform was removed by rotary 
evaporation for 15 min, and a thin film layer was formed at the bottom of the tube.  The lipid 
film was further dried under high vacuum for 1 hour.  While the lipid was drying, a 40 mM 
calcein solution in degassed buffer was prepared.  Approximately 248 mg of calcein and 70 mg 
of potassium hydroxide were added into a vial followed by addition of 8 mL of degassed pH 7.1 
0.1 M PB/0.1 M KCl buffer solution.  The mixture was sonicated to help dissolve the solids, 
yielding an orange solution.  Titration with KOH solution (KOH pellets and pH 7.1 0.1 M PB/0.1 
M KCl buffer) gave the desired pH of 7.1.  The calcein solution was transferred to a 10-mL 
volumetric flask and filled with degassed buffer to the calibration mark.  Dried lipids were 
hydrated in 1 mL of calcein solution by vortexing the mixture for 30 seconds and allowed to 
stand every 2 min for a total of 30 min.  The hydrated lipids went through six-freeze thaw cycles 
using an acetone/dry ice bath and a warm water-bath.  At this point, an Avanti Mini-Extruder 
(Avanti Polar Lipids, Alabaster, AL) was assembled and rinsed with buffer and then with calcein 
solution before injection of the lipid solution into the extruder.  A total of 19 extrusions were 
performed at room temperature (22±2 °C) using one 100-nm diameter pore Whatman 
103 
 
Nucleopore polycarbonate track-etched membrane.  Free calcein was separated from liposome-
encapsulated calcein by column centrifugation method, as follows 100–250 µL of solution was 
added to a 3-mL syringe with glass-cotton frit, packed with Sephadex Fine G-50 and then 
centrifuged for 3 min at 500 x g.  Solutions of liposome-encapsulated calcein were stored in an 
amber vial under argon and then placed in the refrigerator at 8 °C for subsequent experiments.  
Liposome-encapsulated calcein solutions are stable for up to 5 days. 
4.2.3 Characterization of Calcein-loaded Liposomes 
Liposome sizes (diameters) were measured using dynamic light scattering from 
backscattered light intensities (173°, 633-nm red laser) at 25 °C in a Zetasizer Nano ZS (Malvern 
Instruments, Worcestershire, U. K.) particle analyzer.  No significant size differences were found 
previously between calcein-loaded liposomes and calcein-free liposomes.8  Liposome charge was 
obtained by measuring the zeta potential at 25 °C in a folded capillary zeta potential cell using a 
Smoluchowski model. 
4.2.4 Stability and Calcein Release Experiments 
10 µL of calcein-loaded liposomes and 990 µL of pH 7.1 0.1 M PB/0.1 M KCl buffer 
solution were added to a 1-cm quartz cuvette, and an absorbance scan was performed at room 
temperature from 200 to 600 nm in a Varian Cary 50 Bio UV-Visible Spectrophotometer.  The 
peak at 497 nm corresponds to the encapsulated calcein, and its absorbance ranged from 0.06 to 
0.1 a.u. depending on the liposome system.  The peak at 264.9 nm corresponded to the QMe 
headgroup absorbance, when it was equal to 0.55 a.u., meant that the lipid concentration was 100 
µM based on a ɛ265 = 5500 M–1 for the QMe headgroup.13  A ratio between this value and the 
absorbance value measured for a particular experiment containing QMe-DOPE gave the 
corresponding amount of liposome solution needed to have 100 µM liposome in a 3-mL volume.  
In these liposome stability experiments, different assay components were present in the 4-sided 
transparent cuvette by the time the fluorescent experiment start.  All fluorescence intensity 
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experiments were performed at 25 °C on a Perkin-Elmer LS 55 Fluorescence Spectrometer with 
a PTP-1 Fluorescence Peltier System and PCB 1500 Water Peltier System.  The excitation 
wavelength was λex = 490 nm, and the emission wavelength was λem = 515 nm, both with a slit 
width of 2.5 nm.  Data was acquired every 1 min with a 0.1 second integration time; the total 
experimental time varied from 1 hour to 24 hours.  To avoid detector saturation, two neutral 
density filters (ND 0.3 and ND 0.5, Omega Optics, Brattleboro, VT) were placed inside the 
instrument so as to reduce the total transmission to 16% of the original intensity.  The percent of 
calcein release was calculated as follows: 
                                          % 𝐿𝑒𝑎𝑘𝑎𝑔𝑒 = (𝐹𝑡−𝐹0)(𝐹100−𝐹0) ∗ 100                                            Equation 4.1 
F0 is the intensity value that corresponds to the point before addition of the assay component 
(BSA, NADH, hNQO1, dithionite, liposomes) where there is a 0% leakage.  Ft corresponds to 
the fluorescence intensity observed at the point in time after addition of the assay component.  
F100 is the fluorescence intensity observed after addition of 15 µL of 30% (v/v) Triton X-100 that 
ensures lysing of the liposomes for release of all calcein. 
4.2.4.1 Bovine Serum Albumin 
When BSA was tested with the different liposome systems, the concentration of 
liposomes was calculated as described in Section 4.2.4.  BSA solutions were made using a 10- 
mL volumetric flask containing pH 7.1 0.1 M PB/0.1 M KCl and 0.7 mg or 7 mg of BSA, 
corresponding to a 1 µM or 10 µM BSA solutions.  The experiment started by addition of 
liposome solution to the already present BSA solution in the cuvette or the other way around.  In 
both cases the same result was observed, reaffirming that the addition order had no effect on the 
outcome.  Fluorescence at 515 nm was recorded upon addition of either component. 
4.2.4.2 Reduced Nicotine Adenine Dinucleotide 
When NADH was tested with the different liposome systems, the concentration of 
liposomes was calculated as described in Section 4.2.4.  NADH solutions were made using a 10- 
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mL volumetric flask containing pH 7.1 0.1 M PB/0.1 M KCl and 7.25 mg of NADH, 
corresponding to a 1 mM solution.  300 µL of 1 mM NADH solution were added to the cuvette 
and fluorescence as a function of time was recorded. 
4.2.4.3 Human NAD(P)H:Quinone Oxidoreductase Type 1 (hNQO1) and Type 2 (hNQO2)  
The reaction started when 300 µL of hNQO1 solution were added to the liposome 
solution in the 4-sided transparent cuvette.  The amount of enzyme used in the experiment was 
calculated based on hNQO1 enzyme kinetics assays carried out previously on QMe-COOH.  
Enzyme solutions were prepared from a 50 µL frozen enzyme aliquot (2 mg·mL–1) added to 275 
µL of pH 7.1 0.1 M PB/0.1 M KCl buffer to yield a 5 µM solution.  For inhibition experiments, 
599 µL of pH 7.1 0.1 M PB/0.1 M KCl buffer containing NADH (100 µM) and ES936 (30 µM) 
were added to the hNQO1 enzyme (50 µL frozen aliquot), and this solution was incubated at 
room temperature for 30 min prior to its addition to the 4-sided transparent cuvette.  For heat 
inactivation of hNQO1, the enzyme was heated at 85 °C for 25 min, and then 300 µL were added 
to the liposome solution.  hNQO2 experiments were performed as described for hNQO1 but 
using an enzyme concentration of 2.5 µM.  Fluorescence at 515 nm was recorded upon addition 
of either component 
4.2.4.4 Sodium Dithionite 
Around 15 mL of buffer was purged with argon for 20 min.  The appropriate amount of 
liposome solution and degassed buffer were mixed to yield a total volume of 3 mL and then 
added to a 4-sided cuvette with a screw-cap septum; the solution was purged with argon for 10 
min.  The cuvette was taken to the room where the fluorescence instrument is located, and the 
experiment was started.  Approximate 5.3 mg of dithionite was added to an amber-septum vial 
and then purged with argon for 1 min.  To the degassed vial containing dithionite, 1 mL of 
degassed buffer was added.  The oxygen-free dithionite solution was taken to the fluorometer 
room and an appropriate amount of this solution was injected into the cuvette using a 50-µL 
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Gastight syringe (Hamilton, Reno, NV).  After injection, the cuvette was shaken, and then the 
time-dependent fluorescence was recorded. 
4.3 Results and Discussion 
4.3.1 Stability and Calcein Release for Q-DOPE Liposome Systems  
4.3.1.1 Liposomes Composed of 100% QMe-DOPE  
QMe-DOPE liposomes have been extensively studied in the McCarley group, and their 
contents release curves were reported previously upon addition of dithionite.8,10,13  Therefore, 
there was an imminent curiosity to see how they will behave under hNQO1 assay conditions.  
The appropriate amounts of QMe-DOPE liposome, NADH and BSA solutions were calculated as 
outlined in Section 4.2.  The absorbance spectrum of 100% QMe-DOPE liposomes is presented in 
Figure 4.1.  In this spectrum is clearly observed the quinone headgroup peak (λmax = 264.9 nm) 
used to calculate the liposome concentration as well as the necessary value for the encapsulated 
calcein peak (λmax = 497 nm) to avoid detector saturation.   
 
Figure 4.1. UV-vis absorbance spectrum of 100% QMe-DOPE liposomes in pH 7.1 0.1 M PB/0.1 
M KCl at room temperature. λmax = 264.9 nm corresponds to the QMe headgroup and λmax = 497 
nm corresponds to the encapsulated calcein. 
The first experiment intended to verify if the presence of NADH, an hNQO1 electron 
donor during the ping-pong mechanism,9 has any impact on the liposome stability.  In Figure 4.2 
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is shown the behavior of 100% QMe-DOPE liposome upon addition of 300 µL of 1 mM NADH 
solution.  To our satisfaction, liposomes were stable up to 18 hours (the maximum time 
measured) in the presence of the hNQO1 cofactor.  The stability of the liposomes in the presence 
of NADH confirms the absence of direct reduction between the quinone headgroup and the 
cofactor.  In this matter, any liposome opening should be caused by the enzymatic reduction of 
the quinone headgroup as illustrated in Scheme 4.1.   
 
Figure 4.2. Stability of 100 µM 100% QMe-DOPE liposomes in the presence of 100 μM NADH.  
(↑) the time for addition of 300 µL of 1 mM NADH solution.  No leakage was observed as 
noted by the lack of increase in fluorescence intensity with time.  (●) time at which 100% QMe-
DOPE liposomes were lysed with the addition of 15 µL of 30% (v/v) Triton X-100.  (     ) 
Instrument stopped by itself and was started again by me; no consequences observed on the 
measurement. 
The next enzyme assay component to be tested against the liposomes was BSA, which 
has been mentioned numerous times as an NQO1 activator in a way that to this date is not fully 
understood.14  In Figure 4.3 are displayed both trials made on this liposome system with addition 
of only BSA solution.  Unfortunately, they were not stable in the presence of this protein.  Trial 1 
exhibited a calcein leakage of 44% in 3 hours and 61% in 16 hours and 30 min while trial 2 
resulted in a calcein leakage of 54% in 3 hours and 71% in 15 hours and 12 min.  The shape of 
the release curves varied because of the different order of addition between the liposomes and 
the BSA solution; in both cases this did not affect the % calcein leakage results. The fast release 
-5
15
35
55
75
95
0 500 1000 1500
%
 C
al
ce
in
 R
el
ea
se
 
Time (min) 
↓ 
● 
108 
 
rate of contents for the 100% QMe-DOPE system took us by surprise based on the previous 
knowledge of the interaction of liposomes with BSA solutions.       
 
Figure 4.3. Instability of 100 µM 100% QMe-DOPE liposomes in the presence of 0.007% BSA.  
(↑) the time for addition of 300 µL of 0.07% BSA solution into liposome solution.  (↑) the 
addition time for 100% QMe-DOPE liposomes into 0.007% BSA solution.  (●) time at which 
100% QMe-DOPE liposomes were lysed with the addition of 15 µL of 30% (v/v) Triton X-100. 
Kim and co-workers described that egg phosphatidylcholine (PC) liposomes had a percent 
leakage of ca. 13% in 5 hours and ca. 18% in 10 hours when incubated with approximate 8 µM 
BSA solution (in TES buffer pH 7.4) at 37 °C.15  In addition, Guo and Szoka depicted their 
liposome system (DSPE-PEG/DOPE 1:9) to have a leakage of 13% in 4 hours and 20% in 12 
hours in the presence of 75% of fetal serum albumin (in pH 7.4 0.05 M PB/0.1 M NaCl).16  
Because of the instability of the 100% QMe-DOPE liposomes toward the protein BSA, other 
liposome formulations were investigated with the objective of finding the system that would be 
assay against hNQO1.  
4.3.1.2 Liposomes Composed of 97% QMe-DOPE/3% PEG2000-DOPE  
Based on the previous results with 100% QMe-DOPE liposomes, the liposome 
formulation was adjusted by including 3% of a lipid attached to poly(ethylene glycol), PEG-
DOPE in the mixture.  It is well known that PEG lipids stabilize liposomes containing PEGs of 
2,000 MW with respect to non-specific protein absorption and disruption.  Due to the properties 
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of PEG lipids, long-circulation liposomes, known as “Stealth Liposomes,” have helped improved 
the therapeutic efficiency of liposomes as drug delivery carriers with reported circulatory half-
lives of up to 45 hours.17,18  QMe-DOPE, BSA, NADH and hNQO1 solutions were prepared as 
described in Section 4.2.  PEG2000-DOPE was obtained from Avanti Polar Lipids and dissolved 
in an appropriate amount of chloroform previous to its addition to chloroform solutions of QMe-
DOPE solution.  The absorbance spectrum of 97% QMe-DOPE/3% PEG2000-DOPE liposomes is 
presented in Figure 4.4 and look exactly as the one in Figure 4.1.  Thus, as expected, the addition 
of PEG2000-DOPE did not introduce extra peak that could interfere with the fluorescence 
experiments.  The quinone headgroup peak as well as the encapsulated calcein peak is observed 
as seen previously for 100% QMe-DOPE liposomes.  The new formulation was tested with BSA 
to see its impact on liposome stability.  In Figure 4.5 is shown the behavior of 97% QMe-
DOPE/3% PEG2000-DOPE liposomes upon addition of BSA solution.  Even with 3% 
polyethylene glycol in the liposome formulation, the liposomes were not stable when they came 
in contact with BSA.  The calcein leakage was 59% in 3 hours and 77% in 15 hours and 45 min.   
 
Figure 4.4. UV-vis absorbance spectrum of 97% QMe-DOPE/3% PEG2000-DOPE liposomes in 
pH 7.1 0.1 M PB/0.1 M KCl at room temperature.  λmax = 264.9 nm corresponds to the QMe 
headgroup and λmax = 497 nm corresponds to the encapsulated calcein.  
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Figure 4.5. Instability of 100 µM 97% QMe-DOPE/3% PEG2000-DOPE liposomes in the 
presence of 0.007% BSA.  (↑) the time for addition of 300 µL of 0.07% BSA solution into 
liposome solution.  (●) time at which 97% QMe-DOPE/3% PEG2000-DOPE liposomes were lysed 
with the addition of 15 µL of 30% (v/v) Triton X-100.  
At this point, two hypotheses can be presented for the way that BSA interacts with the Q-DOPE 
liposomes: 1) the attraction of BSA to the liposomes is based on surface-charge interactions 
or/and 2) the attraction of BSA to the liposomes is based on hydrophobic interactions between 
the protein and the lipid bilayer.  Hypothesis 1 is less feasible based on the fact that BSA is a 
negatively charged protein at pH 7.1 (isoelectric point between 4.5–4.9)19-21 and the liposomes 
also present a highly negative surface charge (Table 4.1), thus, electrostatic interactions at pH 7.1 
should be minimal or none.  Sweet and Zull indicated that other factors, besides electrostatic 
interactions, are involved in the interaction of BSA with phospholipid membranes.21  The same 
authors later stated that electrostatic interactions between negatively charged membranes and 
BSA would be more probably near or below the isoelectric point of BSA (4.5–4.9).19  In 
addition, Kim and co-workers came to the conclusion that BSA attacks the lipid bilayer whether 
it is at the inner or at the outer phase of the bilayer and induces leakage of the entrapped 
materials.15  Therefore, it is more probable that BSA caused the release of calcein from the 
liposomes by penetrating into the lipid bilayer.  The observations that Sweet and Zull found for 
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their systems19 made me think of the possibility that hNQO1, with an isoelectric point of 8.91,22 
could have electrostatic interactions with our negative liposomes and induce leakage of contents 
by a different mechanism that the one proposed on Figure 4.1.  Therefore, the 97% QMe-
DOPE/3% PEG2000-DOPE liposomes were evaluated in the presence of only hNQO1.  
 
Figure 4.6. Instability of 100 µM 97% QMe-DOPE/3% PEG2000-DOPE liposomes in the 
presence of 0.5 μM hNQO1.  (↑) the time for addition of 300 µL of 5 µM hNQO1 solution into 
liposome solution.  (●) time at which 97% QMe-DOPE/3% PEG2000-DOPE liposomes were lysed 
with the addition of 15 µL of 30% (v/v) Triton X-100.  
Upon inspection of Figure 4.6, a calcein release of 80% was observed in 70 min and 91% 
in 2 hours and 36 min after exposure of 97% QMe-DOPE/3% PEG2000-DOPE liposomes to 
hNQO1.  In fact, the calcein release rate provoked by hNQO1 was faster than the one caused by 
BSA.  Such a difference in the release rate could be a consequence of the apparent different 
mechanisms for the proteins acting on the liposomes.  Human NQO1 seems to interact by surface 
charge attractions that would disrupt the liposomes (faster release), while on the other hand, BSA 
seems to interact by penetrating the lipid bilayer (slower release).   
At this moment, the attention was focused on the fact that the liposome opened by the 
sole presence of the enzyme by a path different from the one proposed in Scheme 4.1.  In this 
regard, another experiment using hNQO1 and NADH was performed to see if the rate of leakage 
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was increased from the results obtained in Figure 4.6.  The addition of NADH provides the 
necessary component for the enzyme to act through its ping-pong mechanism.9   
 
Figure 4.7. Instability of 100 µM 97% QMe-DOPE/3% PEG2000-DOPE liposomes in the 
presence of 100 μM NADH and 0.5 µM hNQO1.  (↑) the addition time for 300 µL of 5 µM 
hNQO1 solution into liposome/NADH solution.  (●) time at which 97% QMe-DOPE/3% 
PEG2000-DOPE liposomes were lysed with the addition of 15 µL of 30% (v/v) Triton X-100.  
 
Figure 4.8. Overlap of the calcein release curves for 100 µM 97% QMe-DOPE/3% PEG2000-
DOPE liposomes in the presence of 0.5 µM hNQO1 (red line) and 100 µM 97% QMe-DOPE/3% 
PEG2000-DOPE liposomes containing 100 µM NADH in the presence of 0.5 µM hNQO1 (blue 
line).  (↑) the addition time for 300 µL of 5 µM hNQO1 solution into liposome/NADH solution.  
(●) time at which 97% QMe-DOPE/3% PEG2000-DOPE liposomes were lysed with the addition 
of 15 µL of 30% (v/v) Triton X-100.  Times were offset to compare the curves.  
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In Figure 4.7 is displayed the behavior of 97% QMe-DOPE/3% PEG2000-DOPE liposomes 
in the presence of NADH and hNQO1, showing minimal difference with respect to Figure 4.6.  
In fact, both curves can be almost overlapped as shown in Figure 4.8.   
The instability of 97% QMe-DOPE/3% PEG2000-DOPE liposomes in the presence of 
bovine serum albumin and hNQO1 lead me to investigate more liposome formulations with the 
aim of finding one that is stable under hNQO1 assay conditions. 
4.3.1.3 DOPC Liposomes  
The new liposome formulation described in this section is devoid of the QMe-DOPE lipid; 
no quinone headgroup is present in this liposome system.  In that way, I could investigate how 
much the presence of the QMe headgroup affected liposome leakage when they came in contact 
with BSA or hNQO1.  Unfortunately, DOPE lipids do not form stable liposomes at pH 7.1,23,24 
therefore, DOPC lipids where used instead.  DOPC has a similar structure to DOPE, with the 
difference being the polar group as illustrated in Figure 4.9; therefore, the fluidity of the bilayer 
is not changed because the transition temperature of the lipids are very similar (Tm DOPE = –16 
°C and Tm DOPC = –20 °C). 
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Figure 4.9. Structure of DOPE and DOPC lipids. 
In Figure 4.10 is presented the absorbance spectrum of DOPC liposomes containing 
calcein.  As can be seen, the quinone peak at 264.9 nm is absent, as expected, and the peak at 
497 nm corresponds to the encapsulated calcein.  In effect, the encapsulated calcein peak was 
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used to approximate the concentration of this liposome formulation to be 100 µM as it was for 
our previous experiments.  DOPC liposomes were tested in the presence of BSA and also with 
hNQO1. 
  
Figure 4.10. UV-vis absorbance spectrum of DOPC liposomes in pH 7.1 0.1 M PB/0.1 M KCl at 
room temperature.  The peak of λmax = 497 nm corresponds to the encapsulated calcein. 
In Figure 4.11 is shown the stable behavior of DOPC liposomes with BSA for almost 17 
hours.  The lack of interaction between BSA and DOPC liposomes, lead me to believe that the 
QMe headgroup played an important role in liposome leakage.  In the previous section, I referred 
to BSA as a protein that interacts with liposomes through the lipid bilayer; it could happen that in 
the QMe-DOPE liposome systems, the hydrophobic quinone mediated the interaction between 
BSA and the liposome membrane, permitting the protein to penetrate the QMe-DOPE liposome 
system. 
In Figure 4.12 is displayed the stability of DOPC liposomes in the presence of hNQO1 
for approximately 15 hours.  The absence of interaction between DOPC liposomes and hNQO1 
could be credited to two things: 1) the almost neutral surface charge of DOPC liposomes (Table 
4.1) and/or 2) the absence of the QMe headgroup in the liposome formulation.  The first one 
would definitely decrease any electrostatic interaction that the positively charged enzyme could 
have with the slightly negative charge liposomes, and the second one would lead me to the 
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option that hNQO1could just embrace the quinone headgroup of the liposomes inducing bilayer 
destabilization and liposome leakage.    
 
Figure 4.11. Stability of 100 µM DOPC liposomes in the presence of 0.007% BSA.  (↑) the 
addition time for 300 µL of 0.07% BSA solution into liposome solution.  No leakage was 
observed as noted by the lack of increase in fluorescence intensity with time.  (●) time at which 
DOPC liposomes were lysed with the addition of 15 µL of 30% (v/v) Triton X-100.  
   
Figure 4.12. Stability of 100 µM DOPC liposomes in the presence of 0.5 µM hNQO1.  (↑) the 
addition time for 300 µL of 5 µM hNQO1 solution into liposome solution.  No leakage was 
observed as noted by the lack of increase in fluorescence intensity with time.  (●) time at which 
DOPC liposomes were lysed with the addition of 15 µL of 30% (v/v) Triton X-100.  
The stability of DOPC liposomes toward both proteins proved the fact that QMe 
headgroup played a significant role in the instability of Q-DOPE liposomes toward BSA and 
hNQO1.  For the development of enzyme-responsive liposomes the presence of quinone 
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headgroups into the liposome formulation is essential because of the inherent substrate affinity of 
hNQO1 towards quinones.9  Therefore, a potential solution for liposome stability is to create 
liposomes based on mixtures of QMe-DOPE and DOPC lipids.  
4.3.1.4 Liposomes Composed of 90% QMe-DOPE/10% DOPC and 80% QMe-DOPE/20% 
DOPC  
 
With the intent of finding a stable system that contains QMe-DOPE, two different 
formulations that included DOPC were prepared as described in Section 4.2.  Those formulations 
were intended to decrease the amount of QMe-DOPE and consequently decrease the leakage of 
liposomes when they come in contact with BSA or hNQO1.  In addition, a calcein release 
experiment initiated by chemical reduction using dithionite (which resembles the reduction by 
hNQO1) was also performed with the aim to demonstrate that these liposome formulations also 
follow the proposed mechanism illustrated in Scheme 4.1.  In Figure 4.13 is shown the 
absorbance spectrum for 90% QMe-DOPE/10% DOPC and 80% QMe-DOPE/20% DOPC 
liposomes.  It is observed that both liposome formulations exhibited the peak at 264.9 nm that 
corresponds to the quinone head group and the peak at 497 nm that corresponds to the calcein 
encapsulated in the liposomes.  In Figure 4.14 is revealed the behavior of 90% QMe-DOPE/10% 
DOPC and 80% QMe-DOPE/20% DOPC liposomes in the presence of BSA.  The 90% QMe-
DOPE/10% DOPC system had a calcein leakage of 40% in 66 min while 80% QMe-DOPE/20% 
DOPC liposomes had a calcein leakage of 13% in 3 hours and 31% in 11 hours and 24 min.  
Both examples show that decreasing the amount of QMe-DOPE helps to slow down the leakage 
process when BSA is present.  The reasonable stability observed for 80% QMe-DOPE/20% 
DOPC liposomes in the presence of BSA, provides hope for testing the same system with 
hNQO1. 
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Figure 4.13. UV-vis absorbance spectrum of 90% QMe-DOPE/10% DOPC (blue line) and 80% 
QMe-DOPE/20% DOPC (red line) liposomes in pH 7.1 0.1 M PB/0.1 M KCl at room 
temperature.   λmax = 264.9 nm corresponds to the QMe headgroup and λmax = 497 nm 
corresponds to the encapsulated calcein.  
 
Figure 4.14. Unstable behavior of 100 µM 90% QMe-DOPE/10% DOPC and 100 µM 80% QMe-
DOPE/20% DOPC liposomes in the presence of 0.007% BSA.  (↑) the time for addition of 300 
µL of 0.07% BSA solution into the 90% QMe-DOPE/10% DOPC liposome solution.  (↑) the 
addition time for 80% QMe-DOPE/20% DOPC liposomes into 0.007% BSA solution.  (●) time at 
which 90% QMe-DOPE/10% DOPC and 80% QMe-DOPE/20% DOPC liposomes were lysed 
with the addition of 15 µL of 30% (v/v) Triton X-100.  
In Figure 4.15 is displayed the behavior of 80% QMe-DOPE/20% DOPC liposomes in the 
presence of hNQO1.  These liposomes experienced a calcein release of 48% in 70 min and 68% 
in 3 hours.  Although these liposomes are not stable in the sole presence of the enzyme, the rate 
of leakage is decreased when compared with the previous liposome formulations that contained 
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QMe-DOPE.  The inclusion of DOPC lipids in the liposome formulation resulted in reduced 
leakage in an inverse relationship, with more DOPC being present leading to less calcein release.    
 
Figure 4.15. Instability of 100 µM 80% QMe-DOPE/20% DOPC liposomes in the presence of 
0.5 µM hNQO1.  (↑) the addition time for 300 µL of 5 µM hNQO1 solution into liposome 
solution.  (●) time at which 80% QMe-DOPE/20% DOPC liposomes were lysed with the addition 
of 15 µL of 30% (v/v) Triton X-100.  
After performing the stability experiments, it was important to see how the QMe-
DOPE/DOPC liposomes behave when they are opened by chemical reduction.  In that way, I 
could predict the time that liposomes will take to open and deliver their cargo by the proposed 
mechanism, and see if adding more DOPC lipids to the liposome mixture was feasible.  The 
calcein release curves for both formulations for sodium dithionite addition are shown in Figure 
4.16.  Upon introduction of the reducing agent into the liposome solution, a “lag” phase 
happened that corresponds to the reduction of the QMe headgroup and its detachment from the 
DOPE lipid.  Such action initiates a bilayer destabilization (as labeled in Scheme 4.1), and 
subsequent opening of the liposome occurred as noticed by the increase in fluorescence intensity. 
The 90% QMe-DOPE/10% DOPC liposomes exhibited a lag time of 31 minutes, and 
reached a maximum in 20 min, with a total calcein release of 63%.  However, the 80%QMe-
DOPE/20% DOPC liposomes experienced a lag time of 38 min and took 3 hours to reach the 
maximum with a total calcein release of 55%.       
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Figure 4.16. Calcein release curves of 100 µM 90% QMe-DOPE/10% DOPC and 100 µM 80% 
QMe-DOPE/20% DOPC by chemical reduction using 5 eq. of sodium dithionite.  (↑) the time 
for addition of sodium dithionite solution into the 90% QMe-DOPE/10% DOPC liposome 
solution.  (↑) the time for addition of sodium dithionite solution into the 80% QMe-DOPE/20% 
DOPC liposome solution.  (●) time at which 90% QMe-DOPE/10% DOPC and 80% QMe-
DOPE/20% DOPC liposomes were lysed with the addition of 15 µL of 30% (v/v) Triton X-100.   
The increase in DOPC content from 10% to 20% in the liposome formulation caused the lag time 
to rise by 7 minutes and the time to reach maximum contents release to be reached 160 min later.  
The important decrease in the rate at which calcein is released required me to take a different 
approach for the formulation of QMe-DOPE liposomes, because it was anticipated that the 
amount of DOPC content necessary to make the system more stable toward proteins will create 
liposomes not suitable for hNQO1 enzyme assay (too slow to open). 
4.3.1.5 Liposomes Composed of 70% QMe-DOPE/30% Cholesterol (CHO) 
The results in Section 4.3.1.4 directed me to look for a new liposome system that is stable 
in the presence of BSA and hNQO1.  A review by Pagano and Weinstein published in 1978 
described that up to 50% of cholesterol can be added to liposomes to decrease their leakage.25  It 
was also mentioned in the literature that the addition of CHO decreases liposome fluidity and 
permeability of contents across the membrane.25,26  CHO-containing liposomes were prepared as 
described in Section 4.2.  In Figure 4.17 is shown the absorbance spectrum for 70% QMe-
DOPE/30% CHO liposomes and as seen previously no unpredicted peaks are present.   
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Figure 4.17. UV-vis absorbance spectrum of 70% QMe-DOPE/30% CHO liposomes in pH 7.1 
0.1 M PB/0.1 M KCl at room temperature.   λmax = 264.9 nm corresponds to the QMe headgroup 
and λmax = 497 nm corresponds to the encapsulated calcein. 
To make sure that CHO does not prevent liposomes from opening, the calcein release 
profile of 70% QMe-DOPE/30% CHO liposomes opened by chemical reduction was investigated.  
In Figure 4.18 are presented the calcein release curves for 70% QMe-DOPE/30% CHO liposomes 
caused by sodium dithionite.  Upon introduction of the reducing agent into the liposomes 
solution, a “lag” phase is noted where the reduction of the QMe headgroup and its detachment 
from the DOPE lipid occurs.  Such action initiates bilayer destabilization (as labeled in Scheme 
4.1) and opening of the liposome as noticed by the increase in fluorescence intensity.  The 
current liposome system exhibited a lag time of 27 min and took 12 min to reach the 
fluorescence maximum with an average calcein release of 71%.  It is interesting to notice that 
when cholesterol was included in the mixture, the release of contents happened much faster than 
when DOPC was present at the same level in the formulation.  In addition, the “lag” phase 
differed a little in shape from the one observed for QMe-DOPE/DOPC liposomes in Figure 4.16. 
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Figure 4.18. Calcein release curves of 100 µM 70% QMe-DOPE/30% CHO by chemical 
reduction using 5 eq. of sodium dithionite.  The arrows (↑ and ↑) depict the time for addition of 
sodium dithionite solution into the 70% QMe-DOPE/30% CHO liposome solution for each trial.  
(●) time at which 70% QMe-DOPE/30% CHO liposomes were lysed with the addition of 15 µL 
of 30% (v/v) Triton X-100.   
After confirming that the CHO-containing liposomes opened upon chemical reduction, 
stability experiments were performed on these systems.  As a rule, the first experiment made on 
the new liposome system was to test the integrity of it in the presence of BSA.  In Figure 4.19 is 
shown the behavior of 70% QMe-DOPE/30% CHO liposomes in the presence of BSA.  As it was 
expected, calcein leakage was lower than in the other formulations with a 15% in 1 hour and 
20% in 3 hours and 10 min.  The favorable results with liposomes containing CHO agreed with 
the statement previously made on the mechanism of action of cholesterol by other scientists 
because its inclusion diminished the penetration of the BSA molecules into the lipid bilayer 
resulting in less leakage of liposome contents.26   
After the satisfactory behavior of the liposomes with BSA, the next obvious step was to 
test them with hNQO1.  Displayed in Figure 4.20 is presented the behavior of 70% QMe-
DOPE/30% CHO liposomes with hNQO1.  Unfortunately, the enzyme still caused a liposome 
leakage of 47% in 1 hour and 61% in 3 hours. 
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Figure 4.19. Instability of 100 µM 70% QMe-DOPE/30% CHO liposomes in the presence of 
0.007% BSA.  (↑) the time for addition of liposome solution into the 0.007% BSA solution.  (●) 
time at which 70% QMe-DOPE/30% CHO liposomes were lysed with the addition of 15 µL of 
30% (v/v) Triton X-100. 
 
Figure 4.20. Instability of 100 µM 70% QMe-DOPE/30% CHO liposomes in the presence of 0.5 
µM hNQO1.  (↑) the addition time for 300 µL of 5 µM hNQO1 solution into liposome solution.  
(●)    time at wich 70% QMe-DOPE/30% CHO liposomes were lysed with the addition of 15 µL 
of 30% (v/v) Triton X-100.  
The difference in observed behavior between BSA and hNQO1 with the CHO-liposomes 
confirmed the previous hypothesis of the mechanisms in which the proteins interact with the 
liposome system.  For BSA, it is clear that hydrophobic interactions are the driving force in the 
BSA-liposome contact.  On the other hand, hNQO1 attacks the liposomes by electrostatic 
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interactions or by just embracing the quinone headgroup which causes bilayer destabilization and 
liposome leakage.   
A series of 3 experiments was performed on 100% QMe-DOPE liposomes to have more 
knowledge about the mode of interaction between hNQO1 and the liposomes.  The first 
experiment corresponds to the interaction of inhibited hNQO1 with the liposomes.  100% QMe-
DOPE liposomes were assayed with 0.25 µM hNQO1 and also with inhibited 0.25 µM hNQO1.  
Human NQO1 is known to be completely inhibited by ES936, an inhibitor that alkylates one of 
the tyrosine residues in the active site of the enzyme.27,28  The results of UV-vis experiments for 
QMe-COOH (quinone headgroup of the QMe-DOPE lipid), hNQO1, NADH and ES936 
confirmed the mode of action of ES936, as seen in Figure 4.21.  If hNQO1 inhibition prevents 
liposome leakage, then it will be clear that the mechanism of action of hNQO1 is the embracing 
of the quinone headgroup by the enzyme.   
  
Figure 4.21. UV-vis spectra for hNQO1 assay (A) and hNQO1 inhibition assay (B).  A) QMe-
COOH and NADH (blue line) and QMe-COOH and NADH and hNQO1 after 1 min (pink line).  
B) QMe-COOH and NADH (blue line) and QMe-COOH and NADH and hNQO1 after 30 min 
(pink line), after 1 hour (green line) and after 4 hours (cyan line). 
The behavior of 100% QMe-DOPE liposomes with inhibited hNQO1 is shown in Figure 
4.22.  It is clear that inhibition of hNQO1 by ES936 did not preclude the enzyme from causing a 
liposome leakage as noted by the observed 56% release of contents in 2 hours and 3 min, while 
54% calcein leakage was seen with the non-inhibited hNQO1.    
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Figure 4.22. Instability of 100 µM 100% QMe-DOPE liposomes in the presence of 0.25 µM 
hNQO1 (red line) and 0.25 µM inhibited hNQO1 (blue line).  (↑) the addition time for 300 µL 
of 2.5 µM hNQO1 or inhibited hNQO1 solution into liposome solution.  (●) time at which 100% 
QMe-DOPE liposomes were lysed with the addition of 15 µL of 30% (v/v) Triton X-100.  
A second experiment to see if electrostatic interaction was the factor of attraction 
between hNQO1 (isoelectric point of 8.91)22 and the 100% QMe-DOPE liposomes was 
performed using the human enzyme NQO2 with an isoelectric point of 5.87 that will have a 
negative charge under the experimental conditions.22  The protein sequences of hNQO1 and 
hNQO2 can be aligned without insertions or deletions, and are 49% identical over their shared 
length.29,30  The major differences are that hNQO2 is 43 amino acids shorter than hNQO1 at the 
C-terminal domain and 10 amino acids present at the C-terminal domain of hNQO2 have no 
sequence homology with the corresponding residues in hNQO1.29,30  Also hNQO2 uses 
dihydronicotinamide riboside (NRH) instead of NAD(P)H as an electron donor.29,30  Therefore, 
the active sites of hNQO1 and hNQO2, both having the FAD prosthetic group are very similar in 
nature.  If hNQO2 provokes liposome leakage, then electrostatic interactions would not be the 
driving force for the hNQO1-liposome interactions.   
In Figure 4.23 is shown the behavior of hNQO2 versus hNQO1 in the presence of 100% 
QMe-DOPE liposomes.  HNQO1 caused a calcein leakage of 54% in 2 hours and 3 min while 
hNQO2 caused a calcein leakage of 37% in the same amount of time.  It is clear that hNQO2 
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caused liposome leakage in a very similar manner to that of hNQO1, indicating that the quinone 
is the reason why liposomes open in the presence of these enzymes and not surface charge 
interactions. 
 
Figure 4.23. Instability of 100 µM 100% QMe-DOPE liposomes in the presence of 0.25 µM 
hNQO1 (red line) and 0.25 µM hNQO2 (blue line).  (↑) the addition time for 300 µL of 2.5 µM 
hNQO1 or hNQO2 solution into liposome solution.  (●) time at which 100% QMe-DOPE 
liposomes were lysed with the addition of 15 µL of 30% (v/v) Triton X-100.  
 
Figure 4.24. Stability of 100 µM 100% QMe-DOPE liposomes in the presence of 0.25 µM heat 
inactivated hNQO1.  (↑) the addition time for 300 µL of 2.5 µM heat inactivated hNQO1 
solution into liposome solution.  (●) time at which 100% QMe-DOPE liposomes were lysed with 
the addition of 15 µL of 30% (v/v) Triton X-100.  
The last experiment of the series of 3 performed on the 100% QMe-DOPE liposomes was 
heat inactivation of hNQO1 and its behavior with the liposomes.  In Figure 4.24 is shown no 
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content release for Q-DOPE liposomes in the presence of heat-inactivated hNQO1, indicating 
that the active site of the enzyme is the one responsible for the calcein leakage from the 100% 
QMe-DOPE liposomes.  These three experiments performed on 100% QMe-DOPE liposomes 
demonstrate that the mechanism of interaction between hNQO1 and quinone-based liposomes is 
through the quinone head group.   
In summary, after examining all the quinone-based liposome formulations, there is still 
the need of a stable system in the sole presence of hNQO1.  
4.3.2 DLS and Zeta Potential of Q-DOPE Liposome Systems  
Liposome diameters and surface charge were measured for each of the liposome systems 
to help me understand the interaction of BSA and hNQO1 with liposomes.  In Table 4.1 are 
presented the average values of diameter and zeta potential for each system.  
In general, the QMe-DOPE liposome systems fall in the expected range of 100–120 nm, 
as previously reported in the McCarley group.10,13  DOPC liposomes are almost identical in 
diameter to the 100% QMe-DOPE liposomes, with values that overlap considering the error 
associated with them.  The equal value in diameter between the liposome systems indicates that 
the size of the liposomes has no effect on their interaction with the proteins. 
Table 4.1 Average diameters and zeta potentials of QMe-DOPE liposome systems.  Experiments 
performed at 25 °C in pH 7.1 0.1M PB/0.1M KCl.  Results are the average of 3 determinations ± 
one standard deviation.  aPolydispersity indexes ≤ 0.3 are considered acceptable.  bReference 2; 
pH 7.4 0.05 M PB/0.075 M KCl.  cMeasurement done by Dr. Martin Loew. 
Liposome System Avg. Diameter (nm) Avg. PDIa Avg. Zeta Potential (mV) 
100% QMe-DOPE 123±1 0.06±0.02 –60±3b 
97% QMe-DOPE / 
3% PEG2000-DOPE 
117±1c 0.12±0.01c not measured 
100% DOPC 126±3 0.06±0.02 –7±2 
90% QMe-DOPE /  
10% DOPC 112±1 0.08±0.02 –48±4 
80% QMe-DOPE /  
20% DOPC 119±1 0.09±0.01 –52±2 
70% QMe-DOPE / 
30% CHO 119±2 0.20±0.05 –50±3 
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  The surface charge values for all the QMe-DOPE liposome systems measured in pH 7.1 
0.1 M PB/0.1 M KCl ranged between –44 to –53 mV.  The zeta potential of 100% QMe-DOPE 
liposome system (–60 mV) was measured by a colleague in 0.05 M PB/0.075 M KCl pH 7.4.10  
The surface charge of DOPC was measured to be –7 mV, much less negative than the systems 
that included QMe-DOPE.  The consistency of negative surface charge in all QMe-DOPE 
liposome systems is an indicative of the potent attraction of  hNQO1 (isoelectric point 8.91)22 at 
pH 7.1 to those liposomes; interaction that is not observed with DOPC liposomes.  It also 
supports the hypothesis that BSA (isoelectric point 4.5–4.7)19,20 would rather interact with the 
QMe-DOPE liposome systems by penetrating into the lipid bilayer (hydrophobic interactions) 
than by surface charge interactions.  
4.4 Conclusions 
Five different liposome formulations containing QMe-DOPE and one containing 100% 
DOPC were tested against the common components of an hNQO1 assay.  To my disappointment, 
none of the formulations were completely stable in the presence of BSA or hNQO1.  However, 
important conclusions can be made from the results obtained, and they are summarized in Table 
4.2.  All the liposomes systems had an average diameter between 100 and 130 nm as previously 
seen in the McCarley group for similar systems.10  Also, the liposome systems containing QMe-
DOPE lipids experienced a negative surface charge between –44 and –53 mV, while 100% 
DOPC liposomes presented an almost neutral surface charge of –7 mV.  After examining the 
stability experiments, it is clear that the inclusion of the QMe headgroup facilitates the interaction 
of BSA with the lipid membrane as seen by the absence of leakage of DOPC liposomes.  
Likewise, the interaction of hNQO1 with the liposomes is also mediated by the presence of QMe 
headgroup as seen by the different experiments performed on the quinone based liposome 
systems.  The chemical release profiles of new quinone-based liposome systems were 
investigated and different results were seen depending on the nature of the liposome components.  
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The liposomal formulation with 10% DOPC and 90% QMe-DOPE presented a much faster 
calcein release rate than the formulation with 20% DOPE and 80% QMe-DOPE (63% in 20 min 
versus 55% in 3 hours).  From these results I can infer that only a 10% increase in DOPC content 
caused significant changes on the mechanism of release of the liposomes.  On the other hand, the 
inclusion of 30% of cholesterol in the liposome mixture did not decrease the rate of calcein 
release (71% in 12 min) but did affect the mechanism of release as concluded by comparing 
these release profiles versus the chemical release profile for 100% QMe-DOPE liposomes 
performed by a colleague in the McCarley group at pH 7.4 0.05 M PB/0.075 M KCl.13  The 
examination of a variety of liposome formulations reflected the important quality of liposome 
that it is its versatility to change the outcome by incorporation of different lipids.  This versatility 
can be explored further with the aim of finding a liposomal formulation that would only open by 
the mechanism described in Scheme 4.1.   
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Table 4.2. Summarized results from calcein release, DLS, and zeta potential experiments performed on QMe-DOPE liposome systems at 25 °C in 
pH 7.1 0.1 M PB/0.1 M KCl.  aReference 2; pH 7.4 0.05 M PB/0.075 M KCl.  bMeasurement done by Dr. Martin Loew. 
 100%QMe-DOPE 
97%QMe-DOPE 
3%PEG2000 
100%DOPC  
90%QMe-DOPE 
10% DOPC 
80%QMe-DOPE 
20% DOPC 
70%QMe-DOPE 
30% CHO 
0.007%BSA 50% in 3h 60% in 3h Stable for 17 h 40% in 1h 6 min 13% in 3 h 20% in 3h 10 min 
100 µM NADH Stable for 18 h      
0.5 µM hNQO1  80% in 1h 10 min Stable for 15 h  48% in 1h 10 min 47% in 1h 
0.5 µM hNQO1 
100 µM NADH 
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CHAPTER 5 
CONCLUSIONS AND OUTLOOK 
 
5.1 Summary 
The ultimate goal of this research was the development of an enzyme-responsive 
liposome system composed of a fusogenic lipid, DOPE, capped with a quinone headgroup that is 
potentially capable of selectively delivering its contents at a desired tumor site.  In this system, 
the stimulus was the human reductive enzyme NAD(P)H:quinone oxidoreductase type-1 
(hNQO1) that is over-expressed in certain tumor tissues.1-4  The hypothesized mechanism 
involves the interaction of hNQO1 with the liposomes via initial reduction of the quinone 
headgroup (quinone triggers), followed by cyclization of the corresponding hydroquinone 
moiety, subsequent bilayer destabilization, and contents release.  Characterization of the quinone 
trigger groups was important to elucidate the electronic properties, kinetic profiles, and active 
site orientation of these triggers before attachment to the lipid that would be used to form 
liposomes.  
An electrochemical technique named cyclic voltammetry was used to determine the 
reduction potential and cyclization rates of electrochemically-active quinones in aqueous media.  
It was found that naked quinones (no propionic acid handle) are electrochemically 
quasireversible systems because the difference in the anodic and cathodic peak potentials 
deviates from the ideal value of 30 mV.  It was also observed that benzoquinone was the naked 
quinone easiest to be reduced (most positive reduction potential), whereas in the substituted 
benzoquinone series, addition of electron-withdrawing groups resulted in more positive 
reduction potentials, while addition of electron-donating groups resulted in more negative 
potentials.  In the propionic acid quinone series, most of the systems were found to be electron-
transfer irreversible with peak separations over 200 mV.  As observed for the naked quinones, 
propionic acid quinones with electron-withdrawing groups displayed a less negative reduction 
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potential, while the inverse happened when electron-donating groups were present.  It was also 
elucidated that the presence of a propionic acid handle on the quinone moiety made the reduction 
of the quinone more difficult (more negative reduction potential), and that difficulty increased as 
geminal methyls were added or when the whole trimethyl-lock unit was present.  Interestingly, 
the nature of the propionic acid handle did not affect the electronic properties of the quinone 
derivatives based on the results obtained for QMe-COOH and QMe-ETA.  In addition to the 
thermodynamic parameters of quinones, the cyclization rate for the disappearance of the 
corresponding hydroquinone after quinone reduction was determined.  The higher cyclization 
rates corresponded to the quinones containing the trimethyl-lock moiety, in particular the ones 
with a methyl, an iodine or a bromine group at the 2-position of the quinone ring.  Moreover, an 
enhancement in the cyclization rate was observed when buffer concentration was increased. 
Cyclic voltammetry studies on QMe-COOH at various salt concentrations revealed no change in 
the cyclization rate.  
Solution-phase enzyme kinetics and molecular docking studies were applied to a variety 
of quinone propionic acid derivatives with the aim of establishing quinone-hNQO1 interactions.    
These quinone derivatives were divided in three groups: 1) trimethyl-lock quinones varying the 
functional group at the 2-position on the quinone, 2) quinones not possessing the trimethyl-lock 
unit vs. quinones with the trimethyl-lock unit, and 3) charged versus neutral quinones.  In the 
first group, it was found that quinones with a hydrogen or halogen group presented higher 
affinity and faster turnover rates toward the enzyme, while quinones with an electron-donating 
group (methyl or methoxy) presented lower affinity and slower turnover rates.  Docking studies 
in this group revealed that all quinones laid parallel to the isoalloxazine ring, with a slight 
variance in orientation and that the bromine analog was positioned deepest in the enzyme active 
site.  In the second group, it was clear that quinones with no trimethyl-lock unit presented higher 
affinity and good turnover rates.  Moreover, QnogemMe-COOH, which is in this group, was the 
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best substrate for hNQO1 among all the quinone derivatives studied.  It was found that QnogemMe-
COOH was the one quinone located closest to the isoalloxazine ring in the enzyme active site.   
In the third group, no change in binding affinity was observed between quinones.  However, the 
neutral quinone exhibited a higher turnover rate with respect to the charged quinone.  
Superimposed images of these two derivatives exposed that the neutral quinone is located deeper 
in the enzyme active site than the charged quinone.  In addition, from all the quinone derivatives 
analyzed with docking, the preferable atom acceptor for hydride transfer appears to be the carbon 
atom (next to the carbonyl on the opposite side of the propionic acid handle) based on the 
distance measured from the N5 atom of FAD and the closer atoms in the quinone ring.  Docking 
studies also unveiled no strong correlation between the theoretical binding energies and the 
experimental binding affinities. 
Finally, quinone triggers were characterized and ready to use in the design of enzyme-
responsive liposomes.  QMe-COOH was the only quinone trigger group used to form a variety of 
liposome systems.  Stability studies on five quinone-based liposome formulations and one DOPC 
liposome formulation in the presence of hNQO1 common assay components were accomplished.  
DLS, zeta potential and chemical release curves on the liposome formulations were also 
performed.  The liposomal formulation containing only QMe-DOPE was stable in the presence of 
NADH.  None of the quinone-based liposomal formulations designed to date were stable under 
the individual presence of BSA or hNQO1.  Conversely, liposomes composed of only DOPC 
were stable in the presence of BSA and hNQO1.  Inclusion of DOPC lipids or cholesterol in the 
quinone-based liposome formulation resulted in alterations of their chemical release profiles 
compared with the chemical release profile for a 100% QMe-DOPE liposome reported 
previously.  All quinone-based liposomes had an average diameter between 110 and 124 nm and 
a zeta potential between –48 and –60 mV.  The diameter of the DOPC liposomes was 126 nm, 
and its zeta potential was –7 mV.  
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5.2 Conclusions 
The results of this research demonstrated that the electronic properties of quinone 
derivatives can successfully be tuned by addition of various functional groups, as well as by 
inclusion of structural changes such as a handle.  Quinone triggers followed a qualitative trend 
where electron-donating groups retarded the turnover rate with respect to hNQO1 while the 
opposite happened with the inclusion of electron-withdrawing groups.  Docking studies 
qualitatively predicted the position of the quinone triggers, and the trend was in agreement with 
the kinetic outcomes.  The best substrate for hNQO1 corresponds to the quinone located closer to 
the isoalloxazine ring of FAD in the active site of hNQO1.  All quinone-based liposomes were 
destabilized and leaky after addition of BSA or hNQO1.  It is believed that the key factor for the 
leakage of liposomes is the quinone headgroup.  Modifying quinone-based liposomes by 
inclusion of other lipid components can result in a formulation able to release its contents in a 
controllable manner.     
5.3 Outlook 
Carving through the last 20 years of literature, it is clear that a great deal of research is 
focused on prodrugs and carriers for triggerable drug release.  Also there is extensive literature 
on the structure-activity relationships between antitumor quinones and NQO1 for the 
development of new prodrug systems.  Nevertheless, few prodrugs are currently being marketed 
and no triggerable drug delivery liposomal system has made it to clinical use.5-9   
The detailed information provided in this dissertation on simple quinone triggers could be 
useful in the design of new quinone-based prodrugs for fast or slow release as well as for the 
development of carriers where combination of both is also possible.  However, further studies 
need to be performed in order to optimize the quinone-based liposome formulations described in 
this research document.  The optimized formulation would lead to a system that is stable in the 
presence of BSA and hNQO1 (at low concentrations) but unstable at the concentrations were 
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hNQO1 is over expressed in the human body.  This ideal situation has a key piece that is still 
unknown in the hNQO1 field and corresponds to the quantitative information on the 
concentration of hNQO1 in the body.2,10,11  In the absence of that information, it is important to 
investigate the behavior of quinone-based liposomes at various hNQO1 concentrations to obtain 
a correlation between calcein release rates and hNQO1 activity.  Moreover, quinone-based 
liposome stability could be increased by: 1) addition of other lipids such of those with higher Tm 
values than DOPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE Tm = 74 °C)12 or 
1,2-dielaidoyl-sn-glycero-3-phosphoethanolamine (DEPE Tm = 38 °C))12 that could form more 
rigid bilayers, 2) reduction of the quinone-DOPE content in the liposomal formulation to 
investigate if dilution of the quinone prevent the liposomes from leaking, and 3) attach a positive 
charged quinone to decrease the negative surface charge of liposomes. 
The optimized triggerable system will selectively release their contents at the desired site, 
thus maximizing efficacy and reducing unwanted release on healthy cells.  The versatility of 
these systems allow them to be loaded with a variety of units such as drugs, probes, genes and 
virus for application in drug delivery, cell imaging or gene and virus therapy.    
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APPENDIX A: SUPPLEMENTAL INFORMATION 
Table A.1. Extinction coefficient values for NADH in a 96-well plate.  Experiments performed 
at 22±2 °C in 0.007% BSA solution. 
 Trial 1 Trial 2 Trial 3   
NADH (µM) Abs. (a.u.) Abs. (a.u.) Abs. (a.u.) Average (a.u) St. Dev. 
10 0.0304 0.0192 0.0112 0.0203 0.0096 
30 0.1232 0.11105 0.1062 0.1135 0.0088 
50 0.1866 0.2258 0.2128 0.2084 0.0200 
80 0.3336 0.3412 0.3264 0.3337 0.0074 
100 0.3873 0.4078 0.4058 0.4003 0.0113 
120 0.4828 0.5258 0.5028 0.5038 0.0215 
150 0.597 0.6348 0.598 0.6099 0.0215 
200 0.84255 0.8534 0.8306 0.8422 0.0114 
250 1.0858 1.10255 1.0726 1.0870 0.0150 
300 1.3153 1.3058 1.276 1.2990 0.0205 
 
 
Figure A.1. Calibration curve for NADH in a 96-well plate.  Experiments performed at 22±2 °C 
in 0.007% BSA solution. 
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Figure A.2.  Superposition of trimethyl-lock quinones in the active site of hNQO1.  
Representation of QBr-COOH (sky blue), QH-COOH (magenta), QMe-COOH (yellow), QMeO-
COOH (light pink); amino acids (lines display; color by atom type, carbon atoms colored green); 
Tyr 155, His 161 and FAD (stick display; color by atom type, carbon atoms colored green).  The 
figure was created using PyMOL. 
 
 
 
Figure A.3.  Superposition of quinones with and without presence of trimethyl-lock in the active 
site of hNQO1.  Representation of QnogemMe-COOH (sky blue), Q’-COOH (magenta), QMe-
COOH (yellow); amino acids (lines display; color by atom type, carbon atoms colored green); 
Tyr 155, His 161 and FAD (stick display; color by atom type, carbon atoms colored green).  The 
figure was created using PyMOL. 
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Figure A.4.  Superposition of charged quinone versus neutral quinone in the active site of 
hNQO1.  Representation of QMe-ETA (sky blue), QMe-COOH (magenta); amino acids (lines 
display; color by atom type, carbon atoms colored green); Tyr 155, His 161 and FAD (stick 
display; color by atom type, carbon atoms colored green).  The figure was created using PyMOL. 
 
Table A.2.  Associated energies for QBr-COOH when docked in hNQO1 active site.  Above is 
the lowest score energy for each receptor and the components of the Böhm scoring function. 
 
Receptor Score (kJ·mol–1) Match Lipo Ambig Clash Rot 
1 -25.2018 -19.7347 -12.0594 -6.8892 3.8815 4.2000 
2 -24.7270 -19.0412 -11.8116 -7.0926 3.6185 4.2000 
3 -24.1662 -18.5762 -12.2120 -6.9455 3.9675 4.2000 
4 -23.6224 -17.8762 -11.8138 -7.4545 3.9220 4.2000 
5 -24.1743 -19.7347 -11.2013 -6.7019 3.8636 4.2000 
6 -23.6994 -19.0412 -10.9535 -6.9053 3.6006 4.2000 
 
 
 
R1 R2 
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Figure A.5.  Lowest score frames of QBr-COOH in all the receptors.  Representation of QBr-
COOH (stick display; color by atom type, carbon atoms colored grey); amino acids and FAD 
(lines display; color by atom type, carbon atoms colored grey).  Dashed purple lines 
corresponded to hydrophobic interactions. 
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Figure A.6.  Poseview frames of QBr-COOH in all the receptors.  Representation of a 2D view 
of the docked pose of QBr-COOH (line display; color by atom type, carbon atoms colored black); 
amino acids and FAD label in green or structure line display; color by atom type, carbon atoms 
colored black.  Hydrophobic interactions are displayed as green contact curves with only the 
names of the interacting residues attached to these lines.  Dashed lines corresponded to hydrogen 
bond interactions. 
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Figure A.7.  Correlation of estimated theoretical and experimental free energies of binding.   
 
Chemical Synthesis and Characterization of QMe-ETA. 
 
Preparation of N-(2-hydroxyethyl)-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-
dien-1-yl)butanamide (QMe-ETA).  The quinone amine derivative was prepared by adding QMe-
NHS1 (150 mg, 0.4328 mmol) into a 25 mL round bottom flask and letting the solid dry under 
high vacuum for 15 minutes.  Then argon was purged through the flask to have it under inert 
atmosphere; the flow was stopped for two minutes to add 4.5 mL of dichloro methane.  Continue 
argon flow and cooled the mixture to 0 °C.  Then add dropwise triethylamine (310 µL, 2.2241 
mmol) followed by ethanolamine (40 µL, 0.6647 mmol) using glass syringes.  Stopped the argon 
flow and sealed the round bottom flask.  Let the mixture stir for 4 hours.  Reaction was followed 
by TLC (3:1:2 DCM/MeOH/Hex) until no QMe-NHS was present.  After the reaction was 
completed, the mixture was diluted with 50 mL of dichloro methane and washed with 5 % of 
sodium bicarbonate (2 X 100 mL).  Organic layer was dried over sodium sulfate, and evaporated 
to yield 87.8 mg of a yellow solid (75 %). 
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1H NMR (400 MHz, CDCl3): δ 1.44 (s, 6H), 1.95-1.97 (d, 6H), 2.14 (s, 3H), 2.85 (s, 2H), 3.32-
3.33 (q, 2H), 3.65 (t, 2H), 5.82 (s, 1H). 
13C NMR (400 MHz, CDCl3): δ 12.13, 12.68, 14.15, 28.98, 38.34, 42.20, 49.14, 62.48, 137.95, 
138.09, 143.45, 153.12, 173.06, 187.54, 191.35. 
HRMS (ESI+) m/z [M+H]+, calcd = 294.1706 (calcd for C16H24NO4), obsd = 294.1709, 0.9 ppm 
error. 
 
Figure A.8.  1H NMR for QMe-ETA (CDCl3, 400 MHz) 
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Figure A.9.  13C NMR for QMe-ETA (CDCl3, 400 MHz) 
 
Figure A.10.  High resolution mass spectrum (positive ion, electrospray ionization) for QMe-
ETA. 
[M+H]+ 
[M+Na]+ [2M+Na]
+ 
294.1709 
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